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Summary: 
This thesis deals with the quantitative analysis of multiple drugs in the 
neonate, in blood and in meconium as an alternative biological specimen in forensic 
toxicology and is also concerned with the dangers of transmission of drugs used and 
abused by the mother to the foetus and neonate. The aims of the work were to 
investigate methods for performing a full drug screen on small amounts of biological 
specimen and to carry out a survey of illicit drug use during pregnancy in the 
Glasgow area. 
Following brief overviews of toxicology and the main problems facing the 
paediatric toxicologist, the development of analytical toxicology procedures to help 
to overcome them is summarised along with a more detailed examination of solid 
phase extraction (SPE) - theory, advantages and applications to biological samples. 
The initial experimental work established the feasibility of performing a full 
drug screen on small samples of blood such as those obtained from neonates, having 
a volume of 1-2m1. This used a single SPE cartridge for the extraction of a mixture 
of acidic and basic drugs followed by end-step analysis with enzyme immunoassay 
(EIA) and gas chromatography-mass spectrometry (GC/MS). Representative drugs 
from each group were selected for evaluation purposes: butobarbitone, 
amylobarbitone, methaqualone, primidone, and phenytoin drugs for the acidic drug 
group and cocaine, ecgonine methyl ester, morphine, diazepam, and 
desmethyldiazepam for the basic drug group. These were chosen as examples of 
drugs commonly used in the UK. Four analytes (morphine, methadone, cocaine and 
benzoylecgonine) were used to compare two different SPE cartridges, Bond Elut 
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Certify@ and Abselut®, which can be used to extract both acidic and basic drugs. 
The comparison involved four parameters: analyte recovery, lower limits of 
detection, presence of interferences in the extracts and analysis time required by 
each. Recoveries were in the range 60-100% and lower limits of detection were in 
the range 1-25 ng/ml and it was assessed that Bond Elut columns were better than 
Abselut columns. This method was applied to cases arising under the Road Traffic 
Act, which also provide very small samples for analysis and was found to be suitable 
for the intended purpose. 
The background to drug abuse, especially in pregnancy is then reviewed, 
including information on the main groups of illicit drugs analysed in this thesis, on 
their history, chemistry, pharmacology, toxicology and maternal and foetal 
considerations. Then an overview is given of the serious complications that affect 
the foetus prenatally and the neonate due to the use of illicit drugs by the pregnant 
mother along with common congenital anomalies, which are the largest cause of 
infant mortality. Of particular relevance in the Glasgow area is the Neonatal 
Abstinence Syndrome due to opiate abuse. Subsequently, a brief overview is given 
of the structure of the placenta, its circulation, function and the mechanism by which 
drugs pass through it to the foetus. Finally, a review is made of conventional and 
alternative biological specimens used for analytical purposes from the 
mother/foetus/neonate, including blood, urine, hair, nail, amniotic fluid, breast milk, 
and meconium. Particular emphasis is placed on previous analytical methods and the 
advantages of meconium over the other specimens. Meconium gives a wide window 
of detection of drugs, ranging from 12 weeks of pregnancy till delivery, and displays 
high concentrations of drugs. Also it is easily collected and non-invasive. 
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The second experimental study investigated the use of the developed multi- 
drug extraction method for meconium. The target analytes were chosen as the most 
commonly used and abused drugs in the Glasgow area, which are known from the 
casework carried out in the Forensic Medicine Department. These drugs are cocaine, 
and its principal metabolite benzoylecgonine, morphine, codeine, methadone, 
diazepam, temazepam, tetrahydrocannabinol and tetrahydrocannabinol carboxylic 
acid. The drugs were extracted by SPE with Bond Elut Certify columns followed by 
qualitative and quantitative analysis by EIA and GC/MS. The recoveries ranged 
from 50-100% and limits of detection ranged from 1-100ng/gm. The method was 
tested initially on 25 cases from the Glasgow Royal Maternity Hospital. 
An additional method study was required to develop the method to screen for 
amphetamine, methamphetamine and their analogues MDA, MDMA and MDEA, 
which could not be detected by the existing method. A new extraction procedure 
using ZD-Kleen® cartridges was explored. End-step analysis was also done by EIA 
and GC/MS. Recoveries ranged from 60-95%, with lower limits of detection ranging 
from 1-20ng/gm. This meant the method was sufficiently sensitive and specific and 
it was assessed on 12 real cases from the Royal Maternity Hospital. 
The third study was a survey done on neonates born at Glasgow Royal 
Maternity Hospital in the period October 2000 till February 2001. This involved 
applying the developed methods to screen drugs of abuse in meconium (opiates and 
methadone, cocaine and its major metabolites, cannabinoids, benzodiazepines and 
amphetamines). This was the first survey done on meconium analysis in Glasgow to 
see the spread of drug used by pregnant mother and the drug concentrations, which 
are found in the neonate. For the survey, 450 cases were collected during this period. 
The percentages of cases in which drugs were confirmed were: morphine 38%, 
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codeine 29%, diazepam 18.5%, temazepam 12%, THC 10%, THCA 10%, methadone 
4.5%, cocaine 2.5% and benzoylecgonine 2%. A number of polydrug addicted 
mothers were detected. These cases were also analysed for impurities found in street 
heroin, including acetylcodeine, 6-MAM, dihydromorphine, papaverine, and 
thebaine, as markers to distinguish between morphine derived from therapy and that 
derived from illicit heroin use. Nine cases were found to contain one or more of 
these markers. 
The final experimental study investigated two types of hydrolysis of 
cannabinoid conjugates, using glucuronidase and alkali, to improve the sensitivity of 
the method. Several cases were encountered which gave positive results by EIA but 
which were not confirmed by GC/MS, because the cannabinoid metabolites are 
primarily in their conjugated forms. A comparison was made between these two 
methods of hydrolysis and between the methods with and without hydrolysis with 
respect to lower limits of detection and recoveries. The preferred method, using 
alkaline hydrolysis, was applied to some real case samples which had given positive 
results by EIA but negative results by GC/MS and this was found to increase the rate 
of confirmation. 
The thesis ends with conclusions from the work and proposals for its future 
extension. 
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1. General Introduction and Aims 
Toxicology is the study of poisons or toxic substances and their adverse effects on living 
organisms. In some contexts, toxicologists are also involved with the treatment of 
poisoning. A poison may be defined as any agent capable of producing a deleterious 
response in biological system, seriously injuring function or producing death'. Paracelsus 
(1493-1541) wrote: "All substances are poisons; there is none which is not a poison. The 
right dose differentiates a poison and a remedy. " In the UK, the most common causes of 
poisoning relate to drugs, including alcohol, while in other parts of the world, pesticides 
are the main cause of substance-related death2. It is generally accepted that the toxicity of 
a drug or substance depends on not only its toxic properties but also on the dose 
administrated. 
Three specialised areas of toxicology are forensic, clinical, and environmental toxicology. 
Forensic toxicology is a hybrid of analytical chemistry and fundamental toxicological 
principles. It is concerned primarily with the medico-legal aspects of the harmful effects 
of the chemicals on humans and animals. The expertise of the forensic toxicologist is 
primarily invoked to assist in establishing the cause of death and elucidating its 
circumstances in a post-mortem investigation. Clinical toxicology designates an area of 
professional emphasis within the realm of medical science concerned with disease caused 
by or uniquely associated with toxic substances. Generally, clinical toxicologists are 
physicians who receive specialised training in emergency medicine and poison 
management. Efforts are directed at treating the patient poisoned with drugs or other 
chemicals and at the development of new techniques to treat these intoxications. 
Environmental toxicology focuses on the impacts of chemical pollutants found in the 
environment on biological organism. 
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There are many problems facing the clinical toxicologist in paediatric cases. One of the 
main problems is that only small blood samples are generally available, which is not 
enough for a full toxicological screen. Even in the event of fatalities, blood specimens 
recovered can be very small and tissue retention at autopsy is currently restricted. 
Another problem facing clinicians is the wide use of illegal drugs by pregnant mothers, 
which is considered one of the serious problems facing the foetus as it causes severe 
morbidity and mortality, or may cause major congenital anomalies, affecting the foetus 
throughout the pregnancy and also the child after birth, causing physical, mental and 
behavioural disabilities. Proper clinical care of the neonate requires accurate, reliable and 
objective diagnostic tests to identify drug use by the mother, as self-reporting may be 
unreliable. 
This thesis is concerned with some of the problems facing the paediatric toxicologist and 
the development of analytical toxicology procedures to help to overcome them. The aims 
can be stated as follows: 
to investigate and validate methods for the analysis of multiple drugs in small samples 
of blood, not exceeding Iml, which is typically obtained for routine analysis from the 
newborn; 
" to extend the applicability of the method to allow it to be applied to meconium 
samples from neonates, as this type of specimen is easily obtained, contains high 
concentrations of drugs and their metabolites and has a wide time window for 
detection of drugs; 
" to apply the analytical procedures in an epidemiological survey of cases admitted to 
the Glasgow Royal Maternity Hospital, with the aim of knowing the true incidence of 
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drug abuse during pregnancy in the Glasgow area and the concentrations of drugs 
which are transmitted to the infants; 
" to investigate alternative analytical procedures for the detection of cannabinoids and 
identify those which give the highest sensitivity i. e. the % of true positive cases 
identified. 3 
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2. Review of Solid Phase Extraction and Analysis of 
Drugs from Biological Specimens: 
2.1. Introduction 
Reliable and reproducible isolation of toxicologically relevant compounds from 
biologically matrices is the first, the most important, and the most critical step in 
systematic toxicological analysis. Among different extraction methods currently used in 
analytical toxicology, solid phase extraction (SPE) has shown a dynamic development. 
Thus, various methodological and technical aspects of SPE have been comprehensively 
studied4. 
The use of SPE columns as an alternative to liquid-liquid extraction for the isolation of 
drugs started in the mid-1970's and gained popularity over recent years because of the 
reported excellent recoveries and ease of operation. Urinary drug analysis, whether for 
post mortem forensic purposes, doping control, pre-employment screening, or clinical 
purposes, is an expanding area of commercial interest for which such rapid, reproducible, 
analytical techniques are of great values. 
SPE is widely used in forensic toxicological analysis, for both dedicated and general 
unknown procedures, mainly in the treatment of biological fluids of low viscosity, like 
urine or serum. It has also found application in the isolation of drugs from various other 
biological tissues and gives high purity biological extracts in comparison with liquid- 
liquid extraction (LLE)6. SPE has many advantages over LLE, which has many 
complications and disadvantages: for example, LLE needs more time and money spent on 
method development. The most common complications of LLE are that the extracts 
obtained are not clean and contain many impurities, the method can be non-reproducible, 
it can involve several sample handling steps, and can give low recoveries and sensitivities. 
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By contrast, the advantages of SPE are that it can result in higher sensitivity of detection; 
it produces clean extracts; as the analytes are retained and removed by elution, it is more 
reducible as it depends on specific molecular interactions. As a result, SPE is used for a 
wide range of drug analyses needed for systematic toxicology, and where there is a need 
for higher throughput due to automation. SPE extracts often cause less contamination of 
GC systems because they contain less extraneous material. Other advantages include 
elimination of time-consuming centrifugation and filtration steps and elimination of 
sample loss through emulsion formations. 
For these reasons, SPE is considered a powerful technique for the pre-treatment of 
biological samples for clinical and toxicological drug analysis. 
2.2. Characteristics of SPE: 
The extraction procedure in SPE involves the interaction between a solid and a liquid 
phase, and is a physical extraction process, similar to liquid chromatography'. However, 
the aims of solid phase extraction are to isolate and then concentrate the compounds of 
interest, with good peak shape and height, and short retention times. The optimisation of 
extraction conditions by SPE depends on the properties of all three interacting factors - 
analyte, sorbent and eluant - which is the subject of numerous studies. 
There are many different types of sorbents available: diatomaceous earth, silica, and 
bonded silica sorbents, in which there are a number of different types of column packing 
materials commercially available for drug extraction. These sorbents can be divided into 
three classes - non-polar, polar and ion exchange - according to the nature of the 
interactions between isolates, sorbents and solvents. 
The majority of solid phase methods for the extraction of drugs from body fluids, which 
have been reported, involves the use of columns packed with non-polar adsorbent 
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materials. These consist of silica to the surface of which are bonded long hydrocarbon 
chains, principally C8 or C 18, producing an essentially non-polar adsorbent phase similar 
to that present in a reversed phase HPLC column8. Most drugs have been extracted using 
non-polar interactions, using C8 or C18 bonded silica columns9, and, although polar 
sorbents are more selective than non-polar sorbents, they are less commonly used10". 
Ion-exchange cartridges are potentially the most useful from a drug screening point of 
view. Several researchers have carried out extraction efficiency comparisons between the 
various types of sorbents available. The use of a granular support material as a column 
packing has been compared with XAD-2 resin and conventional solvent extraction 
methods for various drugs, the diatomaceous earth material giving superior results in 
terms of drug recovery and solvent volumes required 12. 
Therefore, a solid phase extraction approach to sample preparation using bonded sorbents, 
as well as providing more selective screening methods for drugs liable to abuse, is rapid, 
simple, cheap, allows simultaneous extraction of multiple samples and is easily 
automated. 
Recently developed cartridges contain both non-polar substituents and polar ion exchange 
substituents (mixed mode cartridges), which can be used for extraction of both acidic and 
basic drugs. Cartridges with either hydrophobic groups alone or with ion exchange 
groups alone can effectively bind only one type of substance. Taking into account that 
substances of toxicological interest can have acidic, neutral and basic properties and that 
preferably only one SPE column has to be used, a mixture of silica materials in one 
column has the desired selectivity potential. Such a mixed mode bonded silica, in which 
silanol groups are partially derivatised with medium length alkyl chains and partially with 
cation exchange substituents can exert at least two types of interactions. Screening 
procedures using this type of SPE material have been of increasing interest and SPE 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 7 
columns with mixed mode phases are now available from a number of manufacturers, for 
example Bond Elut Certify (Varian Sample preparation Products, Harbor City, CA, USA), 
Clean Screen DAU ( World- Wide Monitoring Corp., Horsham, PA, USA), Isolute HCX ( 
International Sorbent Technology, Hengoed, UK) and TSC (Merck, Darmstadt, 
Germany). Mixed-mode bonded silica can, at a suitable pH, retain acidic and neutral 
substances by hydrophobic interactions with the alkyl chains and retain the basic 
substances by interactions with the cation exchange groups. Differential elution can take 
place by a proper adjustment of the pH and the choice of solvents13. 
2.3. Sorbent Extraction Theory: 
Sorbent extraction is a physical process that involves a liquid and a solid phase. The solid 
phase has a great potential for isolation of drugs. In theory, very selective extractions 
resulting in highly purified and concentrated isolates can then be achieved by choosing 
sorbents with an attraction for the isolate but not for the other sample components. The 
specific properties of a bonded cartridge are a result of the functional group covalently 
bonded to the silica substrate through reaction of the activated silica with organosilanes. 
2.4. Synthesis: 
Bonded silica is formed by the reaction of organosilanes with activated silica. The product 
is a sorbent with the functional group of the organosilane attached to the silica substrate 
through a silyl ether linkage. The intention is to create a surface whose principal 
properties are due only to the functional group, with minimum interactions from the silica 
substrate7. 
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2.5. Physical Properties: 
Chemically-modified surface 
Bonded silica is a rigid material that does not shrink or swell in different solvents. This is 
a distinct advantage over polystyrene-based resins as a wide range of solvents can be 
employed for washing and eluting the isolates. The bonded sorbents equilibrate rapidly to 
new solvent conditions. The particles of the sorbent are usually irregularly shaped, 
nominally of diameter 50 microns, and allow rapid solvent flow through the sorbent bed. 
This does have certain disadvantages in terms of extraction reproducibility, particularly 
from batch to the same cartridges and certainly when cartridges are supplied by different 
manufacturers. 
2.6. Chemical Stability: 
The sorbents are stable within a pH range of 2 to 7.5. Above pH 7.5, the silica substrate is 
susceptible to dissolution in aqueous solutions and below pH 2, the silyl-ether linkage is 
labile. As a result, the functional groups bonded to the surface will begin to cleave, so 
altering the sorptive properties of the adsorbent bed. In practical terms, though, it is 
possible to use the beds over the whole pH range since degradation is a finite process and 
sorbents are usually only exposed to solvents for a short length of time. 
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2.7. Solvation and Conditioning: 
To permit the sorbent to interact reproducibly with an isolate, the sorbent must be 
solvated and conditioned. This means, essentially, wetting the surface of the sorbent in 
order to create an environment suitable for analyte retention. Any solvent which will wet 
both the polar silica surface and the functional group can be used; most commonly 
methanol or acetonitrile is employed. The conditioning solvent must be miscible with the 
matrix of the isolate and the sorbent bed must not be allowed to dry out. 
2.8. Retention and Elution: 
Retention of the isolate is a function of the degree of attraction of a chemical species for 
the sorbent. Introducing a solvent to which the isolate is more strongly attracted than it is 
to the sorbent brings about elution. The eluant should elute the isolate from the bed in the 
smallest volume possible. Ammonia is used during SPE as better recovery rates are 
obtained than when sodium hydroxide is usedla 
2.9. Capacity and Selectivity: 
The capacity, of a given sorbent is defined as the total mass of a strongly retained isolate 
that can be retained by a given mass of the sorbent under optimum conditions. Capacities 
of silica vary, so it is necessary to consider capacity requirements of the isolate as well as 
any impurities likely to be present. Large columns may retain all the isolate but will then 
require large volumes of eluant to remove it. 
Selectivity is the ability of the sorbent to discriminate between the isolate and all other 
sample matrix components. The selectivity is then a function of the chemical structure if 
the isolate, the properties of the sorbent and the composition of the sample matrix. 
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Maximum selectivity is achieved when a sorbent is chosen that interacts through 
functional groups common only to the isolate and not the other components of the matrix. 
2.10. Analysis of Drugs in Biological Samples 
There are many instrumental methods that have been used for drug analysis after the 
sample has been extracted by SPE. HPLC analysis of biological samples after SPE has 
focused primarily on plasma or serum 14-17, urine 18-20 and CSF21. These are all matrices 
which easily pass through SPE cartridges. Fewer methods have focused on the inherent 
problems associated with post mortem specimens, particularly blood, which is often 
haemolysed and degraded, frequently causing column blockage and reducing extraction 
efficiency and recovery. 
Tebbett22 first reported the extraction of morphine and codeine from whole blood. 
Subsequently a modification of Tebbett's method, which again involved sonification and 
dilution, incorporated the use of Bond Elut CertifyTM columns (BECC). However neither 
method reported the isolation and detection of morphine conjugates23. 
Previous attempts to extract all types of drugs of abuse from a single aliquot of urine by 
SPE used lipophilic phases such as C18 or XAD-2, but these gave poor extraction 
efficiencies when selectively eluted, or else required matrix optimisation for each class, 
precluding a single extraction procedure. Many constituents present in the eluates 
interfered with the analysis when non-selective GC was used, but better results with clean 
extraction were obtained when GC-FID was used with a wide bore capillary column. The 
limit of detection was down to IOOng/ml, and recoveries averaged 93% for all drugs 
screened in urine over the concentration range 100-1000ng/m123' 24 
Recently, screening methods have been developed for acidic, neutral and basic drugs in 
urine using a single copolymer SPE column but this was not suitable for barbiturates. 
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However the use of Bond Elut Certify II gave good results. These cartridges contain a 
proprietary substituted silica sorbent that exhibits unique hydrophobic and ion-exchange 
extraction mechanisms and were first used to separate some drugs of abuse from urine 
(amphetamines, barbiturates and opiates) 17 
Determination of morphine in human blood is important for forensic toxicology, because 
of its frequent misuse. Also, it is one of the main metabolites of heroin, which has now 
become one of the most popular illicit drugs. Morphine is an amphoteric drug that may 
exist in different forms depending on the pH of the medium. There are several methods 
for the determination of morphine by GC and most of them need derivatisation. 
BECC's contain a mixed mode bonded silica gel, which consists of hydrophilic and cation 
exchange functional groups. The columns have been successfully applied for the 
extraction of various classes of drugs from plasma and urine as well as whole blood25. 
In a subsequent chapter the use of BECC for extracting drugs from blood is described 
which, as mentioned, is one of the mixed mode columns used for extraction of acidic, 
neutral, and basic drugs in one run. The validation of the method of extracting multiple 
drugs from each group by this column from small (1 ml) blood samples is also described. 
2.11. Components of Blood: 
Blood consists of a pale-yellow, coaguable fluid called plasma, which contains suspended 
various blood cells including erythrocytes, granulocytes, monocytes, lymphocytes, and 
platelets. Blood plasma contains 9% of solids, 4/5 consisting of different proteins which 
are of three types - fibrinogen, albumin, and globulin - which are separated by different 
techniques including salt precipitation, electrophoresis, and ultracentrifugation. 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 12 
The erythrocytes are considered to be slightly different cells compared to others, as the 
erythrocyte contains no nucleus or cytoplasmic organelles, and are responsible for the red 
colour of blood although they are pale reddish yellow in transmitted light. Their function 
transforming 02, therby is giving energy and protecting against oxidising agents26. The 
relatively short life of erythrocytes is 120 days. 
Granulocytes contain cytoplasmic granules and a segmented nucleus, with two masses 
connected by nuclear chromatin, These are highly mobile cells, whose function is to move 
towards infected sites and attack micro-organisms and subsequently envelope them by 
phagocytosis. They consist of three types - neutrophiles, eosinophiles and basophiles. 
Both eosinophiles and basophiles have phagocytic activity, but the phagocytic activity of 
eosinophiles is slower than that of basophiles. Eosinophiles, for example, have a diameter 
of 12-17µm 
Lymphocytes are small cells present in the blood which range in size from 7-12µm, and 
which can be subdivided into two major groups: B-lymphocytes (B-cells) and 
T-lymphocytes (T-cells), both of which are different in origin and function. 
T-lymphocytes are involved in cellular immunity (e. g. against viruses, fungi and low 
grade intracellular pathogens such as mycobacteria) and so have a role in graft rejection, 
tumour rejection, delayed hypersensitivity, interaction with B-cells in production of 
antibodies against certain antigens, and suppression of B-cell function with production of 
eosinophiles. B-cells mature into plasma cells for the production of antibodies as 
immunoglobulins. 
Platelets are small fragments of megakaryocytic cytoplasm, whose function is to produce 
energy, which are derived from the metabolism of glucose by the glycolytic pathway and 
tricarboxylic acid cycle. The energy is held as ATP within a metabolic pool that is 
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distinct from the storage pool of adenine nucleotides situated in the dense bodies. 
Platelets also play an essential role in the haemostatic mechanism. 
Blood is a complex mixture of cellular entities suspended in a fluid medium. Blood may 
change in its chemical rather than anatomical composition, for example, changes in pH at 
any given point vary considerably, as does the oxygen tension. Finally, to make the 
situation more complex, there is the fact that the blood is only one-half of the circulatory 
system, the other half being the blood vessels27. 
For foetal blood, and amniotic fluid discussed later, there have been several reports 
offering information on the concentrations of drugs and/or their metabolites in this 
fluid 28,29 . Drug determination in foetal and maternal blood can 
help identify those drugs 
that produce a therapeutic effect on the mother but do not cross the placenta easily30. In 
this manner it was determined that some drugs reach a concentration equilibrium in foetal 
and maternal blood 31,31,32 whereas others are not readily transferred through the placenta33 
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3. Investigation of Solid Phase Extraction of Multiple 
Drugs from Small Blood Samples 
3.1. Introduction 
The aims of this investigation were to establish the feasibility of performing a full drug 
screen on a small sample of blood such as that obtained from a neonate or infant, typically 
having a volume of I millilitre. Most individual analyses in routine toxicology practice 
use a 1-millilitre aliquot of blood so for 6 analyses, single replicate only, a total volume of 
6 millilitres is needed. 
Three types of approach can be considered. In the first, smaller aliquots than usual of the 
blood sample are analysed for specific drugs or drug groups. This implies that the 
analytical techniques used must be more sensitive, in terms of limits of detection and 
quantification. Analytical instruments continue to develop with respect to their inherent 
sensitivity but there is no likelihood of an imminent quantum leap in sensitivity in sight at 
present. As an alternative, a larger percentage of the extract must be used for each test 
than is used routinely (typically, 2% of an extract is used for each gas chromatography 
analysis). If 0.1 ml blood is extracted, 20% of the extract must be used for each gas 
chromatography run in order to obtain the required sensitivity. This is made possible by 
injecting large sample volumes, using an appropriate inlet such as a programmed 
temperature vaporiser34. 
The second approach is to use a microextraction technique such as solid phase 
microextraction (SPME) or liquid micro-drop extraction. In these techniques, a1 
millilitre aliquot of biological specimen is used but the extraction technique takes out only 
1-2% of the total analyte present and all of this extracted analyte is used in a single 
3s chromatographic run, 36 
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The third approach is to use a1 millilitre aliquot of the biological specimen and extract all 
of the analytes of interest from this one aliquot, i. e. take several extracts from the same 
specimen. Some previous studies have used this approach for routine forensic toxicology, 
typically giving extracts containing acidic, basic or neutral drugs, respectively36. This 
approach readily lends itself to solid phase extraction techniques, which is the method 
adopted in the present study. 
In this study, the previously-published method of Chen et a137. was adapted for use and 
evaluated using blood standards containing representative drugs from different drug 
groups, shown in Table 3.1. 
Table 3.1. Drugs used for Method Development 
Drug Group Representative Drug(s) 
Acidic Drugs Amylobarbitone 
Barbitone 
Butbarbitone 
Methaqualone 
Phenytoin 
Primidone 
Basic drugs Amphetamine 
Cocaine 
Codeine 
Imipramine 
Methamphetamine 
Morphine 
Procaine 
Clonazepam 
Diazepam 
Nitrazepam 
3.2. Experimental Section 
3.2.1. Materials: 
All chemical standards were purchased from Sigma-Aldrich (Dorset, UK). The solvents 
and concentrated ammonia were of HPLC grade supplied from BDH laboratories supplies 
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and Bond Elut Certify® columns with the capacity of 12x75mm test tubes were obtained 
from Varian (Harbor City, California, USA), and Abselut NEXUS columns were from 
Varian-Chrompack, Netherland BV Company (Herculesweg, Middelburg, The 
Netherlands). A Baker-20 SPE vacuum manifold system was obtained from international 
Sorbent Technology. Bistrimethylsilyltrifluoroacetamide (BSTFA) containing 1% by 
volume trimethylchlorosilane (TMCS) as catalyst was obtained from Pierce-Warriner 
(UK). Pentafluoropropionic anhydride (PFPA) was obtained from Sigma-Aldrich UK. 
Phosphate buffer (0-IM) was prepared by dissolving 6.81g of potassium dihydrogen 
phosphate in 450ml of deionised water, adjusting the pH to 6.0 ± 0.1 with 1. OM potassium 
hydroxide, then making the total volume up to 500m1 with de-ionised water. 
A 0.01 M acetic acid solution was prepared by adding 57.5 µL of glacial acetic acid to 
100ml of de-ionised water. 
Eluant (I) was prepared daily by mixing Chloroform to Acetone in the ratio 1: 1 v/v. 
Ammoniated ethyl acetate (2%) was used as elute (II) and prepared daily by adding i ml 
of ammonia to 49m1 of ethyl acetate. Both were sonicated for at least 5 minutes before 
use. 
The Internal standard for GC was prepared by dissolving the appropriate amount of 
prazepam in methanol/ ethyl acetate (1: 1) to make the solution equivalent to 200 µg/ml. 
Internal standards for GC/MS were deuterated morphine, cocaine, and benzoylecgonine 
purchased from Sigma-Aldrich, and deuterated methanol which was purchased from 
Radian Corporation (Austin, TX). 
Instrumental enzyme immunoassays were carried out using kits from STC 
Technologies, Inc. (Bethlehem, Pennsylvania). 
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3.2.2. Instrumentation 
(a) Gas chromatographic analyses were performed with a Hewlett-Packard Model 5890 
Series II gas chromatograph equipped with a flame ionisation detector (FID, 
temperature: 300°C). Helium (10ml/min) was the carrier gas. The analytical column 
was a Hewlett-Packard (HP I fused silica capillary column, 30m x 0.53 mm id x 
1.5µm film thickness). A 1.0 pl aliquot of each sample was injected using a HP 7673 
injector (injector temperature: 275°C) into the GC system described earlier. The 
column temperature was initially held at 80°C for 2 min and then programmed to rise 
to 215°C at a rate of 20°C/min and then to 285°C at 5°C/min. The temperature was 
held at 285°C for the final 2 minutes of the chromatographic analysis. Identification 
was achieved by comparison of retention times (tR) and quantification was based on 
the ratio of peak areas of analytes to the internal standard with the aid of standard 
calibration curves similar to the one presented in Figure 3.1 below. 
(b) Gas chromatography-mass spectrometry was carried out using a Hewlett-Packard 
5890 Series II instrument connected to a mass spectrometer detector and equipped 
with a fused silica capillary column (HP5,30m x 0.32 mm id, x 0.35 µm film 
thickness). Samples (volume 11il) were injected via a split-splitless injector with an 
injection port temperature of 200°C and an initial split valve off time of 1 minute. 
Helium was used as the carrier gas at a flow rate of 1.5 ml/min. The initial column 
temperature was 200°C and was programmed to NOT at a rate of 10°C/min. 
immediately after injection. The column was subsequently maintained at NOT for 1 
minute. The mass spectrometer was a VG Analytical 70/250 S double-focussing mass 
spectrometer operated at a resolution of 1000 amu and data were recorded by a 
Maspec 1 data system. The spectrometer was used in the EI+ mode with an electron 
energy of 70 eV and source temperature 220°C. The instrument was tuned daily using 
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PFK according to the manufacturer's recommendations. Mass spectra were obtained 
by scanning from 600 to 40 amu at a scan rate of 0.3 s/scan. 
3.2.3. Enzyme Immunoassay (EIA) Procedure: 
The EIA method used was an Enzyme Linked Immunosorbent Assay (ELISA) from 
Standard Technology Company (STC). This assay involves the enzyme horseradish 
peroxidase, which produces a blue colour with its substrate. 
All the reagents and samples were allowed to come to room temperature (15-30°C) before 
use. An aliquot of the extract after evaporation (200µ1) was diluted 1: 5 v/v in EIA buffer 
before use. All the samples, calibrators and controls were analysed in duplicate, using a 
25 µl aliquot of each. For each drug assay, calibrators at four different concentrations 
were used, comprising a negative calibrator, one at the relevant cut-off value, and one 
each at medium and high concentrations. The calibration curve was checked before the 
results were accepted. After addition of the test sample (blood extract, calibrator or 
control) to the microplate well, enzyme conjugate (100 41) was added and incubated for 
30 minutes. Using a suitable plate washer, each well was washed six times with 300 gI of 
distilled water. Substrate Reagent (100 µl) was added to each well and incubation 
proceeded for 30 minutes at room temperature. Stopping reagent (100 µl) was then added 
to each well and the absorbency was measured within 15 min at dual wavelengths of 450 
and 630 nm. All samples with an absorbance less than or equal to the Serum Cut-off 
Calibrator were considered to be positive, and if the absorbance was higher than that of 
the Cut-off calibrator they were considered to be negative. 
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Table 3.2: Cut-Off Values for EIA 
Drug Group Cut-Off (ng/ml) 
Opiates 5 
Methadone 25 
Cocaine 10 
Benzoylecgonine 10 
Barbiturate 20 
3.2.4. Solid Phase Extraction procedure: 
The SPE procedure was evaluated using standard drug solutions prepared in blank blood 
and generally consisted of the steps described below. 
(a) Sample preparation: 
Aliquots of blood (1 ml) in clean 20m1 test tubes were spiked with different drugs 
representing the acidic (methaqualone, barbitone, amylobarbitone, phenytoin, 
butobarbitone and primidone), basic (morphine, cocaine, ecgonine methyl ester, diazepam 
and desmethyldiazepam) and neutral drug groups, at a concentration of l0µg/ml for each. 
Phosphate buffer (3ml, pH 6.0) was added to each tube, which was then vortex-mixed to 
make them homogeneous. An amendment to this procedure, in some cases, involved 
adding the phosphate buffer first to the tube before the blood specimen to assist in its 
dispersion. 
(b) Column preparation: 
SPE Columns (130 mg size) were used for the analyses. The columns were conditioned 
with 2 ml of methanol followed by 2 ml of 100 mM phosphate buffer (pH 6.0). 
(c) Sample application: 
The blood samples were then applied to the SPE columns at a rate of 1-2 ml/min. 
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(d) Column wash: 
Following sample application, the columns were washed with I ml of de-ionised water 
followed by 0.5 ml 1.0 M acetic acid (pH 3.3). The columns were then dried for 4 minutes 
under full vacuum, then 50µl methanol was added under full vacuum to ensure complete 
removal of water. 
(e) Analyte elution: 
The analytes were eluted from the SPE columns with two eluants: one for acidic drugs, 
consisting of Ix4 ml acetone/chloroform (1: 1 v/v) and the second for basic drugs, 
consisting of 2x2 ml 2% ammoniated ethyl acetate, both at the rate of 1-2 ml/min. 
(fi End step analysis: 
Subsequently, the eluates were concentrated by evaporation under a stream of nitrogen on 
a hot plate set at 40°C. Extracts to be analysed by Enzyme Immunoassay (EIA) were 
evaporated until 400 µl remained. Extracts to be analysed by gas chromatography with a 
flame ionisation detection system (GC-FID) were evaporated under a stream of nitrogen 
at 40°C till l00µ1 remained, and for that analysis 100µl prazepam solution, previously 
prepared at a concentration of 200 µg/ml was used as internal standard. Extracts analysed 
by GC/MS were evaporated under nitrogen until l00µ1 remained then deuterated internal 
standards (cocaine d3, benzoylecgonine-d3, morphine d3, and methadone-d3,10ng of each) 
were added to each residue. The extracts for both GC and GC-MS were then derivatised 
with BSTFA catalysed with 1% TMCS for 20 minutes at 60°C. An additional evaluation 
was made of an alternative derivatising agent, pentafluoropropionic anhydride (PFPA) 
and these derivatives were compared with the trimethylsilyl derivatives with respect to 
their chromatographic properties and suitability for the developed method. For this 
procedure, the extracts, after evaporation, were dissolved in 100 µd of reagent containing 
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40% by volume of PFPA in ethyl acetate and then heated at 60°C for 30 minutes. After 
this time, the derivatised extracts were evaporated to dryness to remove the excess reagent 
and redissolved in 50 µl ethyl acetate prior to analysis. 
3.2.5. Comparison of two types of SPE column: 
A comparative study was made of two types of SPE column, Bond Elut Certify® and 
Abselut NEXUS®, for the simultaneous extraction of both acidic and basic drugs. This 
comparison was carried out using four test drugs only (methadone, morphine, cocaine and 
benzoylecgonine), by the same extraction method and the extracts were analysed by GC- 
MS as described above. The comparison between the two columns involved four aspects: 
recovery, lower limit of detection, cleanliness of the extracts, and analysis time for each. 
For measurement of recoveries, the internal standards were added after extraction and the 
analyte: internal standard ratios compared with those of unextracted standards. 
3.2.6. Method Validation 
Drug-free blood samples were spiked with different amounts of mixtures of drugs 
including barbiturates, cocaine, morphine, methadone, and ecgonine methyl ester and 
prazepam internal standard and analysed as described above. In this way, the limits of 
detection of the method and extraction recoveries were calculated for all the drug analytes 
of interest, which appear in figure 3.1. Identification was achieved by comparison of 
retention times (tR) and quantification was based on the ratio of peak areas of analytes to 
the internal standard with the aid of standard calibration curves similar to the one 
presented in Figure 3.2 below. 
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3.2.7. Application to cases: 
This method was applied to 12 cases resulting from the Road Traffic Act Section 4( which 
deals with cases of impaired ability to drive), each one consisting of blood not exceeding 
1 ml (i. e. a small amount) and these were initially analysed as described before by EIA, 
screening for methadone, opiates, cocaine and benzoylecgonine as examples of basic 
drugs, and barbiturates as a representative acidic drug group. 
3.3. Results and Discussion 
The mixtures of acidic drugs (methaqualone, barbitone, amylobarbitone, phenytoin, 
butobarbitone and primidone), basic drugs (morphine, cocaine, ecgonine methyl ester, 
diazepam, and desmethyidiazepam) were extracted by SPE then analysed in sequence by 
EIA for four drug groups (cocaine, benzoylecgonine, morphine, and methadone) as 
example of common drugs found in some road accidents, by GC/FID, using prazepam as 
IS, then by GC/MS. The same methods were used for two types of SPE column, both of 
which were suitable for mixtures of basic and acidic drugs. - The columns that gave good 
results were subsequently used for application to real road accident cases as an example 
of small samples (each one not exceeding 1 ml). For each instrumental method, the 
retention time for each drug was established, calibration curves were prepared, and lower 
limit of detection measured. 
3.3.1. Gas Chromatography 
The retention times for drugs obtained by analysing standards by GC-FID, are shown in 
Table 3.3. 
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Table 3.3 Retention times of drug standards in the GC-FID system. 
Drug Retention time 
(min) 
Ecgonine methyl ester 7.8 
Butobarbitone 8.9 
Amylobarbitone 9.2 
Methaqualone 13.7 
Cocaine 14.2 
Morphine 14.5 
Primidone 14.6 
Phenytoin 16.0 
Diazepam 17.5 
Desmethyldiazepam 18.2 
Prazepam 20.4 
The calculated recoveries based on analysis of spiked samples containing the 
representative drugs was as shown in Figure 3.3. 
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Figure 3.1 Percentage recovery of drugs by SPE based on GC-FID analysis of 
extracts 
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Calibration curves for quantitative analyses were linear, with correlation coefficients (r2) 
in the range 0.987-0.986 for all drugs. A typical example is shown in Figure 3.2. 
Co 0.6 
a) c 0.5 
`3 ß 0.4 
Q'0.3 
m in 0.2 
c 
Q 0.1 
c) (L) 0 
123456 
Concentration in ug/ml 
Figure 3.2 Typical calibration curve, in this example used for the quantification of 
cocaine in blood. 
The lower limits of detection by this method varied from one drug to another so for 
barbiturates ranged from 2-25 ng/ml, while for the basic drugs cocaine, methadone, and 
ecgonine methyl ester it was 1 ng/ml and for morphine is was l Ong/ul. Derivatisation was 
carried out using two reagents, BSTFA and PFPA. With PFPA the test drugs appeared in 
form of clean peaks with no background noise, but some of the drugs had the same 
retention times. As a result, the separation was not good enough for this derivative to be 
used routinely. Also, the limits of detection and ultimate sensitivity of the method were 
lower than when derivatised by BSTFA. When BSTFA was used, all of the standard 
peaks had different retention time as shown in Table 3.3 Silanisation was subsequently 
selected as the most appropriate procedure for the final method. 
The combination of solid phase extraction with gas chromatographic separation proved to 
be a valuable one in which all the drug appeared with no significant interference either 
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with each other or with co-extracted materials and the eluates were clean extracts. This 
method was applied subsequently to other biological fluids. 
3.3.2. GC/MS: 
The extraction procedure was carried out as described earlier using, as representative 
drugs cocaine and its major metabolite benzoylecgonine, morphine and methadone. In 
this procedure, deuterated internal standards were used for each drug, and extracts were 
derivatised with BSTFA prior to GC/MS analysis. The instrument was operated in the 
selected ion monitoring (SIM) mode. Quantification was based on determination of the 
response factor against the deuterated form. Retention times and the ions used for 
quantification were as shown in Table 3.4. Calibration curves were also linear for 
GC/MS. 
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Table 3.4 Selected ions used for quantification and retention times 
for drug standards 
drug Molecular ion Retention time (min) 
cocaine 303 7.2 
cocaine-d3 306 7.2 
benzoylecgonine 361 8.2 
benzoylecgonine-d3 364 8.2 
morphine 429 9.1 
morphine-d3 432 9.1 
methadone 72 4.5 
methadone-d3 75 4.5 
2.5.1 Comparison between two columns: 
GC/MS was used to compare two types of SPE column, both of which were suitable 
for simultaneous extraction of acidic and basic drugs, Bond Elut Certify as used and 
described above for the GC-FID procedure, and Abselut NEXUS columns. This 
comparison was carried for four drugs mentioned above, following the same extraction 
method and derivatisation using BSTFA before GC-MS analysis (using the instrumental 
conditions mentioned earlier). The comparison between the two columns involved four 
points (recovery, lower limit of detection, presence of interferences in the extracts and 
analysis time required by each). Each analysis was carried out in duplicate, in one set 
adding the IS before the extraction, and in the other adding the IS after the extraction. 
The former showed relative recoveries whereas the latter showed absolute recoveries. 
The recoveries obtained were as shown in Figures 3.3 and 3.4. In general, lower 
recoveries, both relative and absolute were obtained with Abselut columns. 
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Figures 3.3 Recovery with IS added before the extraction. 
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Figure 3.4 Recovery with I. S added after the extraction. 
Comparison between the two column with respect to the lower limits of detection 
indicated that the Bond Elut Certify columns were generally more effective and permitted 
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the detection of methadone down to I ng/ml, morphine to 10 nglml and cocaine and 
benzoylecgonine to 20 ng/ml, while the absolute column gave a lower limit of detection 
for methadone of 10 ng/ml, for morphine 10 ng/ml and for cocaine and benzoylecgonine 
of 50 ng/ml. 
The last points in the comparison were purity of the extracts and the time consumed. 
The evaluation indicated that the time required was more for the Bond Elut columns, 
which took about 25-30minutes to complete the extraction, while the Abselut columns 
took about 15-20 minute. However, the background noise due to co-extracted impurities 
was more significant with the Abselut cartridges than with Bond Elut. The columns used 
for the evaluation all came from the same batch. 
From the evaluation, it was assessed that Bond Elut columns were better than Abselut 
columns and the final method therefor consisted of SPE with Bond Elut Certify followed 
by silanisation with BSTFA and analysis by GC/MS. 
3.3.3. Application to real cases: 
This method was applied to 12 cases resulting from the Road Traffic Act Section 4, which 
were analysed by EIA and GC/MS. Having established the linearity of the method, 
quantification was based on a reduced calibration set of two spiked blank bloods with 
known concentrations of standards (IOng/ml, and 50ng/ml). 
The results of analysis of the 12 cases by EIA and GC/MS are given in Tables 3.5 and 3.6 
below 
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Table 3.5 Results of EIA analysis of 12 blood specimens from car drivers. 
Case No Methadone Opiate Cocaine Benzoylecgonine Barbiturate 
1 negative negative negative positive positive 
2 negative negative positive positive positive 
3 negative negative negative negative positive 
4 negative negative negative negative negative 
5 negative negative positive negative negative 
6 negative negative negative negative negative 
7 negative negative negative negative negative 
8 negative negative negative negative negative 
9 positive positive positive negative negative 
10 positive positive positive negative negative 
11 negative negative positive negative negative 
12 negative negative positive negative negative 
Negative negative negative negative negative negative 
Control 
Table 3.6 Results of GC-MS analysis of 12 blood specimens from car drivers. 
Cases Concentrations of detected drugs 
Methadone Morphine Cocaine Benzoylecgonine 
1 negative negative negative 89ng/ml 
2 negative negative 60ng/ml 120ng/ml 
3 negative negative negative negative 
4 negative negative negative negative 
5 negative negative 66ng/ml negative 
6 negative negative negative negative 
7 negative negative negative negative 
8 negative negative negative negative 
9 35ng/ml 215ng/ml 36ng/ml negative 
10 50ng/ml 125ng/ml 50ng/ml negative 
11 negative negative 8Ong/ml negative 
12 negative negative 11Ong/ml negative 
Control negative negative negative negative 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 30 
3.4. Conclusions 
SPE has been established as a useful technical procedure in analysis of mixture of drugs 
especially in small samples. It has been shown that analysis can be carried out using a 
single column, saving both time and expense, but at the same time giving good results and 
high sensitivity. 
The survey of the current state-of-the art presented above clearly shows that the 
determination of drugs in blood can be carried out using small amounts of blood for both 
the analytic and confirmatory test, by EIA, GC/FID and GC/MS. This solves the 
problems which face the analyst when only limited material is available for testing, such 
as impairment testing in drivers, as well as in blood from the foetus or neonate. In the 
subsequent studies carried out for this project, these analyses were used to establish if 
mothers consumed drugs during pregnancy following further evaluation of the method to 
establish its applicability to meconium. 
Subsequent Chapters review the use of illicit drugs with particular reference to the mother 
and foetus and then the biological specimens which have previously been used to assess 
maternal drug use during pregnancy. 
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4. Review of Illicit Drug Use 
The work described in this thesis is largely concerned with the use and abuse of illicit 
drugs. Some background information on the pharmacology of these substances is relevant 
to setting the perspective by which the problems tackled during this project should be 
assessed and is presented below for three of the main groups of illicit drugs. 
4.1. Cocaine 
4.1.1. History 
The world coca comes from Aymara KhoKa meaning the tree. Large quantities of 
cocaine and nicotine have been detected in 3,000- year old Egyptian mummies, although 
there is no known route by which coca might have been available in ancient Egypt. 38 it 
grows best on the moist, warm, slopes of mountains ranging from 1,500 to 5,000 feet, 
where the coca shrubs grow to heights of 6-8 feet. The trunk of the plant is covered by 
rough, somewhat glossy bark that has a reddish tint. It has greenish yellow leaves which 
are elliptical pointed at the apex and dark green in colour. The cocaine refining process is 
done by adding potassium permanganate to remove impurities, for example 
cinnamoylococaine is converted to ecgonine which is water soluble and easy to separate 
from cocaine. If the process is allowed to continue for too long, the cocaine itself is 
degraded and the yield drops. Norcocaine, which may be hepatotoxic, is formed at the 
same time. 39 
The first isolation of cocaine was in 1857 by Tschudi, 40 and many papers have been 
published on the effects of cocaine on humans. In the early 1880's, the Parke Davis4' 
company began marketing a fluid extract containing 0.5 mg/ml of semipurified cocaine 
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and after that it was used in a variety of elements. Two events occurred in 1884 that 
significantly changed the pattern of cocaine use in the United States and Europe. The first 
was the publication of Freud's paper which discussed the benefits of cocaine use. The 
second was Koller's discovery that cocaine was a local anaesthetic, which first led to its 
use in opthalmological surgery, then to the treatment of morphine addiction and in 1870 
to its use in haemorrhoid surgery and hay fever. 42 
4.1.2. Chemical Properties 
COOCH3 
CH3 N OCO 
Figure 4.1 Chemical structure of cocaine 
The free base has the formula C17H21NO4 with a molecular weight of 303.4. The pure 
form has colourless crystals or white crystalline powder. It is odourless and has a bitter 
taste. Its melting point is 98°C. However it becomes volatile at 90°C. The pKa at 15°C is 
5.5943. It is soluble in water, acetone and ethyl acetate. The most important compound is 
cocaine hydrochloride, with a formula weight of 339.8. This has a slightly bitter taste. 
The melting point is 195°C and it is also soluble in chloroform, glycerol, and acetone. 
Solutions are stable for at least 21 days, provided the temperature is below 24°C and pH 
below 4.0.44 
4.1.3. Routes of Administration 
Cocaine is taken by many different routes: leaf chewing, snorting, injection and smoking. 
The average blood level is 38ng/ml one hour after administration by chewing. When 
snorted, the peak plasma concentration is proportional to the amount of cocaine ingested45 
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as it inhibits its own absorption but if taken in large amounts the time for absorption will 
be longer, but there is no difference between snorting and chewing. When taken by the 
intranasal route, the blood level is lower, especially in surgical applications (plastic surgery 
or otohumonagologists) as it is used in combination with epinephrine to maintain a dry 
field. The highest concentrations are obtained after intravenous administration, but this 
produces more complications, especially inflammation. 
Genital or rectal application is used, especially in homosexuals and gives high blood level 
as it is highly absorbed by the transdermal route, hence its use in local anaesthesia. 46 The 
plasma level of cocaine in many children is found to be high due to the use of crack 
cocaine by their parents. ( passive rout) 
The last main route for absorption is by the gastrointestinal tract (GIT) and this is 
important in the body packer syndrome which is due to absorption of a large amount of 
packed cocaine after one or more packages is ruptured or leaked. These can be observed 
by abdominal X-radiography, CT scanning and barium contrast studies. 47 
4.1.4. Maternal / foetal Considerations 
The effect of cocaine use by pregnant mothers is studied in animal models and it has been 
found that after 5 minutes of maternal infusion the foetal concentration reaches about 12% 
of that of the mother. 48 In the lactating mother, after 30 min-2 hour cocaine levels 
become 3-4 times higher in liver than in the blood; after 30-90 min. foetal brain 
concentrations were 50-90% those of the mothers and 1-5 times higher than blood; 
cocaine also appeared in the mother's milk. There is research on identification of cocaine 
and benzoylecgonine, along with cotinine and caffeine, in cord blood49 
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The human placenta has high affinity biniding sites for cocaine. In isolated perfused 
cotyledons of normal term human placenta, cocaine is passively, but rapidly transported 
without undergoing metabolic transformation. In the in-vitro model, the direction of 
transport depends entirely upon the relative concentrations of cocaine in the mother and 
foetus: when foetal levels are higher than maternal levels, equally rapid transport back 
across the placenta occurs. The results obtained with perfused human cotyledons suggest 
that the placenta may, under appropriate circumstances, act as a depot, initially absorbing, 
then slowly releasing, both cocaine and benzoylecgonine into foetal circulation. If the 
placenta acts as a buffer, then it may keep the infant from being exposed to large doses of 
cocaine taken as an IV bolus. On the other hand, storage and slow release by the placenta 
probably would ensure that the foetus is chronically exposed to low levels of drugs. The 
results of animal studies suggest that high maternal/ foetal cocaine ratios occur in humans 
as well as in animals. The ratio was 9/1: this high ratio may reflect cocaine-induced 
vasospasm and reduced flow to uterus. 50 
In cases of infant crib death it was found that the level of cocaine is higher in hair than in 
urine, and the amount found in foetus is due to cocaine metabolism in foetus as it cannot 
clear as quickly as the mother. Cocaine could be measured in saliva, vitreous, 
cerebrospinal fluid (CSF), breast milk, urine, amniotic fluid but gave the highest 
concentrations in meconiums t 
Neonatal exposure to cocaine, opiates and cannabis, can be detected in meconium by 
modified standard immunoassays. Comparing meconium to cord blood, it contains a 
greater number of cocaine metabolites than the blood, including norcocaine and 
benzoylecgonine. These same drugs can also be detected in hair and, if available, brain. 52 
If a high concentration of benzoylecgonine can be detected with low or absent cocaine 
level, this suggests a pattern of long term exposure during pregnancy but no recent drug 
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abuse, and the opposite means recent exposure to cocaine. The presence of cocaethylene 
indicates that the mother was also consuming alcohol but as the cocaethylene has much 
longer half-life than cocaine, no cocaine may be detected, even though other cocaine 
metabolites will be present. 53 
4.1.5. Metabolism: 
Cocaine is rapidly cleared from the blood stream with a steady state volume of 
distribution of 2 L/Kg. Elimination clearance is 2.0 L/minute and the half-life varies from 
0.5-1.5 hours, all these measurements being done in volunteers. It may differ in that 
cocaine is stored, with changes in its rate of excretion, when cocaine consumption is 
measure in gram quantities, as in crack cocaine users, with small amounts of cocaine 
being excreted in urine. 
In the absence of alcohol, benzoylecgonine (BEG) and ecgonine methyl ester (EME) are 
considered the principal breakdown products. EME is formed by hepatic esterase and 
plasma cholinesterase, but if these enzymes are deficient, cocaine is shunted via the BEG 
route. There is evidence that the cholinesterase level affects the toxicity of cocaine. The 
half lives of BEG and EME are much longer than that of cocaine, equalling 6 and 4 hours 
respectively. Benzoylecgonine can be detected in plasma for 24 hours but this differs 
according to route of administration. BEG is stable for as long as 3 years in urine samples 
with pH in the region of 3.5, but if increased to pH 9,100% will have disappeared in 30 
days. 54 
Neither of the metabolites is pharmacologically active, although results have shown that 
benzoylecgonine is cytotoxic and causes spasm of coronary and /or cerebral vessels. 
Spasm induced by cocaine is due to its adrenergic effect even although benzoylecgonine 
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is not an adrenergic agent, and the possibility exists that it causes spasm through other 
mechanisms such as calcium flux and calcium channel regulation. 55 
4.1.6. Foetal Metabolism: 
The human placenta plays a role in protecting the foetus as it has cholinesterase activity 
and metabolises cocaine, possibly affording the foetus a degree of protection. In animal 
studies, newborns develop higher blood levels than adults receiving the same dose, and 
their plasma and tissue levels decline. Infants born to cocaine using mothers may have 
persistently elevated cocaine levels for days. However, there is a causal relationship 
between persistently elevated levels and prenatal stroke or intraventricular haemorrhage. 
The reverse occurs with its metabolites, as benzoylecgonine, which increases its activity 
in pregnancy. 56 The mother clears the metabolites much more quickly than the foetus. In 
a recent study by Meeker and Reynolds (1990)57 it was found that the metabolite level in 
the mother is about 20-30 times higher than in the foetus, but there is low or no ecgonine 
methyl ester as the enzymatic pathway required to form this is poorly developed. 
4.1.7. Pharmacological Effects 
The effects vary according to the level in blood, so if it is rising it causes euphoria and 
mood elevation and if it increases above 5,000 ng/ml it causes seizure, respiratory 
depression or even death. In chronic users, a decrease in its level causes dysphoria. 
However, there is no level that can be considered either safe or toxic. 58 
Cocaine is lipophilic so it easily crosses the blood brain barrier giving high concentrations 
in the CNS, which has a high density of cocaine receptors in striatum. Cocaine, like some 
drugs of abuse causes its effects through disturbance of catecholamine systems (cocaine is 
a potent sympathomimetic agent). These also produce most of the complications as there 
are two types of receptor: Bi receptors are found in the heart and when these receptors are 
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stimulated, another G-protein is activated and adenyl cyclase activity is increased. The 
results include increase in heart rate, contractility, and conduction velocity. B2 receptors 
are found on bronchi and smooth muscle, and also exert their effects by activating a G- 
protein and adenyl cyclase. Stimulation of the B2 receptors causes dilation of bronchi and 
blood vessels. When the receptors on vessels are stimulated, adenyl cyclase is inhibited, 
sympathetic flow increases catecholamines, leading to increased alfa-adrenergic 
stimulation of coronary vascular smooth muscle, leading in turn to vasoconstriction and 
ischaemia. 59 The oxygen demand is increased when cocaine is used, with changes in 
membrane potentials, which causes malignant ventricular arrhythmia. In chronic users, 
sudden death may occur. The concentration of cocaine increases in the heart 2-3 minutes 
after injection, causing changes in myocardium to produce contraction and necrosis. 
Cocaine causes perforated septum, crack keratinitis (anaesthesia of the cornea also), 
erosion of the enamel of the upper front teeth (due to the teeth being bathed with acidic 
cocaine hydrochloride), and crack thumb, described in 1990. Crack smokers produce 
burns to the thumb with the serrated wheel of a lighter or torch, which present on the ulnar 
aspect of the thumb, and also contact with the heated crack pipe causes superficial burns 
on the palmer aspect of the hands. 60 Chronic users display blackened hyperkeratotic 
lesions on the palmer aspect of the hands, bite marks on the lips and tongue and also 
experience seizure activity as a terminal event. 
Subcutaneous drug injection is more common amongst heroin than cocaine users, and 
cocaine users who elect to use this route generally experience fewer complications in the 
form of cellulitis, lymphangitis, lymphadenopathy, and oral infections which may 
required treatment with antibiotics or with severe cases surgery is required. Scleroderma 
is an uncommon disease. 61 Scleroderma and cocaine abuse share certain common 
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features. Vascular abnormalities are common in both, particularly in the heart, especially 
myocardial infarction. 62 
4.1.8. Cocaine related Deaths 
The first case of death due to cardiac arrest was reported in 1986 and in 1987,50 cases of 
cocaine toxicity were reported, four of which were fatal. 63 In 1994, the DAWN survey 
reported 3,981 but in the 1992 report, 3.220 and in late 1994 6,500 comprising 75% men, 
56% in whites, 30% black, 12% Hispanics, 45% ruled accidental, 22.4% suicides 46% 
unknown in 26-34 year age group, 53% due to cocaine while in age 35.44 (49%). 58 In 
Scotland a recent survey of cases of drug related deaths no cases were determined as 
cocaine deaths in 1998, and around 1% cases in 1999, and no cases again had cocaine as 
the cause of death, but cocaine was recorded in 2% as a contributory cause along side 
other drugs in 2000. 
4.2. Methadone 
4.2.1. Introduction: 
The discovery of methadone has been attributed to two German scientists, Max Bockmuhl 
and Gustav Ehrhart. The drug was first created in 1937 and was initially given the name 
Hoechst 10820 that was later changed to Polamidon. 64 The patent application for 
methadone was filed in September 1941. Although the structure of the new compound 
had no resemblance to morphine, its analgesic and spasmolytic properties were 
ascertained in 1942 when it was handed over to the military under the code name Amidon. 
Since then its use has not become very wide as it has significant side effect, but it was 
discovered that the side effects are due to high dosage. 65 
In 1965, it was introduced as a maintenance drug for heroin addicts. Methadone enjoyed 
little popularity, probably because in some individuals, its half-life can exceed 50 hours. 
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Today, it is the drug of choice for the treatment of heroin addiction and is frequently 
prescribed to cancer patients. It has been suggested that it may even normalise, a 
depressed immune function in heroin addicts, but its use must be controlled especially as 
it also faces big problems of addiction. 66 Despite this, early advertisements in the UK 
claimed little chance of addiction, and the general consensus was that it was better 
analgesic than morphine. 
Home Office statistics on the numbers of methadone users found only 21 methadone 
addicts in 1955. By 1960 the number had risen to 60 cases, then in 1968 with the 
introduction of the Home Office Notification System, 297 methadone addict were 
registered, which in turn increased to 1687 cases in 1969 with the introduction of new 
drug clinics. 
At present in the UK, most Health Authorities have a methadone prescribing service of 
some kind. At the present more than half of methadone adduct are known to the Home 
Office because methadone is a prescribed drug by law. 
4.2.2. Prescription: 
The principle use is for morphine/heroin addiction, but methadone is also used as a linctus 
for the treatment of coughing in terminal illness. It is prepared in form of liquid 
methadone, concentration 1 mg/ml, which is the licensed medicine in the UK for treatment 
for of coughing in terminal illness and as a suppository, which is not preferred in the 
treatment of opiate addiction. The other form is a 5-mg tablet (Physeptone®). Most 
addicts prefer this as it is easily crushed and injected. The last form is injectable 
methadone, concentration 10mg/ml, used IV, IM or subcutaneously. The IV route is 
preferable to addicts as it produces a rapid effect. 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 40 
4.2.3. Chemical Properties 
CH3 
C2HS000CH2CHN(CH3)2 
Figure 4.2 Chemical Structure of Methadone (C12H27NO) 
Methadone (6-dimethylamino-4,4-diphenyl-3-heptanone) has a complex structure with a 
wide range of effects67. It was found that methadone has two active sites in its structure - 
the nitrogen atom and the phenyl groups. Its effect is principally on the peripheral 
nervous system and due to the two phenyl rings produces opiate-like actions and on the 
central nervous system, hence its use in opiate addiction to control withdrawal symptoms 
and relief of distress, but it may cause anxiety, and some psychological discomfort. 
4.2.4. Absorption and Metabolism 
Methadone is taken either orally or by injection. It is absorbed rapidly when taken orally 
the peak blood concentration being reached after 15-30 minutes. The volume of 
distribution is quite large, with high concentrations of the drug being found in the liver, 
lungs, kidney and spleen. The clearance rate is slow, but this is affected when taken with 
other drugs, which may increase toxicity, and with alcohol, which increases its 
metabolism leading to withdrawal symptoms, and with cocaine, leading to an increase in 
its excretion, so to decreased plasma levels. 68 
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Methadone has two major metabolites, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
(EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-l-pyrrolidine (EMDP), both of which are 
inactive. There are other minor pathways including hydroxylation to methadol, and N- 
demethylation to normethadol: there are more than eight metabolites known. 
4.2.5. Pharmacokinetics: 
The methadone causes development of tolerance in individuals with increases in the dose 
until it causes death, sometimes due to respiratory depression with increased level in 
plasma, and when the level decreases below 50ng/ml this leads to withdrawal symptoms. 
The main route of excretion is via the kidney into urine, mostly within 24 hours, with up 
to 33%, as unchanged methadone, 43% EDDP and 5-10% EMDP. The half-life ranges 
from 12-25 hours, although this changes when taken as a single dose or multiple dose. 69 
The LD50 for methadone is 50mg/Kg, however tolerance may appear slowly compared to 
other opiates. Other pharmacokinetic data are: volume of distribution 5 L/Kg, clearance 
rate 2 ml plasma /min/Kg, plasma to whole blood distribution is 1: 3, with 90% bound to 
protein. 67 
4.2.6. Leal Status 
The Misuse of Drugs Act put methadone (Physeptone) under Schedule 2 as it is 
considered a Class A drug. This means that it is illegal to possess methadone without a 
prescription or other authority. 
4.2.7. Methods of Analysis of Methadone 
There is a method for the detection of methadone in the neonate, which will be 
mentioned. There are many methods used for its analysis in adults, but the more specific 
method is by GC/MS using SIM70 also use GC/FID7' extracted by L. L. E from plasma and 
urine, and from blood urine stomach content, bile and other tissue. Other use GC/ECD72 
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detects it from serum or extracted from plasma and urine by GC/MS73 or use GC/NPD74 
All this method extract sample first by L. L. E, also SPE with LC-MS used by Verweij, et 
al 1996 75 or followed by HPLC 76 and CE 77 from serum, urine, and hair. 
4.2.8. Matemal/Foetal Considerations: 
Maternal methadone levels correlate significantly with neonatal plasma methadone and 
metabolite levels at least during the first day of life. There are symptoms of CNS 
withdrawal which appear with decreasing infant plasma methadone levels. Measurement 
of the methadone level 16 hours after delivery found a maternal concentrations of 
183ng/ml while in the infant it was 26ng/ml. Methadone levels decrease in the infant at 
the average rate of 0.2± 0.3ng/ml hour. 78 
4.2.9. Methadone Related deaths 
There are many cases of death due to methadone reported in the 1994 DAWN survey, 
which reported 367 methadone related deaths, which represent 4.1% of all reported 
narcotic deaths in this year. This was a decrease percentage of death gradually declining 
from 7.5% in 1990, the cause of this is not known but may be due to an increase in the 
total number of methadone maintenance programmes. 79 
The autopsy findings often include bronchopneumonia, since the most common cause of 
death is respiratory depression. Chronic persistent hepatitis is a frequent finding in 
methadone related deaths. Inflammatory infiltrates, without evidence of necrosis, are 
commonly seen in the portal triads of heroin abusers. Opiate abusers enrolled in 
methadone programs are very likely to be infected with hepatitis C, with or without 
histological changes-80 In Scotland in the last three years it was found that the proportion 
of methadone deaths is around 3% in 1998, and 1999, while it decreased to 1% in 2000. 
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However, methadone was also present in cases involving other drugs - around 10% in 
1998, and 14% in 1999 and 2000. 
4.2.10. Tissue Concentrations 
Methadone tends to concentrate in the liver, but often blood levels equal or exceed hepatic 
levels when measured at autopsy. 
4.3. Opiates 
4.3. I. Introduction 
The opiates are a group of drugs derived from the opium poppy (papaver somniferum). 8' 
Opium poppies can be seen on coins and in drawings that antedate written mention in the 
Greek literature by at least 1,000 years. 82 In Greece the poppy was called opion. The 
term was derived from the word for juice (opos). Translated into Latin, opion becomes 
opium. It was used for sleep, occasionally everlasting. The cup given to Socrates 
contained the standard solution used at the time for purposes of euthanasia and suicide, a 
mixture of hemlock and opium, also used as analgesics dates back as early as 7th century 
BC in the Assyrian medical tablets. 83 
Opium was used after that in medicine in Europe, then in 1868 when the first pharmacy 
act became law its use was restricted. In addition, after World War I, Britain 
implemented an international agreement to prohibit non-medical use of opiates due to the 
large number of post war addicts. 84 Opium poppies contain morphine and codeine, both 
used as pain killers. C. R. Wright, a researcher at St. Mary's Hospital was the first to 
synthesise heroin (diamorphine) from morphine. At the beginning it was used for 
treatment of morphine addiction due to ignorance of its liability for abuse. 85 After that a 
number of synthetic opiates were manufactured as pain killers, including pethidine, 
dipipanone and methadone. These are often referred to as opioids to distinguish them 
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from substances that come directly from opium. Heroin is considered to be one of the 
major problems affecting health and a Home Office Notification system was set up in 
1968. In 1993, the number of registered addicts was 27,976. This estimation depends on 
the number of persons who register with their GP and is an under estimation - the number 
of actual opiate addicts may be greater than 125,000. 
4.3.2. Prescription: 
The most important use for opiates is as painkillers, but they are also used as cough 
suppressants and anti-diarhoea agents. 86'87 Table 4.1 shows the opiates/opioids 
commonly prescribed and their uses and names. In the U. K. morphine is favored by most 
doctors for the treatment of severe pain. 
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Table 4.1 Opiate-Based Medicines 
Name Proprietary name(s) Treatment indication 
Alfentanil Rapifen Pain 
Buprenorphine Temgesic Pain, premedication 
Codeine Diarrest, Cocodamol Anti-diarrhoea, pain 
Dextromoramide Palfium Pain 
Dextropropoxyphene Co-proxamol, Distalgesic Pain 
Diamorphine Pain (IV), cough 
Dihydrocodeine Dfl 18 Forte Pain 
Diphenoxylate Lomotil, Tropergen Anti-diarrhoea 
Dipipanone Diconal Pain 
Fentanyl Durogesic Pain 
Loperamide Imodium, Loperagen Anti-diarrhoea 
Meptazinol Pain 
Methadone Physeptone Pain, cough 
Morphine MST Continus, Kaolin®, Oramorph 
SR®, Sevredol® 
Nalbuphine Nubain Pain, premedication 
Oxycodone Pain 
Papaveretum Pain 
Pethidine Parnergan' Pain 
Phenazocine Narphen Pain 
Phenoperidine Pain 
Pholcodine Copholco, galenphol Cough 
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Tramadol Zydol SR Pain 
4.3.3. Chemical Properties 
2 
7 
Figure 4.3 Chemical Structure of Opiates 
Changing the group RI (at position C3) and R2 (at C6) gives the structures of the three 
most important opiates: diamorphine, which contains COCH3 at R1 and R2; 6- 
monoacetyl morphine (6-MAM) which has COCH3 at R2 and H at R1; morphine in 
67 which H is present at both RI and R2. 
4.3.4. Metabolism& Elimination: 
(a) Morphine: 
Once morphine enters the blood stream, it is quickly distributed throughout the body to 
the areas with the highest blood flow, so the highest levels can be measured in lung, 
kidney, liver, spleen and muscle. 88 Morphine also crosses the blood-brain and placental 
barriers. One third of morphine is protein bound and any change in this ratio (like in 
hepatic disease) causes an increase in the level of free morphine. Small amounts are 
excreted unchanged in the urine (10%) and about 70% is converted to glucuronide and 
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excreted through the kidney. Any disease affecting the kidney causes changes in 
elimination. Morphine enters the enterohepatic circulation and morphine excreted in bile 
had an average concentration of 312 mg/1.89 
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Figure 4.4 Metabolic Pathways of Opiates 
Morphine is rapidly absorbed whatever the route of administration: if taken orally it is 
completely absorbed after 30-90 minutes, but the resulting plasma peak concentrations are 
only 10% of those obtained if taken IV. After absorption, morphine then undergoes 
metabolism in liver so its bioavailability is reduced. The degree to which morphine is 
subjected to extraction and metabolism by GIT is affected by many factors including age, 
liver disease, gender, food effects, disease state and genetic polymorphism. Because of 
these effects less than a quarter of a given dose enters the blood stream. The plasma 
levels after rectal administration are higher than with oral morphine, but less than IV 
levels. As morphine is not sufficiently fat soluble it is poorly absorbed through the skin in 
quantities sufficient to produce psychological effects, but other opioids, particularly 
fentanyl, sulfentanyl and meperidine are well absorbed. 90'91 Therapeutic plasma morphine 
concentrations are usually in the range of 0.0 1 -0.07mg/l. 
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The elimination of morphine is best described as a biphasic process, in the first phase 
which take few minutes and rapidly disturbed through the tissues with the highest blood 
flow, transformed to its principal metabolite morphine 3-glucuronides which is done 
rapidly and small amount of M-6-glucuronides. The second phase take from one to eight 
hours, with two hours as the most widely accepted value, for the conversion of morphine, 
both metabolites are highly ionised and lipophilic so cross the blood brain barrier 
rapidly. 92 
(b) Diamorphine 
Diamorphine is the active ingredient of heroin. It is rapidly absorbed and hydrolysed after 
about 3 minutes to 6-MAM in blood, then slowly to morphine. A small amount is 
converted to normorphine. All of the metabolites can be conjugated with glucuronic acid 
to form glucuronide derivatives. After intravenous administration of 4-5mg diamorphine 
the blood concentration declines to O. Olmg/l within 10 min. The estimated LD50 for 
diamorphine in man is 200mg. However, addicts can tolerate up to 10 times this amount 
and fatalities have been known after only 10mg. The peak heroin concentration in blood 
can occur within five minutes of intranasal or intramuscular administration. The mean 
elimination half life was 5-4 minutes after intranasal administration compared to 4-2 
minutes after IM, and the elimination half life was longer for 6-MAM than for heroin 
when taken by inhalation and its peak declines within 30minutes of smoking. 
Morphine and heroin are present also in saliva but saliva measurements must be taken 
with caution since the oral or intranasal use of these drugs may result in very high saliva 
levels due to contamination of the oral cavity. 93 A comparison between saliva, plasma, 
and urine disclosed that urine concentrations were 100 times greater than the levels in 
saliva and 16 times higher than in plasma. Heroin appears in saliva much more quickly 
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than morphine, but neither compound can be detected in saliva for much longer than 12 
hours. The correlation between saliva and plasma levels of methadone appear to be 
excellent, and this drug can also be measured in CSF. 93°9a 
4.3.5. Maternal/Foetal Considerations 
It has been recognised for more than a century that morphine can be transmitted from the 
mother to her foetus through the placental barrier before birth and through breast milk 
after birth. Depending on their lipid solubility, narcotic agents passively diffuse across 
the placenta. In morphine users, the peak placenta levels were reached within a few 
minutes, and were half the maternal levels. After an hour, foetal levels were higher than 
those in the mother. The concentration in liver is quickly elevated, and quickly falls. 
Once the narcotic agents are taken up by the foetus, they are metabolised and excreted. 
They may be detected in amniotic fluid, 95 hair96 and meconium. 97 
The results of animal studies suggest that morphine metabolites, chiefly morphine 3- 
glucuronide, enter the amniotic fluid more slowly than morphine itself 
4.3.6. Legal Status 
The raw form of opium is not licensed for medicinal use and cannot be supplied, possessed 
or administered except in accordance with a Home Office Licence. The opiates are 
classified between class A (for morphine, heroin, methadone, fentanyl and pethidine) and 
Class B (for codeine and dihydrocodeine) except if taken by injection, when they are 
considered Class A drugs. Dextropropoxyphene and buprenorphine are Class C drugs. 
Dilute mixtures of codeine, morphine, opium are over-the-counter drugs used for many 
routine medical purposes such as coughs or diarrhoea98. 
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4.3.7. Methods of Analysis of Morphine 
Morphine can be analysed in many types of sample. Plasma is the most common one 
and most of the morphine is present in unconjugated form. About 30% is combined with 
plasma protein, but a lot of analyses are done using other biological samples as mentioned 
previously. Several instruments can be used for its detection including GC/MS, which is 
the most sensitive and specific method, especially when using SIM. 99 Also there are other 
methods used for determination of acetylcodeine, 6-MAM and other opiates in urine. '00 
Morphine can be detected by HPLC with UV detection1°' and by HPLC with 
elctrochemical detection102 both of which do not require derivatisation. Many other 
methods which have been published used either GC103 for extracts of morphine from 
blood and bile or GC-FID using blood and plasma104, or blood, serum and saliva'05, or 
urine'06 , or use SPE followed by HPLC for serum, 
107 or more recently have used 
meconium, as mentioned previously. 
4.3.8. Opiate Related Deaths 
Medical examiners participating in the Federally sponsored DAWN program reported 
5,876 opiate-related deaths in 1993, a 15% increase on the previous year, but this 
percentage has seen a sharp decrease since 1995, which may be due to methadone 
maintenance programmes, and this ratio has decreased till 1997. In Scotland the number 
of heroin-related deaths was at a maximum in 1999, but decreased in 2000. These deaths 
represent around 66% of all drug-related deaths in 1998,95% in 1999 and 89% in all 
cases in which represent heroin intoxication, and heroin is one cause besides the presence 
of other drugs. Deaths due to morphine alone also maximised in 1999 then decreased 
slightly in 2000, representing about 13% of drug deaths in 1998 and 1999, decreasing to 
10% in 2000. ( unpuplished data- private communication). 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 51 
5. Congenital Anomalies 
5.1. Introduction 
Substance abuse in women of childbearing age is a serious problem which affects the 
foetus prenatally and the neonate postnatally as it has long term effects, especially as it is 
often the case that these women are using multiple drugs (commonly involving alcohol, 
diamorphine and cocaine). The effects depend on the amount taken, type of drug abuse, 
gestation period during which they are used, duration and the method of use. Also, 
tolerance to opioids develops very rapidly in the foetus/neonate and has been 
demonstrated to occur within a few hours as it depends on the duration of opioid receptor 
occupancy. Therefore continuous administration of opioids may produce tolerance more 
rapidly than intermittent therapy. 108 
Congenital anomalies are the largest cause of infant mortality: the underlying factors are 
multiple, and include environmental, genetic mutifactors and idiopathic causes. 
Congenital anomalies also represent some of the serious complications which accompany 
drug abuse during pregnancy, as about 2-3% of malformations are caused by drugs and 
environmental chemicals, especially when exposure occurs during the organogenesis 
period (4-8a' week of pregnancy) during which the embryo is most susceptible to factors 
interfering with development. 109 
The most common effect of opioids is neonatal abstinence syndrome (NAS), as these 
drugs crosses the placental barrier, causing definite behavioural and neurological effects 
in neonates and infants 91'1 1,110 
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5.2. Neonatal Abstinence Syndrome 
This syndrome has special signs and symptoms and is common in neonates of pregnant 
addicts, using narcotics or on methadone maintenance. NAS varies from a condition 
displaying severe symptoms needing medical treatment to one with mild symptoms 
requiring observation only. 108 
NAS appears rapidly after birth if the mother herself suffers from withdrawal or may 
appear late if its cause is a drug with long elimination half life (for example, methadone or 
barbiturates). The duration of NAS depends on its severity, as acute cases last for 3-4 
days and are then resolved by the 5-7t' day after birth. In severe cases which require drug 
treatment, relapse occurs if treatment stops suddenly, as the signs disappear after 5-7 days 
of treatment but mild signs still continue for 2-4 months. 111 
The abstinence syndrome due to methadone appears in 70-90% of neonates in the first 3 
days after birth, but in some cases may appear some days later (10-32°d day of life) due to 
slow clearance of methadone. NAS due to heroin addiction occurs in 50-80% of cases and 
lasts from a few days to several weeks. Also, there is no relationship between the amount 
taken by the mother and the severity of the syndrome. ' 12 
5.2.1. Common Drugs 
NAS can be induced by all narcotics if taken during pregnancy. It is more prominent in 
morphine and heroin addicts. The use of methadone once daily for maintenance treatment 
of heroin addiction causes NAS as it has a long duration of action. ' 12 
The methadone has a low molecular weight, is lipophilic and is highly protein bound so 
it is excreted in bile and urine with only a small amount unchanged. Its level changes in 
pregnancy and it can pass easily through the placenta to the foetus, so it appears early, at 
the 14-16`h week of gestation, with higher concentrations in plasma than in umbilical cord 
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or amniotic fluid. Excretion in urine along with its metabolites is greatest in the first days 
of life and then slowly decreases, with a time range from 7-21 days. ' 12 
5.2.2. Symptoms and Signs 
Symptoms of CNS excitation such as irritability, jitteriness, coarse tremors, hypertonia, 
and myoclonic movement occur in 5-10% of these neonates. The EEG is normal except 
during seizures, and the neonates can display high pitched crying, seizures, hypothermia, 
hyperthermia and tachypnea. 112 
Respiratory distress, and vague autonomic symptoms, which include yawning, sneezing, 
sweating, stuffy nose, mottling, increased lacrimation, and fever, with tremor which start 
mild in the beginning, and occur when the infant is disturbed, but which progress to the 
point where they occur spontaneously without any stimulation, can also occur. High 
pitched cry, increase muscle tone and irritability develop with increased deep tendon 
reflexes and an exaggerated Moro reflex. The rooting reflex is exaggerated and neonates 
often suck frantically on their fists or thumbs. ' 08 
GIT disturbances arise in the form of incoordination in suckling, with vomiting, so the 
baby is always hungry and agitated, with loose stools. The baby can suffer from 
dehydration, low body weight and electrolyte imbalance, and may regurgitate frequently. 
Because of the uncoordinated and ineffectual suckling reflex, infants may develop loose 
stools, and may be susceptible to aspiration pneumonia, and respiratory alkalosis. "' 
5.2.3. Treatment 
Treatment includes two main lines: general, and pharmacological. The general route 
depends on the severity of the symptoms, so in mild cases keeping the patient quite calm 
with no room light and with a decrease in movement is enough. If accompanied by 
hyperactivity, vomiting or diarrhoea, a follow up must be done by weighing the baby 
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every 8 hours, and supplying the baby with adequate caloric intake, especially in children 
with difficulty in suckling or swelling. III 
The pharmacological route is initiated within 4-6 hours of birth for all infants who meet 
the scoring criteria for pharmacological intervention, and depends on drugs containing 
opium such as paregoric or tincture of opium, which control GIT symptoms with seizures 
or else involves non-opioids in the form of phenobarbital or benzodiazepines. 111 
A delay in initiation of an appropriate pharmacological intervention gives rise to a 
greater risk of increased morbidity 108 
5.3. Ocular Abnormalities 
The development of the eye occurs in the gestation period from day 24 to 40. Any insults 
during this time result in ocular malformations. 109 
5.3.1. Development of the Eye 
The eye develops in different steps. The appearance of early positive waves corresponds 
to the developmental of apical dendrites of pyramidal cells in the occipital cortex. These 
dendrites generate a summated excitatory postsynaptic potential through a highly 
synchronised afferent volley onto or near the soma of maturing deep lying pyramidal 
cells. This dendrite development continues over the first year of life and may contribute to 
the shortening of wave component latencies during the first months after birth. During 
the first few weeks after birth, the visual system is dominated by neurophysiologic 
activity from subcortical centres and with maturation during the first 2 months of life, 
significance synaplogenesis occurs. 113 
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Intravenous drug abuse causes problems due to impurities in the drugs and can result in 
bilateral loss of vision due to particulate microembolisation to the retinal vessels, in a risk 
of HIV infection, and in an increased risk of acute bacterial and fungal endocarditis. 109 
5.3.2. Drugs Affecting the Eye 
There are some drugs that have serious effects on the eye when taken during pregnancy 
which are summarised below. 
(a) Lysergic Acid Diethylamide (LSD): 
LSD is considered to be an hallucinogenic drug, inducing visual hallucinations and 
personality changes. It affects the offspring causing retinopathy, mydriasis and potential 
cycloplegia, leaving the pupil dilated and causing the retina to be more susceptible to 
retinal burns. This finding includes formal holes like lesions or a honeycombed macular 
region. In pregnancy it produces eye deformities, as it causes anterior subcapsular lens 
abnormalities which are pathologically similar to cataracts induced by x-rays. The lens 
epithelium is hyperplastic and the lens itself is widened posteriorly. 
(b) Cannabis: 
Cannabis is used along with other abused drugs and in some neonates causes 
chromosomal abnormalities that appear as breaks in the DNA strand and abnormal cells 
which is inheritable, with some destruction of the eye structure. 
(c) Amphetamine; 
Amphetamine produces some ocular abnormalities, such as microopthalmic eyes. 
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(d) Methadone: 
A published study showed an increased incidence of strabismus in offspring of women on 
methadone maintenance, which increased with low birth babies and if large doses of 
methadone were taken, which may also cause nystagmus and ocular torticollis. 
(e) Cocaine 
Cocaine intoxication in neonates causes iris blood vessel abnormalities with dilation and 
tortosity of the vessels. It was found that these vascular anomalies occurred over 3-4 
months without any loss of vision. Cocaine causes vasoconstriction, which presents in the 
premature infant as unilateral retinopathy, and funds abnormality when the mother used it 
during pregnancy. 109 
5.3.3. Drugs Affecting Power of Spectral Values 
The effect of drugs on the eye of the neonate can known by measuring their 
electrophysiological responses in the brain: usually there are 2 types of 
electrophysiological waves: (P) for positive wave. (N) for negative wave, and it is measure 
in grades N 1, N2, and Ni vision is better than N2. 
If the latency is prolonged this means that the conduction is delyed, which means nerve 
damage, and the same if the amplitude is decreased. PS means near vision. 
These substances produce different effects: 
(a) Alcohol: 
First trimester alcohol exposure results in significant prolongation of N1 and P1 latencies 
at 1 months of age, while in the 2 °d and 3`d trimester it causes prolongation of the N2 
wave at 4 months. Alcohol has also been correlated with an increase in N 1-P 1 amplitude 
(poor conduction through the optic nerve) at 4 months of age for both 2nd and 3`d trimester 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 57 
use there was a decrease in NI and PI latencies at 18 months of age with the first 
trimester alcohol use. 
(b) Cannabis: 
The effects of cannabis are mostly related to 3`d trimester exposure, with little effect from 
first or second trimester exposure. Prolonged latency of P1 wave was found at 1 and 18 
months with 3`d trimester exposure, however P1 latencies were shortened at age 8 with 3`d 
trimester use. There was also a decrease in NI-PI amplitudes at 18 months with first 
trimester cannabis use 
(c) Tobacco: 
Tobacco is the only drug that has detectable effects at birth, as when it is used in the first 
trimester it gives prolonged NI wave latencies at 4 months, prolonged PI latencies at 
18months and increased NI-PI amplitudes at 18 months of age. Tobacco increases the 
latencies and amplitudes of N1-PI, but it is not possible to identify the relation between 
specific trimesters and effects because of high tobacco use across the trimesters' 13. 
5.3.4. Common Ocular Abnormalities with Drugs 
(a) Micropthalmic eyes, with severe deficiency in visual function, which may extend to 
anopthalmia, especially if the parent uses multiple drugs like LSD, heroin and 
methadone. 
(b) Anterior segment anomalies, including corneal opacities with vascularisation and 
shallow anterior chambers, which may develop into attacks of angle closure glaucoma. 
(c) Iris colobomata, which is associated with colobmata of other structures of the lens and 
optic nerve. 
(d) Lens abnormalities, including cortical degeneration with thickened capsules. 
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Retinal changes, ranging from those associated with an anencephalic absence of the nerve 
fibre layer, with loss of the ganglion cells and decreased optic nerve diameter, to retinal 
detachments which could not be explained by trauma or inflammation. 113 
5.4. Central Nervous System Malformation 
Early development of the capacities in normal infants appears to follow CNS maturation 
and development, as specific learned experience, arousal, attention and state regulating 
capacities are fundamental neurobehavioral processes mediated by an adequately 
functioning CNS and form the basis for subsequent development. 
CNS maturation is affected by neonatal CNS injury or intrauterine cocaine exposure at 4 
months before birth. ' 14 
The most common drug affecting the CNS is cocaine, although the influence of cocaine 
exposure remains unknown, as research depends on maternal reporting of drug use or 
urine analysis which gives positive results only if the drug was taken shortly before the 
test. Its effects appear as some neonates suffering from stimulus seeking regardless of 
arousal, which appears after 4 months and not before, and behavioural disturbances 114 
This effect may be mediated by alterations in the mechanism of neurotransmitter 
synthesis and reuptake; especially dopamine. It is intriguing since both cocaine exposure 
and CNS injury produce short and long term alterations in CNS systems in the form of 
attention and arousal behaviours. 114 
In 1967 Auerbach and Rugowiski studied the effect of LSD in the mice embryo, and 
reported that 57% of them had multiple deformities including brain malformation with 
enlarged midbrain and improper closure of the hindbrain. Some deformities in jaw and 
eye position occurred when LSD was injected before day 7 of pregnancy, which 
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corresponds to the time when the neural structures are being formed. There may be 
destructive effects on the developing brain and eyes, causing progressive hydrocephalus 
with aqueduct stenosis. Abnormal cerebral convulsions were noted when the mother used 
LSD, cannabis and amphetamine during pregnancy, which may occur due to the 
combined effects, but not confirmation done on human. 109 
Several investigations have proven the effects of maternal alcohol or cannabis use during 
pregnancy in the form of disturbance of sleep or EEG patterns in children, especially with 
prenatal alcohol, including disturbed sleep architecture and continuity, altered power 
spectral values, and disruption in behavioural state and arousal. ' 13 
Methadone also produces disturbances in sleeping pattern, with CNS irritability in 
EEG's, and it has been that reported sudden infant death syndrome occurs which is 
accompanied by higher respiratory and lower mean heart rates. "2 
5.5. Body Stalk Anomaly 
The body stalk anomaly is a fatal anterior abdominal wall defect affecting 1 in 14000 
new-borns, which may be due to early rupture of the amnion. Prenatal diagnosis is by 
ultrasound scanning and is unequivocal, with absence of a free-floating umbilical cord 
and fusion of the placenta to the herniated viscera. Foetal malformation is often present 
and alpha-fetoprotein in maternal serum is commonly increased. It is confirmed by post- 
mortem. 
This congenital anomaly commonly comes with kyphoscolosis and limb, cranial, facial, 
gastrointestinal, and genitourinary defects as well as an abnormal amniotic band. It 
occurs early in embryogenesis when body folding takes place, and the coelimic cavity is 
usually obliterated by the fourth week of development. 
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Cocaine use is commonly associated with birth defects, especially relating to the 
genitourinary tract, GIT, limbs, and causes destructive e and damaging effects on the CNS 
through mechanisms of foetal vasoconstriction and local haemorrhage. Cocaine also 
causes failure of both the cephalic and the caudal folding, and this would suggest a 
different chronological window in the vascular disruption during embryogenesis or a 
vascular segmental sparing of the effect of cocaine. 115,116 
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6. The Placenta 
6.1. Introduction 
The placenta is an organ, which provides an essential connection between the mother and 
foetus: its integrity is crucial for foetal growth, development, and well being. 
Alternations in placental function may be due to maternal or foetal disorders or may be an 
intrinsic abnormality in the development of the placenta through the course of 
pregnancy. ' 117 
6.2. Development of the Placenta 
The ovum is fertilised in the fallopian tube and enters the uterine cavity as a morula, 
which rapidly sheds its surrounding zona pellucida and converts into a blastocyte. Its 
outer cell layer proliferates into cells which infiltrate between the trophoblastic cell mass, 
from which cells infiltrate between the endometrial epithelium. At this stage of 
development, the trophoblast consists of an inner cell layer( cytotrophoblast) and of an 
outersyncytial cell layer ( the syncytiotrophoblast), these two tissue form the chorion, the 
cells degenerates with the trophoblast, to come into direct contact with the endometrial 
stroma, completed at IO -11t' postovulatory day. The stroma shows oedema and 
congestion which may be due to the action of some substance produced by the cells of 
implantation blastocyte. This congested and oedematous condition of the stoma provides 
nutritive material for the trophoblast, which now thickens rapidly at the region of contact. 
After 13 days of fertilization primary villi appear. At 15 days the villi enriched by an 
extra-embryonic mesenchyme to form secondry villi, which progress to tertiary villi 
enclosing primitive vasculo-blood islets. These islets are the original of the future villous 
circulation. At 21 days the fetoplacental circulation is established, at end of 3`d month 
extensive growth of amniotic cavity flattens the ovular deciduas against the parital 
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deciduas, the uterine cavity is thus obliterated. ' 18 the villi on the side of the chorione 
toward the decidua basalis enlarge and become elaborately branched as pregnancy 
advances, toward the decidua capsularis, then degenerate between the third and the fourth 
month, leaving this side of the chorione smooth and almost non-vascular. Persisting villi 
then assume more branches to form the placenta which is supplied by intervillous 
maternal blood space, which gradually becomes subdivided into sinuses which reach the 
uterine side but not the foetal side. ' 19At the end of 4th month and until term the placenta is 
fully formed with its blood Supply. I18At full term the placenta has the shape of a flattened 
cake and becomes thicker to meet the nutritional requirements though, doubtless, to 
compensate to some extent for thinning of the placental membrane separating the 
maternal and foetal blood streams, thus increasing its efficiency in transmission. After the 
placenta is made up of 15-20 convex areas covered by a very thin decidua basalis and 
separated from one another by irregular grooves. These convex areas are the so-called 
cotyledons. The foetal surface of the placenta is not subdivided and is covered completely 
by the vascular mesoderm of the chorione with its large umbilical vessels. The amnion is 
closely applied to the vascular mesoderm of the chorine with its large umbilical vessels. 
The amnion is closely applied to the chorine on the foetal side and in full term placenta is 
often fused with it, especially near the placental margin. 120 
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Figure 6.1 Relationship between the chorion and vessels( Human Embryology) 123. 
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6.3. Foetal Membrane 
Through pregnancy, a complex systems which is responsible for the nutrition of the foetal 
are developed. Any tissue or structure developed from the ovum, which does not form 
part of the embryo proper, is an embryonic membrane. This of course, includes such 
structures as the placenta and umbilical cord, which are not, strictly speaking, membranes, 
but convenience and custom have sanctioned this broad usage of them. The first 
embryonic membrane, the trophoblast, becomes differentiated in the early blastocyst stage 
when a fluid-filled cavity (blastocoele) appears and partly separates the inner cell mass 
from it, forming a unilaminar foetal membrane. 121 
The foetal membrane consists of four different membranous structures, which are 
involved in placental development, the chorione, the amnion, the vitelline sac and the 
allantoic sac. The chorione is an epithelial layer derived from the outer blastocystic wall, 
the trophoblast. During the course of implantation it is completed by an inner layer of 
mesenchyme which derives from the embryo. The mesenchymal cores never penetrate 
the zones of cytotrophoblast at the decidual attachments of the main villi and hence the 
foetal blood vessels, developed in the mesenchyme, do not come directly into contact with 
maternal decidua or blood. '21"22 
The amnion, also consisting of epithelial layers derived from the embryonic ectoderm 
either by splitting or by folding, has no vessels. The amnion surrounds the embryonic 
foetus as a second inner sheet, but it never replaces the chorione of the yolk sac as the 
outermost embryonic membrane. 
The yolk sac develops as an adenxal and structure of the embryonic midgut, and consists 
of a layer of endothermic epithelium accompanied by vascularised mesenchyme. The 
allantosis is the extra embryonic urinary bladder, which develops from the embryonic 
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hindgut as an extraembryonic sac. Its surrounding mesenchyme is richly vascularised, it 
is barely involved in transplacental exchange procession conclusion the following 
compositions of foetus 
In conclusion, the following compositions of fetal membranes may establish the , 
placenta: 
*Chorionic placenta, first step of placental development in which as an unvascularised 
non-specialised part of the placenta. 
*Choriovitelline placenta, chorionic membrane connected to the foetal circulation by 
vitelline vessels 
*Chorioallantoic placenta chorionic membrane connected to the foetal circulation by 
allantoic vessels. 
*Vitelline placenta yolk sac epithelium with vitelline vessels connecting it to the foetal 
circulation' 22 
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Figure 6.2 The embryo and its membranes. 
TROPHOSLAST 
(From Human Embryology. Hamilton, et-al. 1946)123 
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6.4. Anatomy of the Cervix 
The cervix is the lower part of the uterus immediately posterior to the angle of the 
urinary bladder. This relationship is constant because the cervix is fixed by parametrium 
at the posterior angle of the bladder and project through the anterior wall of the vagina at 
the vaginal vault and has supravaginal and vaginal portions of equal length. The vaginal 
mucous membrane is continuous with that of the cervix, and the folds formed by the 
reflections of this mucous membrane at the front, back and sides of the cervix which are 
known as vaginal fornices. The cervix is roughly cylindrical and is about 3 cm long and 
2.5 cm in diameter but this varies according to number of labours of the woman. The 
endocervical canal is visualised as an echogenic stripe surrounded by hypoechoic fibrous 
stroma, and its length is measured from the level of the internal os to its most caudal 
aspect in the fornix of the vagina. The epithelium covering the cervix is of two types, 
squamous epithelium which is stratified and non-keratinised under the effect of ovarian 
hormones, and columnar epithelium, which also covers the endocerivical canal. The 
majority are tall, thin, mucous secreting cells with basal nuclei, but few of them are 
ciliated. Typically, the amniotic fluid within the lower uterine segment has a funnel- 
shaped configuration and the apex of the funnel forms an acute angle at the internal os. 124 
6.5. Anatomy of the Uterus 
The non-gravid uterus is pear-shaped and about 8-9 cm in length, divided into two 
distinct anatomic segments, a cranial corpus uterus with a smooth muscle wall and caudal 
cervix uteri composed of a fibrous tissue wall. The commonly-used term, fundus refers to 
the top of the corpus. The cavity of the uterine body is flattened anteroposteriorly and 
appears shield-shaped from the front view. It narrow toward the lower end, the isthmus 
grows rapidly in the early stages of pregnancy and produces most of the lower segment of 
the pregnant uterus. The uterine wall significantly increases in thickness during 
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pregnancy largely as a result of the physiologic hypertrophy of uterine blood vessels, 
which comes from uterine branch of the iliac artery on each side. Each uterine artery 
anastomises with the ovarian artery above and with the vaginal artery below. The utero- 
ovarian anastomosis forms a sinuous arterial channel along the lateral wall of the uterus 
within the broad ligament. The vessels penetrate all layers of the uterus and freely empty 
into plexuses at the sides of uterus and broad ligaments. These anastomosis 
corresponding to the physiological vascular changes of the pregnant uterus 125 
6.6. Placental Circulation 
From the functional standpoint the most important features of the placenta are its maternal 
and foetal circulatory systems and the manner in which the two blood streams come into 
relation with one another. There is never, of course, any intermingling of foetal and 
maternal blood. The villi are supplied by an arterio-cappilary-venous system carrying foetal 
blood, and are bathed in maternal blood which flows in and out of the sinuses. The exact 
method of supply and drainage of the maternal sinuses is still controversial. The arteries 
opened into each cotyledonary sinus, usually near to or on the septa, while viens drained 
each sinus from its uterine surface or base. All venous openings are from the so-called 
circular, or border, sinus which is an irregular venous ring about 2.5 cm in diameter, located 
in the periphery of the placenta. Maternal arterial blood enters the fully formed placenta at 
the bases of the sinuses from enlarged coiled arteries of the endometrium. It then follows 
between the spongework of the villi to the foetal surface, where it spreads horizontally 
toward the border sinus through the more or less common intervillous spaces connecting all 
the sinuses between the surface chorine and foetal margins of the septa. Then the blood 
empties into the large endometrial venous plexuses of the region and then into the vein of 
the uterine wall. 127 
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the maternal blood stream provide long distance and its energy source is the maternal 
heart, while foetal energy source is the foetal heart. This arrangement can be visualised as 
a system of two parallel lifts separated by a gate. There is the placental barrier boundary, 
which lets solutes across an inert membrane by simple diffusion or transfer under the 
combined influence of forces. The diffusion depends on the concentration difference, the 
barrier thickness, and surface area of the membrane that separates exchanging 
compartments. 124 
The foetal blood is usually supplied to the placenta by two umbilical arteries which, 
immediately anastomse before entering the organ, into a single arterial vessel. There is 
many branches, due to their exceptional location (a simultaneous blood supply from the 
arteries), which have a particular significance for the physiology of foetal blood 
circulation in the placenta. 126 
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Figure 6.3 The normal placenta and the associated chorion at full term. 
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The umbilical cord normally contains two umbilical arteries and a single larger umbilical 
vein, covered by amnion and surrounded by clear gelatinous Wharton's jelly. The length 
is quite variable, with evidence suggesting that both cord length and spiralling depend on 
foetal activity. The arteries wind around the umbilical vein in a spiral fashion and carry 
deoxygenated blood from the foetus to the placenta; the direction of the cord twisting is 
not random. ' 27 
6.7. Physiology of the Placenta 
The placenta is considered to be a membrane for exchange between mother and foetus so 
it is supplied with a double perfusion system: oxygen and other nutrients such as glucose 
and amino acids, oxygen and water are delivered from the maternal circulation. By 
contrast, C02, nitrogenous end products of foetal metabolism and hormones are removed 
by the same circulation, however most drugs of abuse are lipid-soluble and therefore 
rapidly pass through the placenta. ' 28,129,130 
6.8. Placenta and Drugs 
The passage of drugs through the placenta depend on the properties of the drug and the 
physiology of the placenta. The most important properties of the drug, which affect 
mother/foetal drug transfere are: lipid solubility, molecular size and ionic charge. And the 
most important factors in the placenta which affect mother/feotal drug transferit are the 
foetal and maternal blood flow to placenta, placental structure and permeability 131 
The placenta is a lipid membrane so passive diffusion is the most important mode of 
transport, while hydrophilic compounds pass through water-filled pores and this diffusion 
is limited. 131 
Active transport may occur if the compound is closely related to an endogenous 
substance such as amino acids, for which carriers exist, and lipid soluble drugs will 
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equilibrate across the placenta rapidly. Hydrophilic compounds will equilibrate slowly 
and when the foetal blood concentration equals the maternal drug concentration a steady 
state is achieved during which constant rate maternal infusion will occur. The transport 
depends on foetal protein binding and blood pH relative to maternal parameters, placental 
bio-transformation and whether the foetus has the ability to eliminate the drug' 31 
6.8.1. Lipid-Soluble Drugs 
Cocaine, morphine and nicotine are examples of lipid-soluble compound that readily 
cross the placenta, then are found in amniotic fluid and new-born serum. 
The concept of the placenta as a barrier to xenobiotic exposure is obsolete, the placenta 
does have the ability to selectively filter and metabolise drugs and chemicals. The 
placenta possesses cholinesterase activity which metabolises cocaine to its major 
metabolites, and other drugs are also affected. 132 There is genetic variation in 
cholinesterase activity that are ethnically specific. 
Cocaine hydrochloride is water soluble, and its ability to cross human placentas in 
substantial amount has been demonstrated in spite of its water solubility, but the ability of 
metabolites to pass back into the maternal circulation appears limited due to their high 
polarity. Free base cocaine is lipophilic, hence the ability of the placenta to metabolise 
cocaine is related to the magnitude of exposure of the foetus to the drug, its metabolites, 
and the duration of exposure. 
Foetuses of women who have lowered cholinesterase activity may be at increased risk of 
abnormalities from intrauterine cocaine exposure, because foetuses, regardless of 
maternal enzymes, do not possess cholinesterase activity. However, foetuses do 
demonstrate liver N-demethylase enzyme activity, which is important in the metabolision 
of many drugs. 
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6.8.2. Hydrophilic Compounds 
Metabolites of abused drugs are frequently hydrophilic compounds and can not pass 
directly through lipid membranes, but they diffuse through the placenta via water-filled 
channels in the membrane: this passage is termed diffusion-limited transfer. The sizes of 
the channels vary with species. 
Morphine-3-ß-D-glucuronide, the major metabolite of morphine in man, has a molecular 
weight of 461, in late gestation, this metabolite does not cross the placenta in significant 
amount and if it injected into the foetus, it crosses into the maternal circulation very 
slowly, the permeability surface area of drug increases as the foetus ages increase during 
late gestation. 
Benzoylecgonine, a hydrophilic inactive metabolite of cocaine has greater permeability 
than morphine glucuronide as it has a smaller size. '29 
6.8.3. Peptides 
Placenta permeability to peptides depends on molecular size and lipid solubility. Also, 
cationic molecules cause structural changes in the placenta associated with increased 
permeability. Placental transfer of peptides is reduced by peptidases and histamine 
increases permeability to proteins, for example, oxytocin can cross the placenta133 
6.8.4. Amino acids 
Placenta concentrations of amino acids are higher than the foetal levels, so they are 
transported against the concentration gradient so transport to foetus need carrier- 
mediated, and energy. As the amino acids are required for neurotransmitter synthesis so 
their deficiency results in mental retardation in infants. A prolonged decrease in maternal 
amino acid concentrations causes an increase in placental amino acid transport, by 
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inducing synthesis of new carriers. Hormonal regulation of amino acid transport is 
inhibited by the effect of alcohol and nicotine causes foetal growth retardation. 131 
6.9. Foetal: Maternal Drug Concentration Ratios 
The ratio of foetal to maternal blood drug concentrations is used to make judgements 
about the rapidity and extent of placental drug passage. 
Under steady state conditions, the total drug concentration on both sides of the placenta 
need not be equal if there are foetal and maternal differences in protein binding and pH, 
for it is the unbound and unionised drug that equilibrates across the placenta. Placental 
drug biotransformation would allow lower foetal levels relative to maternal 
concentrations, but placental drug metabolism is negligible for most compounds. The 
foetal blood concentration of an unbound, unionized drug is less than the maternal 
concentration when foetal elimination is present and it significant appears that placental 
passage of drugs, including peptides, is determined by the physical, and chemical 
properties of the drug and the physiology of the placenta. Foetal blood concentrations of 
drugs administered to the mother depends on the time since maternal drug administration, 
dose, placental blood flow, permeability, plasma protein binding, blood pH, placenta 
biotransformation and foetal elimination 125. 
Drug abuse has a serious effect on foetal development and pregnancy outcome either due 
to effects of the drug on placental perfusion and foetal oxygenation or to direct drug 
action. There are various methods used to assess drug exposure in neonates, including 
cord blood, amniotic fluid, neonatal urine, meconium, and hair sample. Complete 
understanding of the pharmacokinetics of these drugs in the maternal-foetal is needed. 134 
6.10. Maternal-Foetal Drug Disposition 
The factors that influence the rate of drug transfer from mother to foetus depend on: 
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*Thickness and surface area of the placental membrane. 
*Molecular size 
*Lipid solubility of the drug molecule. 
*The plasma protein binding of the drug. 
*Relative pH of the blood of the mother and foetus. 
*Rate of placental blood flow especially for lipid soluble compounds. 
When taken intravenously, drugs rapidly rise in concentration in foetal blood until an 
equilibrium is reached, and as the drug continues to be cleared from the maternal plasma, 
the diffusion gradient is reversed and the foetal drug concentration will begin to fall. So 
the foetal level depends on rate of placental transfer and drug elimination in the mother. 
This happens with meperidine, methadone, cocaine and methamphetamine. Foetal drug 
levels were found to be similar to maternal levels for meperidine and cocaine but lower 
for methadone and THC13s 
Drug elimination is a big problem in the neonate, especially after removal of the placenta. 
In the case of repeated drug exposure a steady state plasma drug concentration depends on 
many factors: half life of the drug, placental permeability, foetal maternal drug 
elimination and plasma protein binding. 
6.11. Foetal Drug Elimination 
Foetal drug elimination depends on the presence of drug-metabolising enzymes in the 
foetal liver which are capable of catalysing the N-dealkylation of meperidine and 
methadone and glucuronidation of morphine. This is proved by the presence of certain 
metabolites in foetal plasma that are pharmacologically active and explain the adverse 
effects in the foetus. Foetal renal clearance is also important for drug elimination, 
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especially for the polar conjugates such as morphine 3-glucuronide, which can be detected 
in foetal urine135 
Excretion of drugs into amniotic fluid appears late as it comes from foetal urine but 
concentrations exceed those in the maternal and foetal plasma. Some drugs accumulate in 
amniotic fluid even with complete diversion of foetal urine suggesting other sources of 
drug transfer such as diffusion across the chorioallantoic membrane. For lipid-soluble 
drugs, back-diffusion across the chorioallantoic membrane is the major pathway, and 
provides the final route of drug elimination. For less lipid-soluble drugs, and especially 
for polar metabolites, the final route of elimination is probably by foetal swallowing of 
the amniotic fluid. 
6.11.1. Excretion of Drugs Into Meconium 
Metabolites formed by the foetal liver may be excreted in the bile and deposited in 
meconium. Small amounts come from foetal swallowing of amniotic fluid. Because 
meconium is not normally excreted in uteri, it accumulates throughout the entire gestation 
period. Metabolites of cocaine, morphine and cannabinoids can be detected in meconium 
134 from babies of chronic drug users throughout the second half of gestation 
6.11.2. Excretion of Drug Into Foetal Hair 
Metabolites can also be excreted into foetal hair, for example the concentration of 
benzoylecgonine in neonatal hair is linearly correlated with self-reported cocaine use. 
Hair reflects drug exposure during the last 3 months of pregnancy as it grows in this 
period. Hair grows approximately 1-1.5 cm/month, so it is possible to section the hair to 
assess the time of drug exposure13a 
Analysis Of Multiple Drugs in Small Blood Specimens and Meconium 
Page 76 
7. Review of Biological Samples Used for the 
Analysis of Drugs in Pregnancy 
7.1. Introduction 
Drug abuse during pregnancy has become a problem of epidemic proportions. The 
National Institute on Drug Abuse (NIDA) has estimated that over five million 
pregnant women are drug addicts, with significant increases in the use of crack 
cocaine and its complications to the mother and foetus, such as increase in stillbirths, 
meconium stained amniotic fluid, premature rupture of the membranes, maternal 
haemorrhage (due to abruptio placenta or placentae previa. ), foetal distress with 
increases in morbidity and mortality, asphyxia, prematurity, low birth weight, 
infection pneumonia, congenital malformations, cerebral infarction, drug withdrawal 
and increased risk of AIDS. 136 
Cocaine, if accompanied by methamphetamine can cause maternal hypertension, 
subarachnoid and intracerebral haemorrhage, premature labour, small head size, 
reduced birth weight, ruptured uterus and increase in foetal death with some 
behaviour disturbance. 137 
Exposure to opiates causes many problems, apart from that of withdrawal 
symptoms (Abstinence Syndrome), including irritability, tremors, hyperactivity and 
seizures. Birth defects and other congenital anomalies are thought to be related to 
foetal exposure to drugs, chemical agents, alcohol, or other xenobiotics. '38 
Many other problems appear later in childhood, including delays in physical growth, 
mental affection, learning disability, and sudden infant death syndrome. Maternal 
history, relating to the amounts of drugs used, frequency of use and how long the 
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mother used them, can help in prevention but is not accurate most of the time for fear 
of consequences that may stem from admission of use. Laboratory tests, which must 
be very sensitive, specific and capable of producing a broad drug screen with many 
confirmatory tests, also can help. 137 
Currently, identification of the drug-exposed newborn with toxicological screening 
has become of importance to allow follow-up of the infants by medical and social 
services. Detection can be done by analysis of blood, urine, meconium, hair, nail and 
breast milk. The problem which is encountered in newborn blood analysis is the 
small sample available and difficulty in obtaining it in many countries (this may be 
solved in United Kingdom as blood is collected from every newborn in hospital to do 
routine analysis). 
139 
Frank et al (1998)14°, found that foetal urine analysis gives misdiagnosis of about 
24% of self reported cases of maternal cocaine abuse, with low sensitivity and 
difficulties in collecting the sample. As a result, the focus must move to alternative 
methods of analysis. Hair and amniotic fluid have problems in collection. Amniotic 
fluid and gastric lavage cause many complications, including infection as one of the 
serious problems. 141 
Ostrea et al 198969 found that circulation in the foetus of drugs of abuse and their 
metabolites result in the accumulation of high concentrations of the drugs in 
meconium. Maynard et al, 1991142 made a comparison between meconium and urine 
analysis and found meconium more specific and sensitive. 143 
Meconium which is a relatively recently used as a biological sample, is capable of 
being a very sensitive indicator of maternal drug use, easy to collect by non-invasive 
methods and containing high concentration of drugs and their metabolites. It allows 
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for a wider window of detection than urine as most drugs accumulate in meconium 
until delivery. Quantitative analysis of meconium provides further information on the 
amount, time and duration of foetal exposure. 139,144 
7.2. Meconium 
Unlike drug epidemics of earlier decades, the current drug epidemics have affected 
many women of childbearing age, so intrauterine drug exposure remains a major 
health concern because of the associated high incidence of prenatal complications 
and the high morbidity and mortality rates of the newborn. 
136,137,138 
Clinicians have recognised the importance of identifying drug dependent mothers in 
the prenatal and post-partum periods to provide appropriate treatment and adequate 
follow up. At first, clinicians depended on maternal urine tests in conjunction with 
patient history, but these two routes fail to identify a significant number of drug 
using women. Researchers have explored other methods for identifying drug- 
exposed infants. Recently, attention has focused on testing meconium instead of 
urine. 145 
Meconium, the dark green, viscous, first stool of a newborn, is considered to be a 
mixture of secretions from foetal intestinal glands and amniotic fluid, produces a 
green-stained amniotic fluid. It consists of a collection of debris and is mainly of 
water, but also contains mucopolysaccharides, lipids, proteins, fatty material from 
the vernix caseosa, bile acids and salts, epithelial cells, cholesterol and sterol 
precursors, blood group substances, squamous cells, residual amniotic fluid, enzyme, 
languor and various intestinal secretions. '4 
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The amount of meconium can be estimated by gross examination and has been 
classified as thin (light), moderate, or thick (heavy). Thick meconium, which has a 
"pea-soup" quality, is associated with a significantly increased risk of meconium 
aspiration syndrome. Recently a more objective assessment of meconium content of 
amniotic fluid, called the "meconium crit", is measured directly like a hematocrit and 
has been shown to be linearly related to meconium concentration. 144 
Meconium is seen in approximately 5% of amniotic fluid specimens obtained by 
amniocentesis. In general, meconium staining early in pregnancy is usually not 
caused by haemolytic disease but is usually due to a transient episode of foetal 
comprise. It does not indicate a poor foetal outcome. However, meconium staining 
in general is accompanied by a high foetal mortality rate. '45 
In human foetuses, meconium usually begins to accumulate in the bowel at 
approximately 16 weeks gestation (second trimester) and is not excreted until 
delivery. The foetal liver produces water-soluble metabolites that accumulate in the 
intestine and in urine. The urine is excreted into the amniotic fluid, which is ingested 
by the foetus. Thus drugs and their metabolites can accumulate in the meconium, 
since the foetus does not normally excrete stools in utero, until 1-5 days after birth. 
The meconium accumulates throughout gestation, with higher concentrations of drug 
metabolites than in urine, which is excreted continuously in utero. 
1 07,142,146. 
Drug metabolites have been detected in the urine and plasma of both the human and 
animal newborn. However, it is difficult to determine the metabolic fate of drugs in 
utero. Each of the major metabolic pathways can be promoted by placental and/or 
foetal enzymes and although the reaction rate appears to increase with gestation age, 
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the presence of a metabolite in the foetus does not necessarily reflect the ability of 
the foetus to metabolise the drug. '47 
Drugs reach the foetus by passive diffusion of the small molecules of soluble drugs 
across the placenta, which was once thought to be a protective barrier for the foetus 
disallowing passive diffusion of drugs. The molecular size, the degree of ionisation, 
the hydrophilicity of the drug, the blood flow to the placenta and the degree of 
protein binding to maternal and or foetal plasma proteins affect the rate of drug 
transfer through the placenta. 148 
Meconium analysis has advantages over urinalysis mentioned by many researchers 
such as Ostrea et al. 149, who showed that meconium contained higher concentrations 
of drugs than neonatal urine. 
Ryan et al. 150 stated that meconium testing was more likely than urine testing to 
identify an infant with intrauterine cocaine or opiate exposure, detecting an 
additional 33 % or 12 %, respectively. Maynard et al. 142 found that meconium was 
useful sample for detection because it was easier and more reliable to collect than 
urine and was easy to incorporate into routine procedures. Meconium is more 
sensitive than urine for the detection of cocaine and methadone exposure that 
occurred during the last two trimesters of pregnancy. The amount collected is 
usually sufficient for complete analysis including confirmation tests. The major 
advantage of meconium analysis is in extending the window of detection of drug use 
to approximately the last twenty weeks of gestation compared to urine, which 
provides information about recent drug exposure only (2-3 days before birth. ). '5' 
Meconium has the disadvantage that it is not a homogenous sample and therefore 
must be mixed thoroughly before analysis. 151 
Analysis Of Multiple Drugs In Small Blood Specimens and Meconium 
Page 81 
Meconium is usually passed by the full term newborn within 24-48h, after which 
transition from a blackish green to yellow colours indicates the beginning of passing 
of neonate stools. Infants with low birth weight (less than 1 Kg, which is the major 
problem of the foetus of an addict mother) have been shown to pass their first 
meconium between three and five years after birth. Thus, meconium collection can 
be missed because of delayed passage and also may not be available until soon after 
birth for early detection of intrauterine death syndrome-' 52,153 
Meconium is an unfamiliar matrix, being a sticky material that is more difficult to 
work with than urine. Furthermore, processing of meconium for analysis requires 
weighing and extraction steps that are not needed for urine. 
'sa 
7.2.1. Previous Methods of Meconium Analysis 
Meconium analysis has been carried out using different instruments, including gas 
chromatography (GC), gas chromatography/mass spectrometry (GC/MS), high 
performance liquid chromatography (HPLC) and by immunoassay using enzyme 
multiplied immunoassay technique (EMIT), radioimmunoassay (RIA) and 
fluorescence polarised immunoassay (FPIA). It can also be analysed by colour tests 
or thin layer chromatography (TLC). Many drugs are detected in meconium 
including nicotine, opiates, cocaine, amphetamine, phencyclidine (PCP), 
cannabinoids, methadone, and alcohol. The sample of meconium must be prepared 
by adding concentrated hydrochloric acid, water, buffer or methanol, before doing 
any analysis. 
7.2.2. Analysis of Drugs by GC and GC/MS 
These methods generally need derivatisation of drugs extracted from biological 
samples and have some disadvantages, for example, they are time consuming, 
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expensive and need experience. However, but they are sensitive, provide broad and 
specific screening, and have been used for the detection of several drugs as outlined 
below. 
Nicotine: 
Nicotine is considered to be a serious problem, equivalent to drug abuse, as many 
women smoke heavily, especially in pregnancy: Approximately 26% of adult women 
smoke. Many adverse effects are associated with the foetus of a smoking mother and 
depend on the dose taken. They include facial deformities, oral clefts, congenital 
heart disease, limb reduction defects and gastro-enteritis 
137. Also, there is a 
relationship between smoking and pregnancy resulting in an adverse outcome like 
increased spontaneous abortion, abroptio placentae, placenta praevia, prenatal 
mortality prematurely and poor foetal growth. Also, there are some cardiorespiratory 
changes affecting foetal heart rate, decreased foetal movements and breathing, 
damage to the heart, umbilical cord and foetal vessels, decrease in intervillous 
placenta blood flow and alteration in foetal oxygenation. These can lead to reduction 
in postnatal height, and, in a few cases, development of cancer, or neonatal jaundice 
or infant allergy. Some research has found a relationship between smoking and 
sudden infant death syndrome. 137 
e. 1.1.1.1 Mechanism of action 
Nicotine transfers through the placenta and is found in higher concentrations in 
amniotic fluid than serum. It causes increased levels of cocaine and 
carboxyhemoglobin in the foetus, with vasoconstriction leading to decreased 
placental blood flow, hypoxia and under-nourishment of the foetus. '55 
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Secondary effects on the umbilical vessels, which cause some abnormalities, lead to 
decreased production of prostaglandin and decreased capacity for vasodilatation, 
resulting in histological, morphological and biochemical changes in the placenta. 
Cigarette smoke contains many compounds such as cyanide, which affects the 
metabolism of important elements such as calcium and vitamins such as B12 and C 
and possibly vitamins B6, B1 and A. '40 
e. 1.1.1.2 Methods of detection of nicotine in meconium: 
Ostera et al, 1994 analysed the nicotine metabolites cotinine and trans-3-hydroxy 
cotinine in meconium by GC/MS using a cross-linked dimethyl silicone GC column. 
The instrument was used in the Selected Ion Monitoring (SIM) mode for the 
trimethylsilyl derivatives of cotinine (using the ions at m/z 98,176,119) and 3- 
hydroxycotinine (at m/z 294,144,75), with d3-cotinine as internal standard (IS). 
The amount of metabolites present related directly to the extent of maternal 
smoking. ' 56 
Cocaine 
Clark et al, 1992157 extracted cocaine from meconium by solid phase extraction 
followed by analysis by GC using an HP-5 phenylmethyl capillary column. The 
linearity was up to lOpg/g, with regression coefficients of 0.99 and 0.97 for cocaine 
and benzoylecgonine respectively. 
Abusada, et at, 1993 158 analysed cocaine, ecgonine methyl ester, benzoylecgonine, 
and cocaethylene in meconium in the concentration range 0-1000 ng/g by GC/MS 
with an HP2 capillary column (12m x 0.2 mm x 0.33µm phase thickness). The 
injector temperature was 260°C and the column temperature started at 145°C for 
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4 min, rising to 210°C at a rate of 60°C/min, then to 280°C for 0.25min at the same 
rate. 
Cocaine, benzoylecgonine, norcocaine and cocaethylene were extracted by Solid 
Phase Extraction (SPE), eluted by chloroform: isopropanol: ammonium hydroxide 
(78: 20: 2 v/v/v) followed by derivatisation by PFPA and HFIP and analysis by 
GC/MS. The lower limit of detection was 0.03 µg/g and lower limit of quantification 
was 0.1µg/g. '59 
Opiates 
Wingert et al 1994 160 used a methanol extraction of meconium followed by SPE 
then analysis by GC/MS equipped with an HP-1 or HP-5 capillary column. The oven 
temperature started at 80°C, rising to 190°C at a rate of 40°C/min. Moore et al 
1995 161 confirmed the presence of hydrocodone, hydromorphine, codeine and 
morphine by GC/MS. The column was DB5-MS (25m x 0.2mm ID x 0.33µm film 
thickness). The oven temperature started at 100°C, rising to 230°C at a rate of 
25°C/min, then to 260°C at a rate of 3°C/min. The lower limit of detection was 5ng/g 
for each drug. 
In 1995, a study was carried out to detect morphine glucuronide in meconium but as 
only small amounts of it are transmitted through the placenta to the foetus, the 
absence of morphine glucuronide is not an unusual finding. However, other opiates 
and their metabolites were present in significant amounts and differed from those 
found in urine as there is no need to hydrolyse meconium. Measurable amounts of 
morphine could be detected, but no report of monoacetylmorphine has been 
published. 136 
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Amphetamines 
Nakamura, 1992162 detected amphetamine using GC/MS on an HP-ultra2 column 
(25m x 0.2mm ID x 0.33µm) with the oven temperature starting at 100°C for 30sec, 
rising to 220°C at a rate of 20°C/min. He could detect as little as 1 ng/g, but found 
that the gestation age can affect the sample. ElSohly 1999163 used liquid-liquid 
extraction (LLE) followed by SPE and derivatisation by pentafluoropropionic 
anhydride (PFPA). The limit of detection was l Ong/g. 
Cannabinoids 
Detection and analysis of cannabinoids in meconium is difficult, as they are present 
in small amounts. However, Moore, 1996 147 and ElSohly 1999 163 report a method 
involving hydrolysis by alkali or enzyme, then analysis by GC/MS after 
derivatisation by dimethyl-tert-butylsilyltrifluoroacetamide (MTBSTFA) and bis- 
trimethylsilyltrifluoroacetamide (BSTFA) on a DB-5 MS or HP-1 column (25m x 
0.2mm ID x 0.33 µm film thickness) respectively. The limit of detection with 
alkaline hydrolysis was 2ng/g, with good recovery. 
Phencyclidine 
This drug crosses the placenta to the foetus and is present in urine and plasma. 
There are several methods for its extraction. Moriya, et al 1994 
146 detected the drug 
with a limit of detection of 20ng/g. Moore, 1996 147 tried to decrease the limit of 
detection to 5ng/g by using GC/MS in the SIM mode but no improvement was 
reported, although immunoassay was used to detect other metabolites. Another 
method reported used extraction by SPE with elution by 2% ammonium hydroxide, 
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followed by GC/MS-SIM with a limit of detection of 20ng/g of meconium and 
7ng/ml of urine. 148 
Methadone 
Methadone and its metabolite EDDP was detected first by Winger et al, 1994 27 
using SPE and confirmation by GC/MS. Stolk et al, 1997 164 used FPIA and HPLC. 
The assay was linear over the range 460-3680ng/g methadone and 1000-6000ng/g 
EDDP, and the limits of detection were 99 and 113ng/g respectively. In another 
report, the lower limit of detection was 30ng/g. 145 
Analysis of Multiple Drugs 
Some studies tried to detect multiple drugs using SPE with different eluants, for 
example, Moore et al, 1995161 analysed opiates, amphetamines and cannabinoids, 
each one analysed separately using an HP 1 column (25m x 0.02mm x 0.33µm) and 
quantification by GC/MS. The meconium was prepared by two different methods, 
the first one using 10ml of water and concentrated hydrochloric acid, and the second 
using methanol. The detection rate for cannabinoids by the first method was only 
19.6%, while all the positive cases could be detected by the second one. The rate of 
negative results increased because of the use of an inefficient extraction procedure. 
There were false positive results but the screening is not a problem if confirmed by a 
different technique. This may be due to giving the patient some medical 
prescriptions especially those containing opiates, but other drugs were not confirmed 
due to cross-immunoreactive responses. For example, antibodies for 
tetrahydrocannabinol (THC) and its metabolites cross-react with non steroidal anti- 
inflammatory drugs (NSAID's) while amphetamine assays can give false positive 
results due to cross-reacting substances such as phenylamine and other endogenous 
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compound, which interfere with the polyclonal assay. GC/MS confirmation gave 
positive results in about 74.3% of cases showing positive in the initial screen. 
Another published method used meconium specimens and maternal urine for 
cocaine, benzoylecgonine, cannabinoid metabolites, opiates and amphetamines. 
Drugs were extracted by SPE and derivitised with PFPA. The limits of detection 
were: amphetamine (1000ng/ml), THC (50ng/ml), 11-nor-delta-9-tetrahydro- 
cannabinol-9-carboxylic acid (THC-COOH, 15ng/ml), opiates (morphine, codeine, 
300ng/ml), benzodiazepines (300ng/ml). The results for meconium compared to 
urine were more accurate by 25% and showed higher concentrations for cocaine than 
maternal urine. 149 
Moore147 and ElSohly 1999163analysed opiates, and major metabolites, cocaine, 
benzoylecgonine, amphetamine and cannabinoids, each drug eluted by a specially- 
selected eluant. 
7.2.3. High Performance Liquid Chromatography 
HPLC can be used with electrochemical and diode array ultraviolet-visible 
detectors, but it is expensive, needs significant experience and time consuming but it 
is specific and gives accurate results. 137 
HPLC has been used for the analysis of meconium after SPE to detect cocaine, 
norcocaine and cocaethylene, using onto a C18 column (300mm x 3.9mm ID). The 
quantification limit was 0.1mg/kg and the limit of detection was 0.03mg/kg. '59 
Murphy et al, 1993165 determined benzoylecgonine in meconium by HPLC. The 
calibration curves were linear over the range 0.05-5. Oµg/g of meconium and the limit 
of quantification was 0.05µg/g 136 
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Morphine and amphetamine have been detected by HPLC: in one method, the 
recoveries were 65.6% and 91.8% respectively and the lower limits of detection 
(LOD) were 0.5ug/g and 500ng/g respectively. This represents an increase in LOD 
for morphine of 100 times that obtained with GUMS. HPLC is therefore considered 
less sensitive and specific than confirmation by GC/MS. 13 Another method for 
morphine and amphetamine also used reversed phase system based on a C18 
stationary phase (150mm x 4.6mm ID x 5µm particle size), with a diode-array 
detector and Millennium@ software for identification by matching UV spectra. The 
lower limit of detection was 0.5µg/g of meconium, the regression coefficient 0.987 
and the recoveries 91.8% for amphetamine, 65.6% for morphine. '46 
Stolk et al, 1997164 detected methadone using reversed phase system involving a 
C18 stationary phase and a mobile phase consisting of 530m1 distilled water, 146µ1 
triethylamine and 350µ1 phosphoric acid at pH 3.3. The assay was linear over the 
range 460-3680ng/g for methadone and 1000-6000ng/g for EDDP. The limits of 
detection were 99 and 113ng/g, respectively. 
7.2.4. Immunoassay Techniques 
Multiple drugs have been detected in meconium using the enzyme multiplied 
immunoassay technique (EMIT) which depends on an antigen or hapten labelled 
with an enzyme. It can be semi-quantitative and is relatively expensive. Screening 
of meconium without some degree of extraction is difficult and gives false results, 
especially with EMIT or fluorescence polarisation immunoassay (FPIA) due to 
turbidity in the meconium extract. Chen and Raisys166 used EMIT for detection of 
benzoylecgonine, with a limit of detection of 400ng/g of meconium. 
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Moriya et al, 148 screened for amphetamine, cocaine metabolites, opiates and PCP in 
meconium with a combination of EMIT and SPE. The cartridges were eluted with 
chloroform: propanol (3: 1 v/v) and the extracts were then evaporated to dryness, 
reconstituted with buffer (pH6) and methyl acetate. The lower limits of detection 
were 250 ng/g for benzoylecgonine, 770 ng/g for d-amphetamine, 110 ng/g for 
morphine and 100ng/g for PCP. 
Wingert et al, 1994160 determined cocaine, cannabis metabolites, opiates and 
methadone by EMIT. 
Amphetamine, methamphetamine, cocaine metabolites, opiates and PCP were 
screened by EMIT using the Syvatest plus system. Meconium was considered 
positive for cocaine metabolites when the reaction rate for a specimen minus the 
reaction rate for the negative control exceeded 40 units. 145 
A screen for benzoylecgonine by EMIT had a lower limit of detection of 100µg/1, 
sensitivity of 0.6gg/g, a recovery of 61 % and the cut-off was set to 0.6gg/g. 24 
Comparative analyses of maternal urine and meconium for cannabinoids, 
benzoylecgonine and opioids including methadone which was used to treat cocaine- 
addicted mothers were done by EMIT, TLC and GC/MS. The cut off for EMIT was: 
cannabinoids 50ng/ml, benzoylecgonine 300ng/ml, amphetamine 1000ng/ml and 
opiates 300ng/ml. The results showed that no case gave positive results with urine 
which did not also give the same with meconium, while urine analysis missed 25% 
of the positive cases. From these results, meconium is considered more sensitive 
than urine and to have an accuracy up to 33% above a urine test. 167,168 
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Screening of amphetamine, benzoylecgonine, opiates and PCP was carried out by 
mixing the meconium with methanol and concentrated HC1, then analysing by EMIT, 
followed by confirmation using GC/MS. The detection limits were 100ng/ml for 
benzoylecgonine, 500ng/ml for methamphetamine and morphine, and 75ng/ml for 
PCP. This method had many advantages in that it took a short time, gave clear 
extracts with a low background and had better recoveries than methanol alone. '48 
Another method to screen for cocaine and benzoylecgonine using EMIT had a 
lower limit of detection in the range 300-400ng/g but the sensitivity by this method 
was low as only microgram levels of cocaine/gm of meconium could be detected 
after concentration to give the same result as GC/MS, so methanolic extraction of 
meconium followed by SPE and EMIT assay can be used to screen newborns for 
intrauterine exposure to cocaine. 169 
The other main type of immunoassay which is more popular for the analysis of 
drugs of abuse in meconium is radioimmunoassay (RIA): recent work has been based 
on this method. 
Enrique et al, 1991137 found that RIA analysis is an ideal method which depends on 
the radioactive label competing with the unlabelled drug for binding sites on specific 
antibodies, so it is highly sensitive and semiquntative, but requires experience, is 
expensive, detects only one drug at a time (time consuming) and, as with all 
immunoassays, cross-reactions with other compounds can occur. It has been used 
for the detection of benzoylecgonine and cocaine, opiates and cannabinoids. 169 
The meconium samples were collected, mixed with water and concentrated HC1 and 
centrifuged. The supernatant was analysed for morphine (heroin metabolite) and 
benzoylecgonine (cocaine metabolite) using RIA kits. The recoveries were 84-97%, 
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and 70-105%, respectively for morphine and benzoylecgonine and 97% for 
cannabinoids. 
Another modified method involved mixing the meconium with phosphate buffer and 
methanol and using the ultrafiltrate for the detection of morphine, cocaine, and 
cannabinoids by EMIT, and also mixing the meconium with water followed by RIA 
analysis, with the lower limit of detection being 15ng/0.1 g of meconium. 136 
A more sensitive and specific method for determination of opiates, cocaine and 
cannabinoids was the result of 100% recovery, with no cross reactivity. '50 
Cannabinoids and amphetamines can be screened by RIA with a lower limit of 
detection of 2ng/gm. 170 
A comparison of urinalysis with meconium analysis by RIA found that the lower 
limit of detection used 15ng/0. Ig meconium with detection of a higher percentage of 
cocaine exposures when meconium was used, 11.8% overall more than with urine. '71 
Immunoassay by FPIA is also considered to be very sensitive and to give good 
results. Many researchers have used this method. In 1994 Lewis 169 screened for 
cocaine, cannabinoids, amphetamine and opiates after adding acetic acid and 
methanolic buffer to meconium. After centrifuging, the supernatant was analysed by 
FPIA. 
Franssen et al, 1994107 used FPIA for the determination of morphine and 
amphetamine in meconium, with a lower limit of detection of 1.35µg/g for 
amphetamine and 0.35pg/g for morphine. 
Analysis Of Multiple Drugs In Small Blood Specimens and Meconium 
Page 92 
Another method involves the addition of acetonitrile, vortexing and centrifugation 
with subsequent analysis of the supernatant by FPIA for benzoylecgonine. Precision 
over the linear range of the method were 12% at 0.08µg/g and 6.5% at 4pg/g. 167 
FPIA was used for the determination of cannabis metabolites, cocaine and 
cocaethylene and also gave good results for methamphetamine and PCP. 12 
FPIA reagents were obtained from Abbott Diagnostics, which is considered better 
than the Roche On Line cocaine assay, and uses Kinetic Interaction of Microparticles 
in Solution (KIMS). This was examined as a potential methodology for 
determination of cocaine metabolites in meconium, as this technology has similar 
sensitivity to FPIA and is better than EMIT. KIMS is based on latex beads (1-5µm) 
in diameter, so it can be expected to interact with meconium lipid droplets and give 
false positive results, while FPIA does not interact with lipid, so a decreased 
incidence of false results is obtained. In that study it was found that meconium 
analysis is better than urinalysis. Also, FPIA is a good analytical technique for true 
cocaine exposure whereas the KIMS technique lacks the requisite specificity to be a 
useful screening tool and must be followed by confirmation by GC/MS. Positive 
results obtained by FPIA are an accurate indication of prenatal cocaine exposure. 173 
Some researchers have carried out analyses using simple tests such as colour, or spot 
tests. Ostrea, 1991137 considered this approach to be simple and early tests depended 
on reaction of small amounts of sample which react with the test reagent to give a 
colour. Colour tests are considered to be easy, quick and inexpensive. They do not 
need extensive experience, but can give high rates of false positive or false negative 
results. Colour tests need high concentrations of the analytes in the test matrix. 
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7.2.5. Thin Layer Chromatography 
Thin layer chromatography (TLC) needs extraction and concentration of the drug 
metabolites from the matrix prior to separation and detection, so its identification 
capability is limited. TLC has a broad spectrum for drug detection, so it has low 
specificity. 137 
Fumio Moriya et al, 1994 148 used TLC for the identification of opiates after SPE, 
eluted by chloroform: isopropanol (9: 1 v/v), evaporated under nitrogen then 
reconstituted in ethanol and an aliquot applied to TLC. The plate was developed 
with ethyl acetate: methanol: concentrated ammonium hydroxide (34: 4: 3 v/v/v). 
Spots were visualised with iodoplatinate spray, sensitive enough to detect down to 
300ng/ml in urine. 
Some research compared maternal urine and meconium using TLC. The maternal 
urine was analysed by TLC and confirmed by enzyme immunoassay, gas liquid 
chromatography and ultraviolet spectroscopy. The infant samples were analysed by 
enzyme immunoassay and confirmed by one of the same methods, or by the result of 
maternal urine sample. Quantitative data on these results were considered unreliable 
and eliminated from statistical analysis. 174 
7.3. Hair 
Drugs which cross the placenta and their metabolites are found in foetal hair which 
grows during the 3`d trimester. Therefore hair analysis reflects drug exposure during 
this time period. The growth cycle of neonatal scalp hair is different from infants as 
all hair fibres except those located at the vertex region are lost between 8-12 weeks 
after birth. Also, the amount of hair is very small, so allowing only one test which is 
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commonly performed by radioimmunassay. '53 Hair provides a very sensitive 
indicator of drug use by a pregnant mother, especially if analysed by radio- 
immunoassay. Validation studies have shown hair analysis to have a sensitivity of 
96% and a predictive value of 100%, and that it does not give false positive 
results. 
137 
Each hair consists of the hair follicle, cuticle and shaft. The rate of hair growth is 
1-2cm/month, on average. Deposition of drugs occurs during the growth of the hair 
shaft and the recent portion is near the scalp. Sectional analysis is performed 
monthly to provide information on the duration and time of drug use by the mother. 
Detection and quantification can be carried out, especially for chronic drug users, by 
many methods including collisional spectroscopy. The proximal segment of the 
foetal hair corresponds to the 12th week, approximately, before delivery which gives 
information about the concentration of cocaine and its metabolite benzoylecgonine in 
foetal hair which grows during the 3`d trimester. 137 
Drugs are incorporated into the hair follicle then grow into the cuticle and shaft. The 
concentration of drug varies according to period of exposure. Hair gives information 
on the duration and time of drug use, but it needs consent from the patient as the 
analysis needs a bundle of hair approximately 0.6 cm in diameter from the posterior 
scalp. 140 Hair analysis has some limitations as some precautions are needed in 
collection and the analysis is generally expensive. Hair is affected by many factors 
that modify the quantity and concentration of drugs including its length, any hair dye, 
bleach, cosmetic agents and environmental contamination. So foetal hair must be 
taken in hospital before the newborn reaches home. 137 
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The mechanism of drug transport into hair is not well understood, but depends on the 
physiochemical properties of the drug such as melanin affinity, lipophilicity, and 
membrane permeability. Hydrophilic drugs such as cocaine and heroin in the parent 
form tend to be concentrated in the modulated sections of hair, more than blood. The 
ratio of cocaine and benzoylecgonine concentration in adult hair is 10.5 times higher 
than child hair, as foetal hair has no medulla. 175 
Several drugs can be detected in hair by radioimmunoassay, FPIA, and GC/MS 
including morphine, codeine, monoacetylmorphine, nicotine, cocaine and 
benzoylecgonine. ' 76 Exposure to cocaine and its metabolites is considered a serious 
problem and its detection depends on the time of exposure, as it accumulates early in 
gestation with a short half life and in small quantities. Urine analysis was the first 
biological sample used in its detection but presents many problems such as proper 
specimen collection, time of collection, urine pH, method of analysis, temperature, 
the degree of dilution, and limitation of detection of only one drug alone. 175 
Meconium and hair are biological samples used as alternatives to urine for detection 
of cocaine and its metabolites, which are embedded into the hair shaft and remain for 
the life of the hair or until it is cut. As the hair of the neonate grows during the last 3 
months of pregnancy, a positive neonatal hair test uncovers an addiction pattern in 
which the mother consumed the drug long after she become pregnant. 175 The time of 
hair collection is not critical, but its analysis first requires decontamination, which is 
usually done in several steps. Firstly, it is washed with several solvents (methanol, 
ethanol, dichloromethane, acetone, detergent, or warm water). Drugs are then 
extracted from the hair by incubation with methanol, ethanol, acid, and proteinase or 
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pronase. Then the extract is analysed by RIA (needs 2-5 mg hair) or by GC/MS 
(which needs 1-10 mg hair). 141 
The neonatal hair was not washed prior to analysis as external deposition of cocaine 
from amniotic fluid is an indicator of prenatal exposure 15. The foetus swallows 
amniotic fluid at a rate of 0.5L/day and bathing in it causes toxins circulating in the 
amniotic fluid to reach the foetus via the transdermal route. Because of low 
keratinisation, foetal skin is readily permeable to exogenous substances, although 
external infection is not common. Some investigators prefer meconium to hair, 
although it is available only during the first 2-3 days of life, and on some occasions is 
not excreted even up to three days after birth. Hair testing is also considered to be 
very sensitive and to give good results, especially if the urine test gives a false 
negative result. 175 Cocaine detected in the proximal segment of the mother's hair 
corresponds to her drug exposure history, but in foetal hair gives a sensitivity up to 
78% with GC/MS (compared to 74% for meconium) and 52% with FPIA. Urine 
analysis gives a sensitivity of 38% and can result in misclassification of more than 
60% of cases. In these statistics, sensitivity is defined as the percentage of true 
positives which are detected. 
In summary, analysis of hair samples from the neonate is often not practical because 
of the problems in collecting suitable specimens and surveys may as a result be 
unreliable and often not reproducible. In contrast, drugs accumulate in meconium 
and are deposited in the last half of gestation. The drugs are essentially trapped in 
the meconium due to being tightly bound to cell fragments in the matrix that 
effectively prevent diffusion. 173 
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7.4. Nail 
Nail is formed in the 2"d and 3`d trimesters of pregnancy as it grows from 3`d month 
of gestation and reach the fingertip at the 8t' month. During this time drugs are 
incorporated into the nail from the circulation and by soaking in the amniotic fluid. 44 
At delivery, the composition of the newborn nail reflects drug exposure during this 
period of gestation. The sample size is always sufficient to allow confirmation by 
RIA and GC/MS, as l0mg may be available, while hair usually does not exceed 
1-5 mg. Hair grows in an intermittent cycle while nail grows continuously, so 
assisting epidemiological studies. 
The common drugs which have been detected in nail are morphine, 6-acetyl- 
morphine, codeine, cocaine, and benzoylecgonine. The identification and 
quantification of these drugs has been done by GC/MS. The limit of detection was 
as low as ing/10mg of nail powder for 6-acetylmorphine, morphine and cocaine 
while for benzoylecgonine it was 2ng/10mg of nail powder and for codeine was 
3ng/10mg-nail powder. No other drugs in this study were detected at this limit of 
detection. 153 
7.5. Amniotic Fluid 
Amniotic fluid is the fluid that surrounds the foetus through the pregnancy. All the 
foetal food and secretions are present in it and it contains high concentrations of 
drugs. Amniotic fluid is collected by amniocentesis to show lung maturity. 141 More 
is available in premature rupture of membrane. Generally, analysis of amniotic fluid 
has not been shown to give any benefit over urine analysis. 143 
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Cocaine, benzoylecgonine and ecgonine methyl ester have been screened in amniotic 
fluid by GC/MS. The average limit of detection was 5ng/ml. Cocaine and morphine 
have also been detected by fluorescence polarisation immunoassay using the Abbot 
TDX system. 177 Cocaine and its metabolites can be found in amniotic fluid after 
maternal use, due to foetal urination after 18-20 weeks gestation and the foetus may 
repeatedly exposed to cocaine and its metabolites by swallowing amniotic fluid. The 
concentrations of benzoylecgonine and cocaine in amniotic fluid ranged from 400 to 
more than 5000 ng/ml and up to 250ng/ml, respectively. Neonatal urine contains 
these drugs at 1 /6th of the amniotic fluid level. A comparison of drug levels in three 
biological samples - amniotic fluid, umbilical cord blood and neonatal urine - found 
that benzoylecgonine was present in all three samples but the concentration was 
higher in urine than amniotic fluid, and was lowest in umbilical cord blood. 
However, more cocaine was present in amniotic fluid than urine. 178 
Cocaine and its metabolites reach the foetus by foetal swallowing, through the 
umbilical cord, or by diffusion across the placental surface vessels, so swallowing is 
not the only route. Desmethylation of cocaine by the foetal liver, with subsequent 
deposition into the intestine, then results in accumulation in amniotic fluid. The 
recovery of cocaine from plasma and amniotic fluid was 100% whereas for 
norcocaine and benzoylecgonine it was 86% and for ecgonine methyl ester was 66%. 
The minimal detectable levels were 5,10,5 and IOng/ml respectively. 
145 
The presence of cocaine and metabolites in amniotic fluid did not appear to influence 
foetal oxygenation. Cocaine was found in the largest quantities after 72 hours at a 
concentration of 350ng/ml, followed by ecgonine methyl ester and benzoylecgonine, 
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with very low concentrations of norcocaine. Cocaine, benzoylecgonine and 
norcocaine can be detected in foetal and maternal blood up to 24 hours after 
administration at approximately 3% of the amniotic fluid concentration. Cocaine 
when present in amniotic fluid is metabolised primarily to ecgonine methyl ester, 
benzoylecgonine and norcocaine. This was in vitro but in vivo it was found that 
cholinesterase is present in amniotic fluid and is responsible for the metabolism of 
cocaine to ecgonine methyl ester. This also depends on temperature and pH: the 
higher the temperature and pH the faster the hydrolysis. 179 
7.6. Blood Analysis 
Blood analysis is the longest established method used for detection of neonatal drug 
exposure, especially to morphine, which has been used increasingly in intensive care 
during the past 10 years. Morphine is also used in the newborn with respiratory 
distress syndrome as it reportedly stabilises the fluctuations in arterial blood pressure 
and decreases the risk of intracranial haemorrhage. Morphine elimination may be 
prolonged in the neonate, and some studies have also shown that clearance of 
morphine is reduced in preterm neonate. Analysis of blood and urine indicates recent 
drug exposure while drug detection in meconium is considered to be a marker of 
remote drug exposure. Little is known about the relationship of cocaine metabolites 
in meconium compared with blood. 137 
Esterase activity facilitates the breakdown of cocaine. There is a relation between 
meconium BZE level and cord pseudocholinestrase activity. If benzoylecgonine is 
present in cord blood this means recent drug use and usually BZE is present in lower 
amounts than in meconium, as catabolism in meconium is less complete than in 
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blood, which has no cocaine or little benzoylnorecgonine, while meconium contains 
all of these. This was taken to mean rapid metabolism in the blood in what looked 
like a relapsed cocaine-abusing mother. Foetal biological fluids can be used for 
detection of cocaine metabolism, and similar results were found in both 
cerebrospinal fluid and cord blood, about 1.24pg/ml. Cocaine metabolites in 
meconium indicate past exposure, and their presence is due to slow release or cycling 
through amniotic fluid. Chronic drug use results in excretion of benzoylecgonine for 
up to 3 weeks after last intake, which affects behaviour leading to depression of the 
infant. Also the neonatal irritable syndrome appears after I month when the mother 
uses codeine during pregnancy, which has similar pharmacokinetics to those found in 
cocaine metabolism. 180 
7.6.1. Previous Analytical Methods 
There are several method for the detection of cocaine, benzoylecgonine and other 
metabolites in cord blood. These have been used to investigate the relationship 
between the amount and distribution of cocaine species. Measurements have been 
made of cholinesterase (which is important for hydrolysis of cocaine), catabolic 
capacity and correlation with metabolite levels. 137 
The cord blood has been analysed by HPLC using a C18 column and ultraviolet 
detection. Positive samples were confirmed by GC/MS for the presence of 
benzoylecgonine, norcocaine and cocaine. 180 BZE can be separated from umbilical 
cord by SPE. Also, pseudocholinesterase can be used to detect BZE in serum using 
the Du Pont ACA Discrete Clinical Analyser, which depends on photometric 
measurement of the conversion of the blue dye 2,6-dichlorophenolindophenol to a 
colourless compound when butylthiocholine is hydrolysed by pseudocholinestrase. 
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Calibration and verification were performed according to clinical standards. 
Recovery ranged from 71% to 90% with a coefficient of variation in the range 3.1 to 
6.9% and limit of quantification of 0.10µg/g. '80 
7.7. Breast Milk 
Drugs of abuse can transmitted through breast milk, so if the mother is a chronic user 
it is contraindicated for her to breast feed her child. Chasnoff et al (1989)181 reported 
infant toxicity by exposure to cocaine through breast milk. Cannabinoids and 
alcohol are also transmitted via breast milk and are present for a longer time than in 
serum. If the mother take drugs intravenously, her child may be exposed to hepatitis 
B, C, and HIV. 5 Nicotine can transmitted with its metabolites in breast milk. 
Nicotine is present in milk in concentrations between 1.5 and 3.0 times the 
simultaneous maternal plasma concentration. '82 
7.8. Urine Analysis 
Urine is the most common biological fluid used for drug abuse detection. It has 
some advantages including that it is easily collected by non-invasive procedures, 
exhibits high concentrations of drugs due to the concentrating ability of the kidney, 
large amounts may be collected, it is more easily analysed than blood, drug 
metabolites are stable, especially if it is frozen, and it can be used in all instrumental 
methods. 137,140 
Urine has some disadvantages, for example it can give false negative results, urine 
specimens can easily be exchanged by the donor with another, clean sample, it can 
easily be diluted or other things added, like salt, which interferes with the testing 
methods, and also, it gives information only about recent exposure to drugs. 137 
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It is now uncommon to use infant urine as that is difficult to collect, needing a 
specially positioned bag to obtain it, need repetition to collect a suitable specimen, 
and a skin rash may occur if it is in contact with the skin. The amount collected is 
usually not enough for both a primary and confirmatory test and the time of sample 
collection is very important to be within the window of detection, as after a certain 
period false negative results can be obtained. '4' 
The window of detection depends on many factors: individual drug metabolism, 
hydration status of the subject, route of administration, and frequency of use, as most 
drugs appear in urine if used only 48 to 72 hours before analysis. In chronic heavy 
users of cannabis positive results can be obtained for over I month after quitting. No 
cross-reactions are found with the immunoassays for cocaine or cannabis, but this is 
not so for amphetamines or opiates, as different types of food contain ephedrine or 
phenylpropanolamine, which cross-react with RIA and so give false positive results. 
Therefore, a confirmatory test is necessary. For opiates, immunoassay does not 
differentiate between morphine and codeine, the presence of which is taken as 
conclusive when trying to separate street heroin use from prescribed pain 
medicaments, which often contain morphine as a constituent. Immunoassay gives 
positive results for opiates up to 66 hours after administration. '40 
Several drugs can be detected in urine by different methods, involving extraction by 
SPE and screening by GC/MS. For cocaine, the limit of detection was 5ng/ml urine. 
Cocaine concentrations in urine are the same in mother and foetus. Cocaine 
metabolites are found in high concentrations in meconium but the cocaine 
concentration is lower than its metabolites. '43 
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Another study involved screening by enzyme multiplied immunoassay technique and 
confirmation by GC/MS. The specimens with internal standard added were treated 
with acetate buffer and added to conditioned SPE columns, which were washed and 
extracts were eluted with 6m1 methylene chloride: isopropanol: concentrated aqueous 
ammonium hydroxide (80: 20: 2 v/v/v). The organic phase was evaporated and the 
residue reconstituted in 0.02m1 acetonitrile. Extracts were treated with 0.02m1 
BSTFA (containing 1% TMCS) heated at 60°C for 30min, then analysed by GC/MS 
on an HPI column (12m x 0.2mm i. d x 0.33µm film thickness). The injector port 
was at 250°C and the oven temperature started at 70 °C for 1 minute, rising to 220°C 
at a rate of 35°C/min, then to NOT at a rate of 30°C/min. Full mass spectra were 
collected repetitively over the range 50-550 mass units. The limit of detection was as 
low as 7.5ng/g. The mean concentrations of ecgonine methyl ester and cocaine were 
highest followed by benzoylecgonine and norcocaine, then the lowest was 
cocaethylene. 168 
Susan, et al. (1994)1 83 analysed neonatal urine by RIA, which recovered 31 % of 
positive cases, with a high rate of false negative results, but metabolites of drugs are 
found in high concentration in the gastrointestinal tract of the foetus so it is 
preferable to analyse meconium. 
Urine sample analysis was performed by immunoassay and GC/MS for morphine, 
methadone, barbiturates, phencyclidine, hydrochloride, amphetamine, 
methamphetamine, diazepam, benzoylecgonine, and ecgonine as metabolites of 
cocaine and the positive group of infants was compared with controls and the results 
for maternal urine samples. ' 94 
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Maternal urine was screened and confirmed as follows: cocaine, identified as 
benzoylecgonine by FPIA and confirmed by GC/MS, cannabis metabolites by EMIT 
and confirmed by GC/MS, amphetamine, benzodiazepines and opiate by EMIT and 
GC. Urine samples of infants were analysed for cocaine by FPIA and confirmed by 
GC/MS. The EMIT screening cut-offs were as follows: amphetamine, 1000ng/ml, 
benzodiazepines, 300ng/ml, benzoylecgonine, 50ng/ml, THCOOH, 15ng/ml, 
cannabinoids, 50ng/ml, opiates, 300ng/ml. 
Analysis of infant urine missed 25% of the infants which gave positive results with 
meconium, so meconium is considered a good sample to analyse for cocaine rather 
than urine. 149 Urine was also analysed by RIA, with a lower limit of detection of 
2ng/mg. 17o 
Maternal urine sample analysis required 50m1 urine and infant urine samples were 
tested for cocaine, heroin, methadone and tetrahydrocannabinol by normal TLC and 
confirmed by EMIT. Sensitivity of TLC for urinalysis was 1 mg/ml for opiate and 
cocaine and EMIT had a cut-off set at 0.3mg/I. TLC analysis of urine samples may 
give false negative results so other techniques are preferred. ' 81 
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8. Extraction of Multiple Drugs of Abuse from 
Meconium Using a Single SPE Column: 
8.1. Introduction: 
Previous work with meconium has generally been concerned with the analysis of 
single drugs or drug groups, especially cocaine and its metabolites in studies carried 
out in the United States. For the present project, the ultimate intention was to carry 
out a survey of drug use amongst pregnant mothers in the Glasgow area, based on 
toxicological screening, and a method was required to permit this to be done with 
small samples of meconium. The method described in Chapter 3 of this Thesis, 
involving SPE with Bond Elut CertifyTM columns followed by qualitative and 
quantitative analysis by EIA and GC/MS was suitable for this purpose. However, 
adaptations were required to take into account the differences between blood and 
meconium in the initial sample preparation and treatment steps. 
The target analytes were chosen as the most commonly used and abused drugs in the 
Glasgow area, which are known from the casework carried out in the Forensic 
Medicine Department at Glasgow University. These were: cocaine and its principle 
metabolite benzoylecgonine, morphine, codeine, methadone, diazepam, temazepam, 
tetrahydrocannabinol (THC) and tetrahydrocannabinol carboxylic acid. 
An additional procedure was also introduced separately for the analysis of 
amphetamines, and this is described in Chapter 9. 
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8.2. Materials and Instrumentation 
8.2.1. Materials 
All chemicals were purchased from SIGMA Company (Dorset, UK). The solvents 
and concentrated ammonia were of HPLC grade supplied by BDH laboratories 
supplies. Analytichem International. Bond Elut CertifyTM columns were obtained 
from Varian (Harbor city, California, USA), and the Baker-20 SPE vacuum manifold 
system was from International Sorbent Technology. 
Phosphate buffer (0.1 M) was prepared by dissolving 6.81 g of potassium 
dihydrogen phosphate in 450m1 of de-ionised water, adjusting the pH to 6.0 ± 0.1 
with 1. OM potassium hydroxide, then making the total volume up to 500m1 with de- 
ionised water. Acetic acid solution (0.01M) was prepared by adding 57.5 µl of 
glacial acetic acid to 100ml of de-ionised water. 
The SPE eluant was prepared daily by mixing chloroform and acetone in the ratio 
1: 1 v/v. Ammoniated ethyl acetate (2%) was used as eluant II and prepared daily by 
adding I ml of ammonia to 49ml of ethyl acetate. Both were sonicated for at least 5 
minutes before use. 
Cocaine, benzoylecgonine, morphine, codeine, THC and THC-carboxylic acid 
were purchased from SIGMA, and deuterated materials were from Radian 
Corporation (Austin, TX). 
Enzyme Immunoassay (EIA) was carried out using kits from Cozart Bioscience 
Ltd., Oxfordshire. 
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8.2.2. Instrumentation 
Gas chromatography-mass spectrometry was carried out using a VG Micromass 70- 
250S double focusing magnetic sector instrument. The gas chromatograph (Hewlett 
Packard 5890 Series II) was equipped with a fused silica capillary column (HP5, 
30m x 0.32 mm id, 0.3 pm film thickness). Samples (volume 1 ul) were injected with 
an injection port temperature of 280°C. The column oven was programmed from 
200-300°C. The mass spectrometer was operated at a resolution of 1000 in the EI+ 
mode (ionisation energy 70 eV, source temperature 220°C). The instrument was 
tuned daily using perfluorokerosene according to the manufacturer's 
recommendations. Mass spectra were obtained by scanning from 600 to 40 AMU at 
0.3 s/scan and data were recorded with a Masspec 1 data system from Mass 
Spectrometry Services, Manchester, UK. Quantitative analyses were carried out in 
the SIM mode, using deuterated analogs of the target analytes as internal standards. 
8.3. Methods: 
8.3.1. Sample Collection 
Samples of meconium were collected from diapers of newborn infants delivered at 
the Royal Maternity Hospital, Glasgow 9 these are real case samples). The 
meconium was recovered using a wooden spatula and stored in plastic tubes at -4°C 
until analysed. In addition, 30 samples of meconium were collected from neonates 
delivered in several hospitals in Egypt who were not exposed to drugs in uteri. 
These were used as controls. 
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8.3.2. Sample Preparation 
Each meconium specimen was weighed (range from 0.5g - 0.8g) into a clean vial 
and centrifuged at 2000rpm for 10 minutes to bring it to the bottom. Drug standards 
were added and the samples were homogenized by vortexing and sonicating for 15 
minutes. Methanol (3 ml) was added, and the tubes were vortexed well for 10 
minutes then centrifuged at 3000rpm for 20 minutes. The upper layers were 
transferred to clean tubes and evaporated to dryness under nitrogen, initially at room 
temperature then with slight warming up to 40°C until completely dry. Once dry, the 
residues were dissolved in 700 µl methanol with vortexing. The extraction tubes 
were then centrifuged at 2000rpm for 10 minutes. 
8.3.3. Sample Extraction 
The solid phase extraction (SPE) procedure applied was as follows: 
" the column was prepared by washing with 2m1 methanol, followed 2 ml 
phosphate buffer (pH6); 
" the sample was applied at low vacuum pressure; 
" the column was washed with lml distilled water, followed by 0.5m1 acetic acid 
(1. OM, pH 3.3). 
9 the column was dried at maximum pressure for 4 min, then 50 µl methanol was 
added and the vacuum reapplied for lmin. 
Elution was carried out in two stages: 
- 4m1 of eluant A (chloroform: acetone 1: 1 v/v); 
-2x 2m1 of eluant B (2% ammonia in ethyl acetate). 
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A 500 µl aliquot of eluant B was analyzed by EIA for opiates, cocaine, methadone, 
cannabinoids and benzodiazepines. 
To the remainder of the eluant, the deuterated forms of each target analyte were 
added as internal standards at a concentration of lOng/ul. The extracts were mixed 
well and evaporated to dryness under nitrogen at 40°C until completely dry, then 
50µl BSTFA were added, the vials were capped and incubated at 60°C for 20 
minutes prior to GC-MS-SIM analysis. Selected ions used for quantitative analyses 
are listed in Table 8.1 along with the retention times for each analyte. 
Table 8.1: Selected Ions Used for GC/MS/SIM 
Target analyte Retention 
Time (min) 
Selected ions 
(m/z) 
Internal Standard Selected ions 
(m/z) 
Cocaine 6.21 303 H3-cocaine 306 
Benzoylecgonine 7.34 361 H3- 
benzoylecgonine 
364 
Morphine 8.58 429 2 H3-morphine 432 
Codeine 11.68 371 H3-codeine 374 
Methadone 9.03 72 H3-methadone 75 
Diazepam 8.55 284 H5-diazepam 289 
Temazepam 9.33 372 HS-diazepam 289 
THC 9.15 386 H3-THC 389 
THC-COOH 10.15 488 H3- 491 
8.3.4. Limit of detection and extraction recoveries 
These were determined by spiking blank meconium with the target analytes. Ten 
different meconium samples were spiked with standards and analyzed as described 
earlier in order to determine the extraction recovery of the method. Furthermore, ten 
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meconium samples were spiked with decreasing amounts of drug standards and then 
analyzed as before to determine the limits of detection of the method. To determine 
the extraction recoveries, the internal standards (deuterated form of each drug) were 
added to the eluates obtained by SPE and these extracts were compared with 
unextracted standards. 
8.3.5. Application to Real Case Samples 
The same method was then applied to 25 real cases from the Royal Maternity 
Hospital, Glasgow. Extracts were initially screened by EIA and then confirmatory 
quantitative analyses were carried out by GC/MS- 
EIA Analysis: 
The EIA method used was an Enzyme Linked Immunosorbent Assay (ELISA) 
from Cozart Company. This assay involves the enzyme horseradish peroxidase, 
which produces a blue colour with its substrate. 500 pL of elute B was evaporated 
till dryness under nitrogen then reconstituted in EIA buffer (1 ml). This was then 
analysed for morphine, cocaine, methadone, cannabis, and benzodiazepines using 
EIA kits containing antisera highly specific to free (unconjugated) form of parent 
drug and with a low cross reactivity to codeine. The method followed the same steps 
previously mentioned. The calibration curve was prepared from standards containing 
the analytes at concentrations of 0,10,100 and 500 ng/ml. 
GC/MS 
A 1. Oul aliquot of each standard and each extract was injected into the GC/MS 
instrument. Identification was achieved by comparison of retention times (tR) and 
selected ion of each and quantification was achieved by comparison of the peak area 
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ratios from SIM chromatograms of extracts with those of standards. Meconium 
standards for quantification were prepared by spiking blank meconium at two 
concentrations (5 and 50 ng/g). Each concentration was prepared in triplicate and 
the average result was taken. 
8.4. Results and Discussion 
8.4.1. Method Validation 
The developed method was satisfactory: blank meconium gave negative results and 
the target analytes were successfully extracted from spiked meconium samples and 
quantified. Specimen chromatograms and mass spectra of extracted standards are 
shown in Figures 8.1- 8.3. 
Calibration curves for the target analytes were linear and had linear correlation 
coefficients (r) in the range 0.902 to 0.978. The calibration ranges chosen for the 
analytes were selected from the available literature data. 
Recoveries for the analytes ranged from 50-100% (Table 8.2) but were considered 
acceptable if the method could be generally applied for the intended purpose. The 
lower limit of detection for each analyte is summarised in Table 8.3. 
The reproducibility of the method was established by analysing five replicates of 
standards at five concentrations (10,20,30,40 and 50ng/ml) for morphine and 
codeine, following the same method of extraction. The morphine and cocaine 
calibration curves, created using the means of these replicates, are shown in Figures 
8.4 and 8.5. The stability of the extracts was evaluated by analysing the same 
samples immediately inject after extraction, and same samples are injected after two 
days, after one week and after two weeks. This data was used to measure the mean, 
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standard deviation, and relative standard deviation for each analyte and the results 
are show good reducibility in Table 8.4. 
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Table 8.2 Recoveries for target analytes extracted from meconium 
Drug Recovery (%) 
Morphine 60 
Codeine 100 
Benzoylecgonine 89 
Cocaine 65 
THC 100 
THC-carboxylic acid 50 
Methadone 60 
Diazepam 80 
Temazepam 70 
Table 8.3 Lower Limits of Detection (LLD) for target analytes extracted from 
meconium 
Drug LLD (ng/g) 
Morphine 1 
Methadone 1 
Cocaine 5 
Benzoylecgonine 10 
THC 10 
THC-carboxylic acid 20 
Codeine 25 
Temazepam 25 
Diazepam 25 
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Table 8.4 Mean, standard deviation and relative standard deviation for each analyte 
Days after 
extraction 
drug Conc. 
ng/g 
mean SD RSD 
None codeine 10 4.10 0.100 2.44 
morphine 1.65 0.119 2.34 
codeine 30 7.49 0.195 2.60 
morphine 3.31 0.199 6.01 
codeine 50 9.80 0.117 1.20 
morphine 4.20 0.158 3.76 
Two codeine 10 6.60 0.332 5.02 
morphine 1.98 0.148 7.40 
codeine 30 8.64 0.174 2.01 
morphine 3.78 0.172 4.55 
codeine 50 11.2 0.135 1.21 
morphine 6.40 0.178 2.78 
Seven codeine 10 5.46 0.305 5.58 
morphine 1.94 0.125 6.46 
codeine 30 3.78 0.172 4.55 
morphine 8.46 0.480 5.67 
codeine 50 11.5 0.146 2.46 
morphine 5.10 0.186 2.45 
Fourteen codeine 10 4.44 0.890 5.15 
morphine 1.875 0.083 4.45 
codeine 30 7.66 0.114 1.49 
morphine 3.18 0.179 5.63 
codeine 50 9.20 0.122 2.44 
morphine 5.30 0.148 2.84 
Analysis of Multiple Drugs In Small Blood Specimens and Meconium 
Page 118 
8.4.2. Application to Real Cases 
The developed method was applied to 25 case samples which were collected at the 
Royal Maternity Hospital, Glasgow, from neonate on the first day after delivery 
using special stool vials with integral spoons in their caps. The specimens were kept 
frozen until collected and analysed. 
The samples were first analysed by EIA: some of those which were positive for 
opiates, cocaine, methadone and benzodiazepines gave nominal concentrations which 
were outside the calibration range, while the two cannabinoid positives were both 
within the calibration range. The results of EIA analysis are given in Table 8.5. 
The samples were confirmed and quantified by GC/MS, after adding the IS to the 
remaining eluate. Morphine was detected in 23 of the case samples, the other two 
being negative. The concentration range was 10-1070 ng/g meconium and these are 
plotted in Figure 8.6 below. It can be seen that two cases are significantly higher 
than the others. It became apparent later that most mothers in the Royal Maternity 
Hospital were given diamorphine as a sedative prior to Caesarean section or when 
the mother required it. The two high cases may therefore represent mothers who had 
used heroin during pregnancy. 
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Table 8.5 Results of EIA Analysis of Extracts from 25 Real Case Samples 
Case No. Drug Concentration (ng/ml) 
Benzo Cannab Opiate Methadone Cocaine 
Blank negative negative negative negative negative 
I ++++ negative ++++ ++++ ++++ 
2 20.5 negative 105.9 negative negative 
3 183.6 negative 13.5 negative negative 
4 47.6 4.1 43.3 52.6 negative 
5 ++++ 15.6 387.6 ++++ negative 
6 ++++ negative ++++ negative negative 
7 negative 2.5 82.8 66.1 negative 
8 negative negative 132.8 negative negative 
9 negative negative 243.4 negative negative 
10 negative negative 46.6 negative negative 
11 34.9 negative 109.6 negative negative 
12 negative negative 68.8 negative negative 
13 23.8 negative 59.6 negative negative 
14 negative negative 57.3 negative negative 
15 17.4 negative 60.9 negative negative 
16 negative negative 88.5 negative negative 
17 negative negative 56.6 negative negative 
18 negative ++++ 60.9 negative negative 
19 negative negative 48.7 negative negative 
20 negative negative 62.1 negative negative 
21 negative negative ++++ negative negative 
22 negative negative 72.9 negative negative 
23 -negative negative negative negative negative 
24 negative negative negative negative negative 
25 negative negative ++++ negative negative 
++++ Nominal concentration above the upper calibrator concentration 
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Table 8.6 Results of GC/MS Analysis of Extracts from 25 Real Case Samples 
Drugs Diaz Tem Mor Cod Meth Coca BZE THC THCA 
Blank - - - - - - - - - 
1 114 - 100 80 319 20 - - - 
2 147 - 128 380 1100 - - - - 
3 1281 - 998 - - - - - - 
4 680 432 1070 - 2190 - - 599 - 
5 632 912 120 - 237 - - 1010 - 
6 70 - 30 30 - - - - - 
7 - - 110 60 51 - - 520 154 
8 - - 150 - - - - - - 
9 - - 50 - - - - - - 
10 - - 140 40 - - - - - 
11 23 223 10 - - - - - - 
12 - - 15 40 - - - - - 
13 81 501 14 50 - - - - - 
14 - - 10 - - - - - - 
15 25 125 10 60 - - - - - 
16 - - 10 30 - - - - - 
17 - - 156 - - - - - - 
18 - - 50 15 - - 175 122 
19 - - 70 60 - - - - - 
20 - - 90 110 - - - - - 
21 - - 50 40 - - - - - 
22 - - 30 20 - 140 - - - 
23 - - - - - - - - - 
24 - - - - - - - - - 
25 - - 50 10 - - - - - 
(Diaz = Diazepam, Tern = Temazepam, Mor = Morphine, Cod = Codeine, 
Meth = Methadone, Coca = Cocaine, BZE = Bonzoylecgonine, THC = 
Tetrahydrocannabinol, THCA = THC carboxylic acid metabolite, -= Negative 
sample) 
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8.5. Conclusions: 
The use of drugs by the pregnant mother can be detected by meconium analysis. 
Multiple drug analytes can be extracted by the SPE technique, screened using EIA 
and confirmed by GC/MS. The use of meconium analysis is now gaining more 
support in forensic toxicology laboratories worldwide especially in the United States, 
due to the long-term retention of drugs in meconium and the possibility of detecting 
maternal drug abuse over periods ranging in time from beginning of early pregnancy 
( 12 weeks) till labour. In addition, meconium samples are collected by non-invasive 
procedures, only a small sample size is required, they are easy to store, and they are 
not affected by contamination, like nail, or by race bias, as with hair. Because of 
these advantages, meconium has the potential of becoming a powerful alternative to 
other biological samples for the detection of drug abuse in forensic cases. 
The method was considered suitable for use in a proposed survey of newborn 
infants but additional methodological developments were first carried out to permit 
the inclusion of amphetamines in the study. 
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9. Extraction of Amphetamine and its Analogues from 
Meconium Using a Single SPE Column 
9.1. Introduction and Aims 
Recently drug abuse during pregnancy has become an epidemic problem and has 
serious effects on neonate. As mentioned before in previous chapters, a suitable 
method to extract multiple drugs from blood and meconium has been developed, but 
unfortunately this method can not be used for the amphetamine group (amphetamine, 
methamphetamine and their analogues), perhaps because of the derivatisation method 
or due to losses in the evaporation stage. As they are widespread illicit drugs, there 
has been some research published on estimating amphetamines in infant hair185 and 
in meconium, and this involved liquid-liquid extraction with analysis by GUMS. 136 
Recently also Solohy et al., 1999163 used liquid-liquid extraction, but there is no 
published method of extraction by SPE. 
The aim of this part of the project was to extend the methodology available for 
the extraction of meconium by SPE to amphetamines and provide a suitable method 
for the proposed survey of newborn infants in the Glasgow area. The background to 
amphetamines will first be reviewed. 
9.2. History of Amphetamines 
Amphetamine along with its analogues (for convenience referred to below as 
"amphetamines") is a synthetic stimulant known since 1885. Its synthesis increased 
during the 1930's, when there were concerns that the supply of naturally occurring 
ephedrine might not be sufficient to meet the needs of asthma sufferers. So attempts 
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were made in several labs based to develop new synthetic routes based on the 
phenylisopropylamine molecule, which is considered as the starting point. Some of 
the first syntheses of different types of amphetamine and methamphetamine were by 
Ogata (with the brand name Methedrine) 186 
First amphetamine was used in treatment of schizophrenia seizures, which is 
unfortunate, bearing in mind that amphetamine itself induces psychosis. 
Amphetamines have been used in treating barbiturate overdoses, caffeine mania, 
smoking, multiple sclerosis, myasthenia gravis, head injury, cerebral palsy, migraine, 
urticaria, seasickness, dysmenorrhea, arterial colic, obesity, irritable colon, radiation 
sickness and other seemingly unrelated conditions, including loss of libido' 87. It was 
also used for the treatment of morphine addiction. ' 88. 
Amphetamine is a potent CNS stimulant and the first case of amphetamine-related 
death was reported a few years after its introduction. There are serious complications 
associated with it: stroke, rhabdomyolysis and psychotic behaviour are the most 
common. Also cardiomyopathy is more common than with cocaine, while 
myocardial infarction is less common'89. It was introduced in the 2°d World War to 
soldiers to overcome the effects of fatigue. Its use then spread in the UK, especially 
in London's West End clubs, especially amongst the youth which first used tablets 
called drinamyl (street name "purple heart"). The government tried to withdraw 
these tablets but was unable to stop amphetamine abuse'90. 
Amphetamine abuse has caused social problems in many countries, even more than 
heroin, as abuse of these substances is growing rapidly, and is now a simple 
economic fact. 189 Amphetamine abuse is a relatively minor complication related to 
other drug abuse and accounted for less than 1% of drug emergency room calls and 
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less than 2% of drug related deaths in the DAWN survey for 1990 whereas cocaine 
represented 22%, so a suitable method for their determination is necessary (National 
Institute on Drug Abuse, 1992). 
Methamphetamine is the N-methyl derivative of amphetamine and is used for 
treatment of obesity. Amphetamine and methamphetamine are abused especially in 
the United States, Sweden and Japan. They are classified as Class B, Schedule 2 
drugs in the Misuse of Drugs Act (1971) in the UK. Methamphetamine use has 
increased since 1970s as it gives better sensations than amphetamine but is 
associated with strange and violent behaviour. There is evidence that 
methamphetamine is more commonly abused than cocaine, especially in cigarette 
. 
91 smokers and in white women1°ý92 
The ring substituted amphetamines, in particular 3,4-methylenedioxyamphetamine 
(MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy- 
ethylamphetamine (MDEA) are abused for their hallucinogenic properties. MDMA 
along with MDA and MDEA are Class A, Schedule 1 drugs in the Misuse of Drugs 
Act (1971) and are most stringently controlled. Most common in the United 
Kingdom are ecstasy tablets, which may contain amphetamine, MDA193' 194, 
MDEA195,196 and paramethoxyamphetamine (PMA) 
197 in addition to or in place of 
MDMA. These can cause severe toxicity and death but there is not enough 
information available about their toxicity. A survey done in 1996 reported that the 
most significant rise in drug use over last decade was in the dance drugs especially 
amphetamine'90, LSD and Ecstasy. Another study found amphetamine to be one of 
the most popular illicit stimulants in the UK, even preceding cannabis198 
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Ecstasy was also introduced in the Ist World War to suppress soldiers' appetites'99, 
then spread in U. S in psychotherapy treatment. 200 In the 1980's it spread amongst 
the addicts and at the end of this decade became known in the UK, especially during 
dance events or raves' 96. There is an estimated 500,000 people using ecstasy each 
weekend201. A survey done by Forsyth202, which interviewed 135 participants in the 
Glasgow rave scene, found that they use other drugs beside ecstasy. Another survey 
by Hammersly et al. 203 on 209 individuals found that they used ecstasy once but also 
they used at least one other illicit drug. Another study was done by Handy et a1204 on 
389 participants in the Cardiff area of South Wales where polydrug use and 
experimentation was prevalent. All of these studies concluded that there has been a 
change in the pattern of drug abuse since 1990. 
9.3. Illicit Manufacture of Amphetamines 
In 1958, the annual legal production of amphetamine was 75,000 pounds. By 1970, 
it had risen to over 200,000 pounds, enough to make 10 billion 5 mg tablets. . 
Consumption today is difficult to gauge. As the indications for medicinal 
amphetamine use became fewer and fewer, and more complications were recognised, 
legal production fell off. So illegal labs began to fill the void. In 1980,150 illicit 
methamphetamine (as opposed to ice) labs were seized in the United States and by 
1989 that number had risen to 650205. The first illicit drug syntheses used phenyl-2- 
propanone (P2P) as the precursor and then, when P2P itself became a controlled 
substance, clandestine chemists were also forced to synthesize it. P2P can be 
synthesized in a number of ways. Either (-) ephedrine or (+) pseudoephedrine can be 
converted to methamphetamine by reductive dehalogenation using red phosphorus as 
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a catalyst. If (-) ephedrine is used as the starting point, the process generates 
methamphetamine, while pseudoephedrine produces dextromethamphetamine. 
Regardless of the isomer produced, contaminants will be present. 206 
9.3.1. Chemistry of Amphetamines 
CH3 
LCH2CHNH2 
CH3 
KCH2cHNHcH3 
Amphetamine Methamphetamine 
Figure 9.1 Chemical Structures of Amphetamine (CgH13N) and Methamphetamine 
(CioHisN) 
Amphetamine is commonly available as the sulphate, a white crystalline salt, first 
synthesized in 1887. The molecular weight of amphetamine base is 135, the melting 
point is 300°C and pKa is 9.9.207.208 The d-isomer of amphetamine has 3-4 times the 
central activity of the 1-form. 
Methamphetamine hydrochloride was first prepared in 1919 and forms white 
crystals or crystalline powder. The name "ice" is often used for methamphetamine 
because of the crystalline nature of the salt. Possible chemical designations for 
methamphetamine include N-dimethylbenzenthanamine, d- 
N, Ndimethylphenethylamine, and d-deoxyephedrine. The drug has been sold under 
many proprietary names (Deoxyn, Hiropon, Isophewn, Methedrine, to name a few). 
Its formula is CioH15N, and its molecular weight is 149.2. It has a melting point of 
170-175°C and pKa of 10.1208. The low melting point permits it to be smoked, 
regardless of the crystal size. The crystals have a bitter taste and are soluble in water, 
alcohol, chloroform, and freon. Methamphetamine is not soluble in ether. 
Manipulation of the amphetamine's phenyl ring yields fenfluramine, a widely 
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prescribed anorectic. Manipulation of the side chain has led to the synthesis of a 
series of compounds with varying degrees of sympathomimetic activity. 
cl I 
r 
CHgCHNH2 
MDA 
CH. 
t 
CH., &HNRCHý -. -t 
j CH2CHNCHCH, 
ci 
MDMA 
MDEA 
Figure 9.2 Chemical Structures of MDA (Ci0H13NO2 ), MDMA (C11H15NO2) and 
MDEA (C 12H17N02 ) 
MDA, MDMA and MDEA are ring-substituted amphetamines that have stimulant 
and hallucinogenic qualities in addition to unique pharmacological and psychological 
properties. MDMA was first synthesised in the early part of the 20th century. 
Similar to amphetamine, the d-isomer of MDMA has higher central activity than the 
1-isomer. The molecular weight of MDA is 179, melting point 187-188°C, while 
MDMA has a MW of 193, its melting point is 148-153°C, and MDEA has a MW of 
204, melting point 201-202°C. 
9.4. Routes of administration: 
Amphetamine is commonly administered as the sulphate salt in single oral doses of 
5-15mg, and occasionally in sustained-release form. It may be self administered 
either orally or by intravenous injection. Methamphetamine can be swallowed, 
injected, smoked, or snorted. In spite of the publicity accorded to ice smoking, most 
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users still prefer to inject it intravenously or take it orally. Preference for the 
intravenous route seems to be increasing209. A study done in 1988 found that when 
volunteers took 10 mg orally it produced plasma concentrations of 30-ng/ml one 
hour later210. 
Methamphetamine has a long half-life, if taken by smoking or injection: the mean 
plasma half-life is 11.1 hours for smoked and 12.2 hours for injected MAZ". Peak 
blood levels range from 50-100ng/ml. Amphetamine concentrations were much 
lower reaching peak values of only 4 ng/ml after 3.3 hours. Methamphetamine levels 
in saliva were very high after smoking, but saliva amphetamine levels were 
negligible 211 . In other studies, larger doses of amphetamine 
have been given 
intravenously, but with comparable results. Volunteers given 160-200 mg of 
amphetamine intravenously had one-hour plasma concentration of 269ng/m1212. 
9.5. Disposition in the body 
9.5.1. Amphetamine 
Amphetamine is readily absorbed after oral administration, followed by 
deamination to phenylacetone, which is oxidised to benzoic acid and excreted as 
conjugates. A small amount is converted to norephedrine by oxidation. 
Approximately 30% of the dose is excreted unchanged in urine in 24 hours. 
However this is greatly dependent on the urinary pH. Acidic urine may increase the 
amount of unchanged dose excreted to 74% or it may decrease to 1% in alkaline 
urine. Amphetamine is also a metabolite of methamphetamine, benzphetamine213 
214 and selegiline 
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CHa CHs O &6H 
CHCHNH2 CHZCHNH2 --- \/ 
CH2 CH3 
norephodrine amphetamine 
phenylacetone 
p-hydroxylation glucuronide and COOH 
and conjugation glycine conjugation 
a 
benzoic acid 
Figure 9.3 Metabolic Pathways of Amphetamine. 
9.5.2. Methamphetamine 
Methamphetamine is cleared from the blood by different routes. As mentioned 
before roughly 20% is demethylated to form amphetamine, and ephedrine derivatives 
which are psychoactive. 21 s, 216, and this considered the minor route. (Figure 9.4). 
These metabolites are converted by deamination, to phenylacetone. Current NIDA 
regulations prohibit the reporting of methamphetamine in a urine specimen unless the 
methamphetamine level exceeds 500 ng/ml, and there is more than 200 ng/ml of 
amphetamine present. Oral doses appear to have little effect on either metabolism or 
peak blood levels. The saliva concentration is slightly higher than the concentration 
found in plasma with the average saliva to plasma ratio of 7: 8217. In other studies 
18 MA was found in nail, hair, and meconium2. In urine, acidic pH decreases its 
excretion213. 
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CH3 
CH2c HNHCH3 _-.. -ý- \/C 
Mietamine amphetamine nonphedrine 
damioatio4 P ion and conjugation 
Figure 9.4 Metabolic Pathways of Methamphetamine. 
9.5.3. Ring substituted Amphetamines 
There is little information about the metabolism of MDMA and only limited data 
can be found in Clarke214 or Baselt219. MDMA mainly undergoes N-demethylation 
to MDA and about 65% is excreted unchanged in urine along with 7% as MDA and 
this happens within 3 days220. The ring substituted amphetamines undergo two 
overlapping metabolic pathways, O-dealkylation of the methylenedioxy group to 
form dihydroxy compounds, then methylation of the hydroxy groups and degradation 
of the side chain to N-desalkyl and deamino-oxo metabolites. Further metabolism 
forms glycine conjugates of the corresponding 3,4-disubstitued benzoic acids 
(hippuric acids). 
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Figure 9.5 Metabolic pathways of MDA, MDMA and MDEA 
9.6. Toxicity 
9.6.1. Amphetamine 
The plasma concentration of amphetamine is usually below 0.1 mg/L in therapeutic 
doses. In chronic users it is accompanied by weight loss, hallucination, and paranoid 
psychosis221 with increased heart rate and blood pressure. The lethal dose in non- 
tolerant adults is 200 mg but death is rarely caused by it. If the concentration reaches 
0.2-0.3 mg/L this can cause severe toxicity, while if it reaches 0.5 mg/L it can cause 
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fatalities214. Tolerance occurs so that when 100 mg amphetamine is taken orally on a 
daily basis, a steady blood concentration of 2.0-3 mg/L is maintained. 219 
In seven patients with evidence of amphetamine toxicity, blood levels ranged from 
0.105-0.56 mg/L 210. Different studies have been done on post mortem cases in 
which the cause of death was amphetamine to measure the concentrations of drug in 
different tissues as shown in Table 9.1. 
Table 9.1 Fatal levels of amphetamine (mg/L or mg/Kg) reported in the literature. 
Reference Blood Brain Liver Kidney Urine 
204 0.5-41 
(n=11) 
2.8-3.0 
(n=2) 
4.3-7 
(n=11) 
3.2-52 
(n=6) 
25-700 
(n=8) 
183 1.54 n/a n/a n/a n/a 
212 2.44 5.50 11.7 3.85 33.4 
213 0.25-2.6 
n=3 
n/a n/a n/a n/a 
214 0.45-2.18 
n=6 
n/a n/a n/a n/a 
215 n/a n/a n/a n/a <0.5-320 
n/a-matrix not analyzed. 
Amphetamine and related compounds are responsible for a number of deaths either 
directly (adverse drug reactions, overdose) or indirectly (traffic accidents, 
suicides). 222 The use of amphetamines impairs mental function and causes a number 
of fatalities from road traffic accidents223'224 
9.6.2. Methamphetamine 
Therapeutic doses of methamphetamine range from 0.01-0.05 g, and chronic use 
also causes paranoid psychosis. Overdoses cause anxiety, hallucinations, cardiac 
arrhythmia, convulsion and severe cases result in coma and death. Similar to 
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amphetamine, deaths resulting from methamphetamine overdose are rare. The 
minimal lethal dose in non-tolerant adults is estimated at 1 gram. 214 In 4 cases of 
death after intravenous injection of the drug, blood methamphetamine ranged as high 
as 0.8mg/L. 
9.6.3. Ring- substituted amphetamines 
A literature search reveals very little data on the toxicity of MDA, MDMA and 
MDEA. The estimated lethal dose of MDA for non-tolerant adults is 0.5g. 
Symptoms of MDA overdose include tachycardia, hyperthermia, muscular rigidity, 
convulsions and coma. A non-fatal overdose of MDA resulted in an admission urine 
concentration of 131mg/L of MDA. 219 The victim, a one-year-old child, presented 
with muscle rigidity and seizures and was unconscious. There are many studies 
reporting the level of MDA in postmortem specimens including blood, urine, bile, 
and liver. The concentration ranges were 6-26,46-175,5-9, and 8-17 mg/L or mg/kg 
respectively. 225,226 
MDMA, MDEA and other amphetamines cause hyperthermia227,228, disseminated 
intravascular coagulation 193, rhabdomyolysis229'230, cerebral oedema 231 and cardiac 
arhythmias. Hepatotoxicity 232,233 and sudden cardiac death234 are commonly cited in 
cases of fatal and non-fatal toxicity following MDMA use. Two unusual studies have 
been reported. One concerns a 17 year-old female who collapsed after taking two 
tablets of `specked dove', a combination of MDMA, heroin and cocaine 234. She was 
unconscious, unresponsive and hypothermic with a core temperature of 32.4°C. No 
postmortem toxicological results were reported in this case. The second was reported 
by Jorens 235 about a suicidal ingestion of MDEA and heroin by a 25 year-old male 
who took 40 tablets (approximately 4g) of MDEA and 12g of heroin, two hours prior 
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to admission. Toxicological analysis indicated high serum levels of both drugs but 
no classical signs and symptoms of intoxication appeared. Full recovery followed 
symptomatic treatment. The authors concluded that the opposite pharmacological 
properties of two drugs prevented the patient's death. Survival following a massive 
overdose of MDMA was reported in a 30 year-old male who took 50 ecstasy tablets, 
10 tablets of oxazepam and 5 units of alcohol in 4-5 hours236 
The unpredictable nature of ecstasy is reflected in the fact that thousands of people 
have consumed ecstasy and, while a very few deaths have been reported following 
the ingestion of just one ecstasy tablet, survival after consuming 50 ecstasy tablets 
has also occurred. Two possible explanations for the unpredictable responses are 
contamination of the ecstasy or genetic predisposition. 
In addition to the short-term risks from the toxic effects of MDMA, further research 
is needed on the long-term effects on the brain, liver and heart. Sample and 
Johnstone237 are currently studying the long-term effects of ecstasy use on damage to 
the nerve cells. 
MDMA has been implicated in the onset of both psychological and behavioural 
complications. Researchers have reported an apparent association between MDMA 
use and serotonergic alterations. 238,239 Other studies have found a correlation 
between suicide and low levels of cerebrospinal fluid 5-hydroxyindoleacetic acid, the 
primary metabolite of serotinin 240,241 , considered to 
be more dangerous than acute 
toXiCity242. 
Recorded cases admitted to accident and emergency departments due to the use of 
MDMA at nightclubs increased to more than 48 in 15 months243 while the use of 
ecstasy tablets was doubled. Polydrug use was common with around 40% having 
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consumed ecstasy. Adverse effects vary from feeling dizzy or weak (n=15,31.3%) 
to feeling excessively hot, cold, feverish or shivering (n=7,15%). There were six 
episodes which were classified as severe adverse effects. These included delirium in 
two cases, seizures in three cases and unconsciousness (coma) in one case, but there 
are no toxicological data nor was any confirmation done. 
In the United States the exact number admitted to accident and emergency 
departments due to ecstasy use with related symptoms is not known. Monitoring 
these cases would present a clearer picture of the toxic effects of ecstasy. Full 
toxicological screening of admission urine and blood samples would help rectify the 
lack of available toxicity data for the ring-substituted amphetamines and would be of 
great benefit to the toxicologist. Many studies have measured ring substituted 
amphetamines in blood from postmortem cases and in these cases the concentrations 
range from 0.19 to 4.1 mg/L for MDMA, 193,222 and from 0.04 to 0.49 mg/L for 
MDA, with two cases not having detectable levels, 222,244 while levels of MDEA 
ranged from 0.09-33.0 mg/L with 3 cases not detected. 
222,241,244,245 Some studies 
measured these analytes in urine246,247 A recent study on amphetamine was done in 
248 2001 by Praisler et al. 
9.7. Tissue disposition 
The level of methamphetamine after injection is higher in liver than blood. Also the 
concentration of amphetamine was 8 times highe r249 
Methamphetamine has been measured in breast milk at 10 and 42 days after delivery 
and it was demonstrated that the concentrations were much higher in the woman's 
breast milk than in her plasma250. There is very little evidence that amphetamine 
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relation between this and premature and low birth weight foetuses251. Very little 
data is available on the disposition of amphetamine in the foetus. 
Environmental exposure to abused drugs is an increasing reality, especially in the 
inner city. Studies have repeatedly shown that, at inner city hospitals, 10% or more, 
of children presenting for treatment at hospital emergency rooms are positive for one 
or more abused drugs252,253 As the ability to detect nanogram quantities of drugs 
improves, drugs are being detected in more sick children. The mere fact that these 
drugs are present, however, is not sufficient reason to implicate them as a cause of 
illness or death in adults or in children. 
9.8. Materials & Methods 
9.8.1. Materials 
All chemicals were purchased from SIGMA Company (Dorset, UK). The solvents 
and concentrated ammonia were of HPLC grade supplied by BDH laboratories 
supplies. ZD clean cartridges (20 ml) were from UTDTM and were obtained from 
Varian (Harbor city, California, USA), and the Baker-20 SPE vacuum manifold 
system was from International Sorbent Technology. 
Phosphate buffer (0.1 M) was prepared by dissolving 6.81g of potassium 
dihydrogen phosphate in 450m1 of de-ionised water, adjusting the pH to 6.0 ± 0.1 
with 1. OM potassium hydroxide, then making the total volume up to 500m1 with de- 
ionised water. Acetic acid solution (0.01M) was prepared by adding 57.5 111 of 
glacial acetic acid to 100ml of de-ionised water. 
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The SPE eluant was prepared daily by mixing dichloromethanol- Isopropanol 
alcohol (IPA)-concentrated (78: 20: 2). Both were sonicated for at least 5 minutes 
before use. 
Amphetamine, Methamphetamine, MDA, MDEA, MDMA were purchased from 
SIGMA, and deuterated materials were from Radian Corporation (Austin, TX). 
Enzyme Immunoassay (EIA) was carried out using kits from Cozart Bioscience 
Ltd., Oxfordshire. 
9.8.2. Instrumentation 
Gas chromatography - mass spectrometry was carried out using a VG Micromass 
70-250S double focusing magnetic sector instrument or a Finnigan-Thermoquest 
Trace quadrupole instrument. The gas chromatograph (Hewlett Packard 5890 Series 
II) was equipped with a fused silica capillary column (HP5,30m x 0.32 mm id, 0.3 
. tm film thickness). Samples (volume lul) were injected with an injection port 
temperature of 280°C. The column temperature was initially held at 80°C for 2 min 
and then programmed to rise to 285°C at 5°C/min. The temperature was held at 
285°C for the final 2 minutes of the chromatographic analysis. The mass 
spectrometer was operated at a resolution of 1000 in the EI+ mode (ionisation energy 
70 eV, source temperature 220°C). Quantitative analyses were carried out in the SIM 
mode, using deuterated analogues of the target analytes as internal standards. 
9.8.3. Methods 
9.8.3.1. Sample collection 
Eleven samples of meconium were collected from diapers of newborn infants 
delivered at the Royal Maternity Hospital, Glasgow (these are different from the 
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samples referred in paragraph 8.3.1). The meconium was recovered using a wooden 
spatula and stored in plastic tubes at -4°C until analysed. 30 samples of meconium 
were collected from neonates delivered in several hospitals in Egypt who were not 
exposed to drugs in uteri. These were used as controls. (as mentioned in page 106) 
9.8.3.2. Sample preparation 
Each meconium specimen was weighed (range from 0.5g - 0.8g) into a clean vial 
and centrifuged at 2000rpm for 10 minutes to bring it to the bottom. Drug standards 
were added and the samples were homogenized by vortexing and sonicating for 15 
minutes. Methanol (3 ml) was added, and the tubes were vortexed well for 10 
minutes then centrifuged at 3000rpm for 20 minutes. The upper layers were 
transferred to clean tubes and evaporated to dryness under nitrogen, initially at room 
temperature then with slight warming up to 40°C until completely dry. Once dry, the 
residues were dissolved in 700 gl methanol with vortexing. The extraction tubes 
were then centrifuged at 2000rpm for 10 minutes. 
Half of the extract was analysed by EIA, and the other half followed the SPE 
method. 
9.8.3.3. EIA analysis: 
The EIA method used was an Enzyme Linked Immunosorbent Assay (ELISA) from 
Cozart Company. This assay involves the enzyme horseradish peroxidase, which 
produces a blue colour with its substrate. 500 µL of elute B was evaporated till 
dryness under nitrogen then reconstituted in EIA buffer (Iml). This was then 
analysed for amphetamines using EIA kits containing antisera highly specific to free 
(unconjugated) forms of the parent drugs. The method followed the same steps 
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previously mentioned. The calibration curve was prepared from standards containing 
the analytes at concentrations of 0,10,100 and 500 ng/ml. 
9.8.3.4. Sample Extraction: 
The solid phase extraction (SPE) procedure applied was as follows: 
" The deuterated Internal Standards were added to the other half of the meconium 
extract and mixed well; 
9 the column was prepared by washing with 3ml methanol, followed by 3 ml water 
and 1 ml phosphate buffer (pH6); 
9 the sample was applied at low vacuum pressure; 
9 the column was washed with 3ml distilled water, followed by 1 ml ethyl acetate 
and 3 ml methanol; 
" the column was dried at maximum pressure for 5 min; 
9 the analytes were eluted with 3 ml of eluant (dichloromethane: IPA: concentrated 
ammonium hydroxide, 78: 20: 2 v/v/v) 
9.8.3.5. Derivatisation 
The SPE extract was evaporated to dryness without heating and 50 µ1 of a mixture of 
PFPA: ethyl acetate (2: 1 v/v) was added. The resulting solution was heated at 60°C 
for 20min. At the end of this time, the reagent was evaporated to dryness without 
heating till dryness, then 50µl of ethyl acetate was added. 
9.8.3.6. GC/MS Analysis 
The derivatised extracts were analysed by GC/MS in the SIM mode. The column 
oven temperature was programmed from 80°C-250°C at a rate of 10°C/min. with a 
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final hold time at 250°C of 2 minutes. Selected ions used for quantitative analyses 
are listed in Table 9.2 along with the retention times for each analyte. 
Table 9.2 Retention Times and Selected Ions for AmnhPtam; noý 
Drug Selected 
Ions (m/z) 
Retention time 
(min) 
Amphetamine 190 5.75 
d3-Amphetamine 193 5.75 
Methamphetamine 204 7.08 
MDA 162 9.77 
d6-MDA 168 9.77 
MDMA 204 11.05 
d5-MDMA 209 11.05 
MDEA 218 11.44 
d5-MDEA 223 11.44 
9.8.3.7. Method Verification 
Recoveries were determined by spiking blank meconium with the target analytes. 
Ten different meconium samples were spiked with standards and analysed as 
described earlier in order to determine the extraction recovery of the method. The 
internal standards (deuterated form of each drug) were added to the eluates obtained 
by SPE and these extracts were compared with unextracted standards. Furthermore, 
ten meconium samples were spiked with decreasing amounts of drug standards and 
then analysed as before to determine the limits of detection of the method. 
9.8.4. Application to Real Case Samples 
The same method was then applied to I1 real cases from the Royal Maternity 
Hospital, Glasgow. Extracts were initially screened by EIA and then confirmatory 
quantitative analyses were carried out by GC/MS. 
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9.9. Results and Discussion 
9.9.1. Method Verification 
The developed method was satisfactory: blank meconium gave negative results and 
the target analytes were successfully extracted from spiked meconium samples and 
quantified. Specimen chromatograms and mass spectra of extracted standards are 
shown in Figures 9.6- 9.9. 
Calibration curves for the target analytes were linear and had linear correlation 
coefficients (r) in the range 0.897 to 0.991. The calibration ranges chosen for the 
analytes were selected from the available literature data. Representative calibration 
curves for amphetamine and methamphetamine are shown in Figures 9.10 and 9.11 
Recoveries for the analytes ranged from 60-96% (Table 9.3) but were considered 
acceptable if the method could be generally applied for the intended purpose. The 
lower limit of detection for each analyte is summarised in Table 9.4. 
Table 9.3 Recovery of Target Analytes 
Drug Recovery 
Amphetamine 90.0 
Methamphetamine 60.0 
MDA 95.9 
MDMA 83.9 
MDEA 87.2 
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Table 9.4 Lower Limit of Detection for Target Analytes. 
Drug L. L. D n/m 
Amphetamine 1 
Methamphetamine 2 
MDA 5 
MDMA 1 
MDEA 10 
The reproducibility of the method was established by analysing five replicates of 
standards at three concentrations (10,30 and 50ng/g) for amphetamine and 
methamphetamine, following the same method of extraction. The stability of the 
extracts was evaluated by analysing the same samples immediately after extraction, 
after three days, after one week and after two weeks. This data was used to measure 
the mean, standard deviation, and relative standard deviation for each analyte and the 
results are given in Table 9.5. The R. S. D. ranged from 1.21- 6.55. From these 
results it was found that the reproducibility for this method for both amphetamine 
and methamphetamine were good. 
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Table 9.5 Reproducibility of Method for Amphetamine and Methamphetamine 
Date Drug Conc. Drug/I. S Std. dev. Relative 
(ng/g) (Average standard 
of 3) deviation 
First day AM 10 3.23 0.269 0.175 
MA 4.34 0.250 2.55 
AM 30 8.54 0.597 5.98 
MA. 10.4 0.326 3.13 
AM 50 9.80 0.117 1.20 
MA 14.2 0.158 3.76 
3 days AM 10 3.57 0.250 0.59 
MA 2.72 0.049 1.81 
AM 30 7.22 0.128 1.77 
MA 9.33 1.55 6.55 
AM 50 10.3 0.885 5.34 
MA 14.2 0.8507 5.51 
1 Week AM 10 2.88 0.064 2.21 
MA 2.83 0.061 2.14 
AM 30 8.76 0.576 6.60 
MA 8.01 0.443 5.53 
AM 50 10.6 0.885 5.34 
MA 13.9 0.851 5.51 
2 Weeks AM 10 2.93 0.084 2.90 
MA 3.52 0.172 4.88 
AM 30 9.13 0.493 5.40 
MA 8.20 0.100 1.21 
AM 50 10.8 0.885 5.34 
MA 14.1 0.851 5.51 
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9.10. Application to real cases 
Eleven cases were collected from Glasgow Royal Maternity Hospital from neonates 
in the first day of delivery as usual. The control or blank cases were collected from 
Egyptian General Hospitals, from mothers not taking any drugs during the 
pregnancy. The sample weights ranged from 546mg to 670mg in these cases. After 
extraction, they were analysed by EIA as before. 
Seven cases gave positive EIA results for amphetamine, with concentrations 
ranging from 1-204ng/gm, and nine cases gave positive results for 
methamphetamines with the Cozart kits used (Table 9.6). Confirmation was done by 
GC/MS to see if these were true or false positives, due to cross reaction with other 
endogenous materials. 
Table 9.6 Results of EIA for 11 Case Samples. 
Case No. AM (ng/g) MA (ng/g) 
Blank Negative Negative 
1 129 Negative 
2 188 104 
3 55.1 63.6 
4 58.5 Negative 
5 133 41.6 
Case 6 Negative 41.3 
Case 7 Negative 44.9 
Case 8 Negative 34.7 
Case 9 27.4 84.0 
Case 10 Negative 70.0 
Case 11 43.5 74.0 
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The remaining analyses for confirmation by GC/MS were carried out after adding the 
I. S. at a concentration of 20ng/g, and spiked meconium standards were prepared at 
two concentrations (25,100 ng/g) for quantification. Three replicates were prepared 
at each concentration and the average result was used. The results are given in 
Table 9.7. Specimen mass spectrometry traces are given in Figures 9.12-9.13 
Table 9.7 Results of Analysis of Real Cases by GC/MS. 
Case No. AM 
nm 
MA 
nm 
MDA 
nm 
MDMA 
nm 
MDME 
nm 
1 4.76 2 10 NA 4 
2 204 6 2 3 1 
3 1 NEG NEG NEG NEG 
4 5.6 NEG 2 NEG NEG 
5 7.1 NEG 6.1 NEG NEG 
6 2.8 NEG 2 NEG NEG 
7 25.6 NEG 47.8 NEG NEG 
8 NEG NEG NEG NEG NEG 
9 NEG NEG NEG NEG NEG 
10 NEG NEG NEG NEG NEG 
11 1 NEG NEG NEG NEG 
(NEG=negative) 
From these results it appears that most of the cases which gave positive results by 
EIA gave negative results by GC/MS, and it is concluded that the EIA results were 
false positives due to cross-reaction with endogenous materials. 
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9.11. Conclusions 
The use of amphetamines by the pregnant mother can be detected in their neonate 
by meconium analysis. Amphetamine and its analogues can be analysed in 
meconium by a sensitive and specific procedure based on SPE followed by EIA 
screening and confirmation by GC/MS. The use of meconium analysis is now 
gaining more support in forensic toxicology laboratories worldwide due to its 
advantages, which were mentioned in the previous section. This method is one of 
the rare examples of the analysis of amphetamines in meconium using SPE, as most 
of the previous reports used liquid-liquid extraction. This method could detect all the 
important target analytes in the amphetamines group. It is important not to 
misdiagnose the false positives due to cross reaction in EIA analysis and to use a 
GC/MS confirmatory step after immunoassay. 
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10. Survey of Intrauterine Exposure to Illicit Drugs by 
Analysis of Meconium: 
10.1. Introduction: 
Intrauterine drug exposure in women of child bearing age is increasing these days, 
and most of these women use multiple drugs regardless of the serious complications 
appearing in the neonate and which may also remain until the childhood period2sa-2s6 
One of the most important complications, as mentioned earlier is NAS. In the 
Glasgow Royal Maternity Hospital around 120 infants a year require 
pharmacological management for severe Neonatal Abstinence Syndrome (NAS). 257 
The Maternal Lifestyle Study was set up in the United States as a prospective multi- 
site longitudinal study on the association of drug use during pregnancy with acute 
neonatal events and long term neurodevelopment child outcome, conducted under the 
auspices of the National Institute of Child Health and Human Development 
(NICHD). A fiscal and scientific collaboration was developed with the National 
Institute on Drug Abuse, the Administration on Children, Youth and Families, and 
the Center for Substance Abuse Treatment to design and fund the study. 
The accurate identification of prenatal drug abuse is critical for 2 reasons: 
1- To fully understand the nature and magnitude of the problem. 
2- To determine appropriate medical and psychosocial interventions. 
Accurate information regarding illicit drug using during pregnancy is difficult to 
obtain and depends on the maternal interview or on laboratory analyses. The 
reliability of maternal interview regarding drug use is adversely affected by many 
factors, such as the mothers mistrust of health care givers and fear of the mother for 
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her infant, but is routinely used in spite of its limitations. ZSS, Zsb Ostrea et al. 254 found 
that only 11 % of the mothers admitted to using illicit drugs. Frank et al. 255, found 
that self-reporting misclassified 24% of cocaine users identified by urine toxicology. 
Other methods used to identify prenatal cocaine exposure vary and include self- 
administered questionnaire, intake history, and urine testing of mother and infant and 
testing of infant hair and meconium, resulting in widely disparate estimates of rates 
of cocaine use by pregnant women. 257,258,259 
There are many studies that have used meconium and other specimens or mother 
interview to screen drugs during pregnancy and their transmission to the foetus. 
Those involving cocaine have been in the majority. Estimates of cocaine exposure 
vary according to the population. The 1988 National Maternal and Infant Health 
Survey, reported cocaine use is 0.4%. 260 More recent studies depending on urine 
261 tests reported users as 1.1 % of the total, 
A number of studies suggest that meconium is the most useful specimen for the 
detection of prenatal cocaine exposure. ' 60,254,257-263 Lewis et a1.264 found that 
meconium detected 2.7 times more instances of cocaine use than urine. Casanova et 
al. 265 argued that the methods used for meconium measurement differed in analytical 
sensitivity and specify from the urine screening methods, precluding a direct 
comparison of the performance of urine versus meconium as matrices of detection of 
cocaine. It has even been suggested that serial analysis of meconium specimens may 
reflect both the chronology and degree of drug exposure. It was suggested that 
meconium collected 0-10 hours after birth reflects gestational exposure up to 20 
weeks, that collected after 11 to 20 hours reflects 21-30 weeks gestation, and 21 to 
36 hours more than 30 weeks gestation 
266 
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Biomarkers of in utero cocaine exposure in the neonate include measurement of 
tissues including lung, analysis of biological fluids like blood, urine, hair and 
meconium and, recently, in gastric aspirate and amniotic fluid. Urine has been the 
most widely used specimen. Ostrea el al. 138,262 reported meconium to be more 
suitable than urine for detecting foetal exposure to cocaine, but metabolites can be 
detected not more than 96-120 hours after the last cocaine use. 
Some investigators have advocated the use of quantitative analysis of drugs in 
meconium, as a mean of estimating degree of drug exposure during gestation. Ostrea 
et a1267 reported that the concentration of nicotine metabolites in meconium was 
directly related to the degree of active smoking by the mother. In a similar manner, 
Stolk et a1265 observed a correlation between maternal methadone dose and the 
concentrations of methadone and EDDP, its primary metabolite detected in 
meconium. 
Meconium is not formed by the foetus until the twelfth week of gestation, 
259 thus 
meconium analysis cannot be used to detect illicit drug use before this period. The 
study done by Morales et al, showed that any drugs received by the mother during 
labor can be detected in meconium. 269 If opiates or cocaine are used during the first 
trimester of pregnancy, they can be detected by radioimmunoassay with a high 
degree of sensitivity and specificity. No false positive results were recorded for 
cocaine in meconium, in contrast to hair analysis. But meconium gave around 10.5% 
false positives for opiates, perhaps due to cross reactivity to various 
substances. However, when GC/MS confirmation was done, the opiates were 
identified to be codeine, instead of morphine, and this was consistent with the history 
in the mother of having taken a prescribed codeine-containing analgesic for false 
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labour pains 4 days before delivery. This example clearly reinforces the need for 
GC/MS confirmation of any positive laboratory tests result for drugs particularly if 
opiates are found269 
Accurate identification of prenatal drug exposure is likely to be improved with 
GC/MS confirmation and when the meconium assay is used in conjunction with a 
maternal hospital interview. However the use of GC/MS may have different 
implications for research than for public policy. 
The analysis of drugs in meconium and interpretation of test results are complex 
processes. There are some problems which affect the result of meconium analysis, 
especially at the current stages of development of this new and useful technology. It 
is clear that there are matrix and tissue effects, so special techniques must be used to 
avoid false negative and false positive results, so a confirmatory test is 
required. 259,264,270 
In other surveys done on meconium, the specimens were collected from more than 
one diaper and pooled if the quantity of meconium was small, as often occurs in 
preterm infants, refrigerated, batched and transferred rapidly to the laboratory where 
it was analysed, by EMIT. Screening was carried out for cocaine, opiates, 
cannabinoids, amphetamine, and phencyclidine with the cut-off at the limit of 
detection of the assay, being 50ng/g for cocaine, opiate, and amphetamine 
metabolites, 5ng/g for cannabinoids, and 3ng/g for PCP. Then confirmation was 
done by GC/MS, although amphetamine and PCP were discontinued because of low 
prevalence. 163 The cases were considered negative if the mother denied using 
cocaine and opiate during the interview and EMIT was negative. Maternal use of 
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alcohol, marijuana and nicotine during the pregnancy were treated as background 
variables in both the exposed and unexposed groups271 
False negative results may occur if the immunoassay does not cross react with the 
appropriate analytes or if the analyte is not free to react with the antibody, i. e., if it is 
the glucuronidated metabolite. Moore et a! 272 found that the concentration of 
hydrocodone, hydromorphine and codeine increased markedly after acid hydrolysis 
with a more moderate increase noted in the morphine concentration. This is in 
contrast to a report by Becker et al. 273 in which hydrolysis of meconium was not 
found to significantly increase the morphine concentration. Also, foetal maturity was 
found to be a factor in the detection of methamphetamine in meconium from guinea 
pigs after intraperitoneal injection of the drug at different gestation ages. 162 
Furthermore, gestation age was determined to be an important consideration in 
interpreting quantitative methamphetamine results. 
Lastly, one must address the feasibility of performing these tests in a clinical or 
research setting. Meconium analysis is available for mass screening with an enzyme 
immunoassay kit, or by radioimmunoassay149. The cost of analysis per specimen 
approximates the cost of urine toxicology. On the other hand the analysis of hair for 
drugs is restricted to a few commercial laboratories, and the cost of analysis is 
substantially higher than meconium analysis274. 
In spite of that there are many questions which remain to be answered about the 
disposition of drugs in meconium. Could the presence of a particular analyte be a 
marker for drug exposure at a certain gestational age? How important is enzymatic 
or acid/base hydrolysis of the meconium sample to accurate and sensitive drug 
measurement? Foetal maturity also affects the efficiency of phase II metabolism and 
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the production of glucuronide and other metabolites. It is not yet known which are 
the most appropriate drug analytes to measure in meconium. It is clear that 
cocaethylene and benzoylecgonine should be measured for cocaine exposure 165, and 
El Sohly et al. 275 have recently described the importance of 11-hydroxy-A9- 
tetrahydrocannabinol and 8,11-dihydroxy-d9-tetrahydrocannabinol for detection of 
marijuana exposure. 
There is also uncertainty about possible reabsorption of drugs from the foetal 
gastrointestinal tract during gestation, and foetal metabolism is different from that of 
the adult and is affected by gestation age. Meconium is also not a homogenous 
matrix, and as the drugs diffuse over time so mixing of meconium must be done. 
Another important confounding factor is the possible contamination of the meconium 
by urine, which may affect the concentration of drugs in meconium. 
The importance of using both meconium and maternal self-report is to identify 
mothers who deny use but who did use as evidenced by positive meconium 
confirmation 276. 
The discovery of polydrug use in pregnant mothers was reported277. It is becoming 
increasingly clear that women who use cocaine during pregnancy are also likely to 
use other illicit drugs. Only 13% of the studies reported that cocaine is the only drug 
used. 278 Chasnoff found that 32% of the positive meconium specimens were 
positive for at least 2 drugs, 
261 and only 2% of the mothers reported that they used 
cocaine and no other drugs, and mothers were found to be 49% times more likely to 
use another drug. The cocaine problem has truly become a problem of polydrug use. 
This has implications for the development of improved methods to identify drug- 
exposed infants, especially those exposed to multiple drugs. There are also 
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implications for developmental follow up studies because little is known about the 
effects of drug interactions on child behaviour and development 261. Finally the 
problem of cocaine use has been redefined as one of polydrug use, which has 
implications for the fields of drug toxicology, pediatrics, and child development 278. 
Recently some studies have been done comparing the results of maternal interview 
with hair and meconium analysis, regarding their sensitivity, specificity and false 
negative results in each opiate, cocaine and cannabinoids analysis. A sample of hair 
was obtained for drug analysis from each subject at the beginning of the survey, at 
the end of the second trimester of pregnancy, and within 24 hours after delivery. 
Meconium collection started from the first meconium until the third postnatal day, 
which was collected, frozen and analyzed for cocaine, opiates and cannabinoids. 
Also, this study was accompanied by an interview with the mother279. 
There was a consistency in the detection of drugs in meconium and hair from the 
first to the subsequent samples for cocaine and opiate. If the first meconium sample 
was positive it would be positive for all the samples, and the same was also true for 
hair analysis. The maternal interview showed the lowest sensitivity in detecting 
cocaine and opiate exposures (65% and 67% respectively) but it had the highest 
sensitivity in detecting cannabinoid exposure (58%). Both hair and meconium 
analyses had high sensitivity for detecting cocaine or opiate exposures. Hair analysis 
had a sensitivity of 100% for cocaine and 80% for opiate detection. However it had 
a false positive rate of 13% for cocaine and 20% for opiate, probably as a result of 
passive exposure. Meconium analysis had a sensitivity of 87% for cocaine and 77% 
for opiate detection, but unlike hair analysis it had no false positive test results for 
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cocaine. Both hair and meconium analyses had low sensitivity in detecting 
cannabinoid exposure, most probably because of the sporadic use of cannabis280. 
The principal drawback of hair analysis is its potential for false positive test results 
associated with passive exposure to drugs. Maternal interview is a time consuming 
test of low sensitivity. The high sensitivity of meconium analysis and ease of 
collection make this test ideal for prenatal drug screening278. 
In that study, meconium was analysed for cocaine and for benzoylecgonine, opiates 
(morphine and morphine glucuronides) and cannabinoids (11-nor-delta-9- 
tetrahydro-cannbinol-9-carboxylic acid) by radioimmunoassay according to 
previously published procedures. 5 Cut-off concentrations were 25ng/ml for cocaine 
and opiates and 15 ng/ml for cannabinoids. The inter-assay coefficient of variation 
was 12.6% for cocaine, 4.8% for morphine, and 11.9% for cannabinoids. Positive 
meconium test results were confirmed by gas chromatography/mass spectrometry 281. 
In detection of cocaine, Maternal interview showed a low sensitivity and a false 
negative rate of 55%. On the other hand, hair analysis showed a false positive rate of 
13% in contrast to false positive rates of 0% for both maternal interview and 
meconium analysis278'281'282 
From these previous studies, it is clear that a survey on meconium would be useful 
to detect drug abuse during pregnancy in Glasgow, as no previous studies have been 
done in this area. In a recent quotation in the Sunday Times newspaper on 25 March 
2002, Dr Laurence Gruer, Chairman of the Advisory Council on the Misuse of 
Drugs, March 2002 underlined the size of the problem. We do not have good data on 
the scope of the problem of drug use during pregnancy. This is one of the reasons 
for the survey and why it is desirable to extend it to other areas of Scotland. 
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"Up to 50,000 children in Scotland are being raised by parents addicted to heroin, 
cocaine and other hard drugs. A generation of children will be damaged - physically 
and emotionally - by their parents' habits. " 
The purpose of the present study was to know the exact number of drug-using 
mothers in Glasgow and to estimate the concentrations of drugs transmitted to their 
foetus, using the method previously developed to screen multiple drugs in 
meconium. The method developed can be applied to opiates, including morphine 
and codeine, cocaine and its metabolite benzoylecgonine, methadone, diazepam and 
temazepam, as examples of the benzodiazepine group, tetrahydrocannabinol (THC), 
and tetrahydrocannabinol-9-carboxylic acid (THC-carboxylic acid). The cases which 
were positive for methadone, morphine, and codeine were also analysed for 
6-acetylcodeine, to see if the mother had used street drugs (indicator of addict 
mother) as well as 6-MAM, diamorphine, papaverine, thebaine, and dihydrocodeine. 
These drugs are the most popular drugs in UK. 
10.2. Materials and Methods 
10.2.1. Materials 
All materials were as mentioned in Chapters 8 and 9. 
10.2.2. Instrumentation 
Gas chromatography - mass spectrometry was carried out using a VG Micromass 70- 
250S double focusing magnetic sector instrument or a Finnigan-Thermoquest Trace 
quadrupole instrument. The gas chromatograph was equipped with a fused silica 
capillary column (HP5,30 mx0.32 mm id, 0.3 pm film thickness). Helium was 
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used as the carrier gas. Samples (volume 1µl) were injected with an injection port 
temperature of 280°C. The initial column temperature was 200°C and was 
programmed to 300°C at a rate of 10°C/min. immediately after injection. The column 
was subsequently maintained at NOT for 1 minute, this program was for all drugs 
screened except amphetamine. The column temperature was initially held at 80°C 
for 2 min and then programmed to rise to 285°C at 5°C/min. The temperature was 
held at 285°C for the final 2min. 
10.2.3. Method 
(a) Sample collection 
in addition to the samples collected earlier( p106,137) samples of meconium were 
collected from diapers of newborn infants delivered at the Royal Maternity Hospital, 
Glasgow, from the period of October 2000 until February 2001. The total number 
was 450 cases. The meconium was recovered using a wooden spatula and stored in 
plastic tubes at -4°C until analysed. In addition, 30 samples of meconium were 
collected from neonates delivered in several hospitals in Egypt who were unlikely to 
have been exposed to drugs in uteri. These were used as controls. 
(b) Sample preparation: 
Each meconium specimen was weighed (range from 0.5g - 0.8g) into a clean vial 
and centrifuged at 2000rpm for 10 minutes to bring it to the bottom. Drug standards 
were added and the samples were homogenised by vortexing and sonicating for 15 
minutes. Methanol (3 ml) was added, and the tubes were vortexed well for 10 
minutes then centrifuged at 300 rpm for 20 minutes. The upper layers were 
transferred to clean tubes and evaporated to dryness under nitrogen, initially at room 
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temperature then with slight warming up to 40°C until completely dry. Once dry, the 
residues were dissolved in 700 µl methanol with vortexing. The extraction tubes 
were then centrifuged at 2000rpm for 10 minutes. 
(c) Sample Extraction: 
The solid phase extraction (SPE) procedures applied were the two methods 
mentioned in previous chapters; the first one was for all target analytes except 
amphetamine, which was as follows: 
" the column was prepared by washing with 2m1 methanol, followed 2 ml 
phosphate buffer (pH6); 
" the sample was applied at low vacuum pressure; 
" the column was washed with I ml distilled water, followed by 0.5m1 acetic acid 
(1. OM, pH 3.3). 
" the column was dried at maximum pressure for 4 min, then 50 µl methanol was 
added and the vacuum reapplied for 1 min. 
Elution was carried out in two stages: 
- 4m1 of eluant A (chloroform: acetone 1: 1 v/v); 
-2x 2m1 of eluant B (2% ammonia in ethyl acetate). 
The second method, for amphetamine was as follows: 
" The columns were prepared by applying 3 ml methanol, 3 ml water and 1 ml 
phosphate buffer (pH 6). 
" Then the sample was applied under low vacuum. 
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" The column was washed by 3-ml water, 1-ml acetic acid (pH 3.3), and 3-ml 
methanol. 
" The column was dried under maximum vacuum for 5 minutes. 
" The analytes were eluted by daily-prepared eluant: 3-ml dichloromethanol: 
IPA: concentrated ammonia in the ratio of (78: 20: 2). 
" The eluate was evaporated under nitrogen without heat till completely dry. 
" 50 µl PFPA: ethyl acetate 2: 1 v/v was added and the tubes heated at 60°C for 20 
minutes. 
" The derivatised extracts were evaporated again under nitrogen without heat until 
dryness and the residue reconstitutes in 50µ1 ethyl acetate and then injected into 
the GC/MS. 
A 500µl aliquot of eluate B was analysed by EIA for opiates, methadone, 
benzodiazepines, cannabinoids, amphetamines and methamphetamines. To the 
remainder of the eluate, the deuterated forms of each target analyte were added as 
internal standards. The extracts were mixed well and evaporated to dryness under 
nitrogen at 40°C until completely dry, then 50µ1 BSTFA were added, the vials were 
capped and incubated at 60°C for 20 minutes prior to GC-MS-SIM analysis. 
Selected ions used for quantitative analyses are listed in Table 9.1 along with the 
retention times for each analyte. 
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Table 10.1: Selected Ions Used for GC/MS/SIM 
Drug Ions 
selected 
Internal standard Ions 
selected 
Rt (min) 
Cocaine 303 H3-cocaine 306 6.21 
BZE 361 2H3-BZE 364 7.34 
Morphine 429 2 H3-morphine 432 8.58 
Codeine 371 H3-codeine 374 7.33 
Methadone 72 H3-methadone 75 6.03 
Diazepam 284 HS-diazepam 289 8.55 
Temazepam 372 H5-diazepam 289 9.33 
THC 386 H3-THC 389 9.15 
THC-COOH 488 H3-THC 389 10.15 
AM 190 H3-AM 193 5.75 
MA 204 H3-MA 193 7.08 
MDA 162 HS-MDA 168 9.77 
MDMA 204 2 H5-MDMA 209 11.05 
MDEA 218 HS-NIDEA 223 11.44 
(d) Analysis by GC/MS 
The analysis by GC/MS was done using SIM as mentioned before after SPE 
extraction. The quantitative method used blank meconium with known concentrations 
of analytes (1 ng/g, l Ong/g) and by these known concentrations the unknown 
concentration in positive sample can be calculated, using a calibration curve for each 
drug separately. All the positive samples for opiates by EIA were analysed for 
morphine and codeine. In cases which were positive for cocaine, the analytes were 
cocaine and its major metabolite in meconium, benzoylecgonine. Cases positive for 
cannabinoids during screening were analysed for THC and THCA. Lastly, for cases 
which were positive for methamphetamine and amphetamine the problem of small 
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amounts of specimen remaining, as at least another 400-500mg of meconium was 
needed for analysis. So in 65 cases no meconium was available for analysis, while the 
other 121 cases were analysed. 
10.3. Results and Discussion 
10.3.1. Sample Sizes 
The samples were weighed, and the weights are summarized in the following table: 
Table 10.2 Weights and appearance of each sample. 
Number of 
case 
Total 
Weight 
(mg) 
Weight 
used 
m 
Special character 
Case 1 1980 532. 
Case 2 1532 544. Given as blank 
Case 3 963 522 
Case 4 853 552 
Case 5 659 553 
Case 6 873 547 
Case 7 591 491 Green lung appearance, all the 
sample 
Case. 8 957 613 Slight yellow 
Case 9 1568 601 
Case 10 915 620 
Case 11 845 616 Bright green 
Case 12 329 149 All the sample 
Case 13 950 506 
Case 14 350 216 All the sample 
Case 15 892 523 Stool appearance 
Case 16 566 466 All the sample 
Case 17 910 511 Yellowish in colour 
Case 18 634 529 All the sample 
Case 19 537 537 
Case 20 650 420 All the sample 
Case21 510 451 All the sample, greyish brown 
Case 22 1250 617 
Case 23 895 623 
Case24 212 174 All the sample 
Case25 3380 539 solid 
Case26 621 348 All the sample 
Case 27 795 504 
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Case28 500 499 All the sample 
Case 29 778 445 
Case 30 4323 559 
Case 31 497 254 All the sample 
Case32 836 551 All the sample 
Case 33 3604 562 Stay in freeze for a month. 
Case 34 3915 589 Stay in freeze for a month. 
Case35 1980 573 
Case 36 471 202 All the sample 
Case 37 8480 593 Hard sticky 
Case 38 637 278 The entire sample. 
Case 39 1514 526 
Case 40 1077 528 
Case 41 1166 525 Yellow green water stool. 
Case 42 3261 537 Yellow brown 
Case 43 347 189 All the sample 
Case 44 4443 572 Hard sticky 
Case 45 200 74 All the sample 
Case 46 888 560 Yellow brown. 
Case 47 4389 577 
Case 48 594 340 All the sample 
Case 49 783 533 Yellow brown, the entire sample. 
Case 50 409 258 All the sample. 
Case 51 167 41 All the sample. 
Case 52 162 47 All the sample. 
Case 53 940 566 All the sample. 
Case 54 4339 544 Mucoid has two different green 
colours. 
Case 55 353 90 All the sample 
Case56 9533 568 
Case 57 938 513 
Case 58 2097 579 
Case 59 637 507 All the sample. 
Case 60 1181 548 
Case 61 783 521 All the sample 
Case 62 959 573 
Case 63 570 320 All the sample 
Case 64 2827 537 
Case65 5017 562 Sticky, difficult to weight. 
Case 66 791 543 
Case 67 1509 558 Sticky. Difficult to weight. 
Case 68 597 517 
Case 69 2671 592 
Case 70 840 551 
Case 71 1916 550 
Case 72 1469 577 
Case 73 505 520 Almost all the sample. 
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Case 74 626 538 Sticky, light green. 
Case 75 810 553 
Case 76 729 504 
Case 77 1042 579 
Case 78 765 410 
Case 79 641 410 All the sample used. 
Case 80 775 486 
Case 81 1197 552 Yellow brown. 
Case 82 722 334 
Case 83 423 380 
Case 84 456 253 All the sample used 
Case 85 492 449 All sample used 
Case 86 722 477 All samples used. 
Case 87 1088 577 
Case 88 945 527 
Case 89 7250 578 
Case 90 3093 589 
Case 91 576 428 All the sample used, has green 
star. 
Case 92 1944 520 
Case 93 3544 575 
Case 94 2638 554 
Case 95 597 467 All samples used. 
Case 96 1618 592 Move as one sample. 
Case 97 2122 575 
Case 98 789 375 All sample used 
Case 99 1827 565 
Case 100 570 450 Yellowish brown. 
Case 101 813 519 All the sample used 
Case 102 474 115 All sample used 
Case 103 844 532 Slight yellowish green 
Case 104 1384 575 Has green star 
Case 105 900 509 
Case 106 9401 547 
Case 107 452. 327 All the sample used. 
Case 108 1038 576 
Case 109 4030 573 
Case 110 1528 568 Contain mucous 
Case 111 3540 577 Contain yellow mucous 
Case 112 1062 552 
Case 113 711 551 Yellow brown in colour 
Case 114 643 476 
Case 115 252 248 Used all the sample 
Case 116 533 476 Used all the sample 
Case 117 911 521 Smooth wate stick on wall 
Case 118 640 435 Used all the sample 
Case 119 1749 577 
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Case 120 1328 574 
Case 121 582 521 Watery, all sample used 
Case 122 360 312 Green brown, all sample used 
Case 123 605 360 Green brown, all sample used 
Case 124 545 409 Green brown, all sample used 
Case 125 1188 577 Yellow brown, all sample used 
Case 126 527 377 Yellow brown, all sample used 
Case 127 605 375 All sample used 
Case 128 820 541 Used all the sample 
Case 129 556 511 Used all the sample 
Case 130 455 377 Used all the sample 
Case 131 733 526 Used all the sample 
Case 132 462 319 Used all the sample 
Case 133 611 454 Used all the sample 
Case 134 867 562 
Case 135 1219 550 Soft sticky to wall 
Case 136 964 540 
Case 137 2058 560 
Case 138 953 562 Yellow brown 
Case 139 1132 550 
Case 140 547 365 Smooth, sticky, used all sample 
Case 141 2586 567 
Case 142 672 550 Bright green(MOHABBA)used all 
Case 143 2143 564 
Case 144 3005 565 
Case 145 640 503 
Case 146 1120 563 
Case 147 522 395 Sticky, used all the sample 
Case 148 3531 566 
Case 149 634 494 
Case 150 655 514 Almost all the sample 
Case 150 655 514 Almost all the sample 
Case 151 3089 549 
Case 152 381 370 All the sample 
Case 153 906 532 
Case 154 572 422 All the sam le used 
Case 155 8626 578 
Case 156 742. 500 
Case 157 560. 434 Green in colour, soft, all used 
Case 158 1065 547 Green brown 
Case 159 558 409 Nearly all sample used 
Case 160 579 444 
Case 161 569 531 All the sample used 
Case 162 532 466 Brown yellow, soft, all sample 
used 
Case 163 806 515 Green brown in colour 
Case 164 666 518 Green brown, all sam le used 
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Case 165 221 150 All sample used 
Case 166 420 312 All sample used 
Case 167 482 347 All sample used 
Case 168 251 122 Yellow brown, all sample used 
Case 169 250 121 All sample used 
Case 170 549 475 Green in colour, all sample used 
Case 171 988 566 
Case 172 2453 566 
Case 173 232 144 All sample used 
Case 174 212 136 All sample used 
Case 175 310 223 All sample used 
Case 176 320 254 Green brown in colour, nearly all 
used 
Case 177 813 547 Yellow brown in colour 
Case 178 1302 570 
Case 179 3222 565 
Case 180 1789 537 Green brown 
Case 181 2069 548 
Case 182 7300 564 
Case 183 4567 575 
Case 184 3989 572 
Case 185 1420 569 
Case 186 813 529 
Case 187 672 449 
Case 188 892 536 
Case 189 877 506 
Case 190 910 550 
Case 191 320 252 All sample used 
Case 192 614 545 Nearly all sample used 
Case 193 5202 545 
Case 194 2102 547 
Case195 964 535 
Case 196 571 475 All sample used 
Case 197 539 420 All sample used 
Case 198 3297 547 
Case 199 513 409 All sample used 
Case200 846 526 Yellow brown in colour 
Case 201 601 522 All sample used 
Case 202 874 544 
Case 203 666 465 Nearly all sample used 
Case 204 998 500 
Case 205 837 528 
Case 206 642 448 From two container, green lungy 
in appearance 
Case 207 1136 513 Green in colour 
Case 208 412 393 All sample used, green brown 
Case 209 587 439 All sample used 
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Case 210 1643 529 
Case 211 499 404 All sample used 
Case 212 754 538 
Case 213 789 540 
Case 214 449 340 All sample used 
Case 215 699 537 
Case 216 978 520 
Case 217 512 407 All sample used 
Case 218 602 421 
Case 219 510 360 Green brown, all sample used 
Case 220 107 91 All sample used 
Case 221 410 349 All sample used 
Case 222 350 226 All sample used 
Case 223 813 540 Yellow brown 
Case 224 469 380 Nearly all sample used 
Case 225 500 340 Nearly all sample used 
Case 226 350 267 All sample used 
Case 227 515 456 Nearl all sample used 
Case 228 459 339 
Case 229 433 341 All sample used 
Case 230 410 305 All sample used 
Case 231 971 527 
Case 232 1216 534 
Case 233 1169 552 Green brown 
Case 234 1303 521 Yellow brown 
Case 235 1255 528 
Case 236 2390 533 
Case237 2732 554 
Case238 710 534 
Case 239 9449 552 
Case240 6920 55. 
Case241 699 553 Green brown in colour 
Case 242 702 532 
Case 243 3250 555 
Case 244 963 546 
Case 245 699 543 Nearly all sample used 
Case 246 678 533 
Case 247 783 540 Yellow brown in colour 
Case 248 633 540 All sample used 
Case 249 549 436 All sample used 
Case 250 5163 554 
Case 251 659 530 Yellow reen in colour 
Case 252 5102 453 All sample used 
Case 253 564 466 Has part white green in colour, all 
sample used 
Case 254 839 504 Nearly all sample used 
Case 25S 381 285 All sample used 
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Case 256 437 326 Green in colour, all sample used 
Case 257 310 254 All sample used 
Case 258 1065 511 
Case 259 1461 547 
Case 260 773 530 Green watery in consistency 
Case 261 954 554 
Case 262 310 245 All sample used 
Case 263 1261 552 
Case 264 622 497 Brown, watery, nearly all used 
Case 265 613 533 
Case 266 732 535 Green brown in colour 
Case 267 451 332 All sample used 
Case 268 452 307 All sample used 
Case 269 7302 545 
Case 270 499 490 All sample used 
Case 271 312 253 All sample used 
Case 272 350 235 All sample used 
Case 273 307 266 Green brown in colour, all used 
Case 274 401 396 All sample used 
Case 275 200 164 All sample used 
Case 276 422 376 Green brown in colour, all used 
Case 277 608 434 Green brown, nearly all used 
Case 278 370 301 Green brown, all used 
Case 279 362. 310 Green brown, all used 
'case 280 2063 557 
Case 281 510 477 All sample used 
Case 282 4255 551 Green brown in colour 
Case283 1296 554 
Case 284 964 531 
Case 285 639 466 Soft, green in colour 
Case 286 5162 550 
Case287 934 520 
Case 288 499 466 All sample used 
Case 289 898 548 Water in consistency, brown in 
colour 
Case 290 1353 557 
Case 291 592 479 Bright green, all sample used 
Case 292 459 363 Green brown, all sample used 
Case 293 500 409 Green, all sample used 
Case 294 320 228 All sample used 
Case 295 340 258 All sample used 
Case 296 1210 543 
Case 297 382 311 Present with case 296 in same 
envelo e, all sample used 
Case 298 2063 542 
Case 299 621 508 Green colour, nearly all sample 
used 
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Case 300 1581 564 Has some white area 
Case 301 1277 536 
Case 302 873 544 Brown green in colour 
Case 303 1802 507 
Case 304 2201 548 
Case 305 982 536 Green in colour 
Case 306 782 503 Soft in consistency 
Case 307 202 167 All sample used 
Case 308 863 524 
Case 309 10327 544 
Case 310 4831 544 
Case 311 320 300 All sample used 
Case 312 812 544 
Case 313 341 296 All sample used 
Case 314 520 489 
Case 315 290 230 
Case 316 80 76. All sample used 
Case 317 870 530 
Case 318 223 148 All sample used 
Case 319 205 172 All sample used 
Case 320 434 378 Yellow brown in colour, all used 
Case 321 192 163 Yellow brown, all used 
Case 322 264 223 All sample used 
Case 323 290 240 Yellow brown, all sample used 
Case 324 3201 555 
Case 325 1147 557 Has area white yellow 
Case 326 978 542 Green brown, soft 
Case 327 4102 552 
Case 328 893 562 Green colour, soft 
Case 329 3617 549 
Case 330 5101 553 Soft 
Case 331 2650 553 Light dark green in colour 
Case 332 551 473 All used 
Case 333 597 535 Yellow brown, nearly all used 
Case 334 531 467 All used 
Case 335 392 332 All used 
Case 336 461 376 All sample used 
Case 337 609 471 All sample used 
Case 338 530 434 Green brown, all used 
Case 339 573 441 All used 
Case 340 350 256 Yellow brown, all used 
Case 341 1100 529 
Case 342 1680 515 Present in brown envelope 
Case 343 831 526 
Case' 344 1230 556 Yellow green 
Case 345 1093 540 
Case 346 1100 533 
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Case 347 3577 542 Has small yellow mucous area 
Case 348 462 407 Green colourful used 
Case 349 291 225 All sample used 
Case 350 509. 453 All sample used 
Case 351 349. 264 All sample used 
Case 352 4119 548 Green yellow in colour 
Case 353 750 515 
Case 354 863 526 
Case 355 601 535 
Case 356 1463 550 
Case 357 2320 543 
Case 358 1793 558 
Case 359 2633 547 
Case 360 763 554 Nearly all the sam le 
Case 361 733 560 Nearly all the sample 
Case 362 402 382 All sample used 
Case 363 863. 535 
Case 364 763. 548 
Case 365 1201 550 Yellow green in colour 
Case 366 5093 552 
Case 367 3681 553 
Case 368 852 549 Brown green in colour 
Case 369 871 556 Brown green in colour 
Case 370 720 551 
Case 371 5926 416 Nearly all the sample used 
Case 372 5208 365 
Case 373 510 372 
Case 374 420 396 All samples used. 
Case375 1210 542 
Case376 867 529 
Case377 1812 550 
Case378 601. 409 Nearly all samples used. 
Case379 5312 550 
Case380 749. 547 
Case381 916. 546 
Case382 1571 550 
Case383 2166 547 
Case384 1210 551 
Case385 5691 557 
Case386 210. 169 All samples used. 
Case387 512. 494 All sample used, alternation 
yellowfoci. 
Case388 410. 305 
Case389 310. 225 
Case390 450. 364 
Case391 1007 543 
Case392 1352 546 
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Case393 710. 552 Yellow brown colour 
Case394 871. 546 
Case395 520. 313 
Case396 1144 547 
Case397 560 364 
Case398 340 294 All sample used 
Case399 491 367 
Case 400 320 254 
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10.3.2. Results of EIA: 
The results of analysis of cases by EIA are given in Table 10.3 
Table 10.3 Results of EIA Analysis Of 400 Cases 
Case 
No 
Benzo Cann Opiate Metha- 
done 
AM MA Cocain 
e 
Blank - - - - - - - 
1 ++ 4.1 ++++ ++++ -- - ++++ 
2 21 - 106 - - - - 
3 184 - 14 - - - - 
4 48 - 43 - - - - 
5 ++++ 16 388. ++++ - - - 
6 ++++ 27 ++++ 91 - - - 
7 26 3 83 - - - - 
8 39 - 133 ++++ - - - 
9 118 7 243 - - - - 
10 - - 47 - - - - 
11 35 - 109 - - - - 
12 - - 69 - - - - 
13 24 - 59 - - - - 
14 - - 57 - - - - 
15 17 - 61 - - - - 
16 - - 89 - - - - 
17 - - 58 - - - - 
18 - +++++ 60 -- - - - 
19 128 - 48 - - - - 
20 - - 62 - - - - 
21 - 14 - - - - - 
22 -- - 73 +++++ - - - 
23 23 - 70 +++++ - - - 
24 - ++++ - - - - - 
25 11 - - - 128 - - 
26 118 - - - - - - 
27 - 14 - - - - - 
28 370 - - - - 107 - 
29 12 - 43 - - 57 - 
30 - - - - - - - 
31 - - - - - - - 
32 - 32 83 - - 53 - 
33 - - 18 31 - 
34 - - 94 - - 44 11 
35 - - ++++ - - - - 
36 - - 23 -- - - - 
37 34 -- - - - 
38 - - - - - 30 11 
39 - - 152 - - - - 
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40 
41 44 - - - - 40 - 
42 - -- - - - - - 
43 - ++++ - - - - ++++ 
44 - ++++ - - - - ++++ 
45 - 13. 52 - - - ++++ 
46 - ++++ - - - - ++++ 
47 - 17 103 - - 29 - 
48 - 9 ++++ - - - - 
49 159 ++++ - - 188 104 - 
50 34 28 23 - - - - 
51 - ++++ ++++ - - - - 
52 - 9 - - - - - 
53 - 3 127 - - 33 - 
54 - ++++ - - - - - 
55 - 17 66 - - - 108 
56 202 11 - - - - 31 
57 - ++++ - - - 46 17 
58 - ++++ - - - - - 
59 45 +++++ - - - - - 
60 - - - - - 42 - 
61 15 - - - - 48 - 
62 - - - - - 33 - 
63 - - 226 - - - - 
64 - - - - - - - 
65 -- - - - - 31 - 
66 - -- - - - 67 - 
67 - - 42 - - - - 
68 - - - - - - - 
69 - ++++ - - 55 64 - 
70 - - - - - 55 - 
71 - 8 63 - - 41 - 
72 - - - - - - - 
73 - - - - - 58 - 
74 - - - - - 33 - 
75 - - - - - - - 
76 - 39 58 - - 31 - 
77 - - - - - 44 - 
78 - - - - - - - 
79 - - - - - - - 
80 - - - - - 36.240 - 
81 - - - - - 106.184 - 
82 - 41.196 - - - - - 
83 -- - - - - 68.456 - 
84 - - - - - - - 
85 - - - - - - - 
86 - - - - - 49 - 
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87 - - ++++ - - 71 - 88 - - - - - - - 
89 - - -- - - 35 - 90 - - 259 - - 36 - 
91 - - 10 - -- 47 - 92 - - 45 - - 45 - 
93 - - - - - - - 
94 - - - - - 47 - 
95 - - - - - 32 - 96 - - 16 - - - - 
97 - 6 - - - - - 
98 - - 37 - - 42 - 
99 - - 12 - - - - 
100 - - - - - 37 - 
101 13 20 - - - 38 - 
102 - - - - - - - 103 - - 203 - - 37 - 
104 33.868 50.000 ++++ +++++ - 26 - 
105 - - - - - - - 
106 - - - - - 26 - 107 - - - - - 60 - 
108 - - 13 - - - - 
109 - - - - - - - 
110 - - 27 - - - - 
111 - - - - - - - 
112 - - - - - - - 
113 - - 31 - - 44 - 
114 - - 132 - - - - 
115 - - - - - - - 
116 - - - - -- - - 
117 - - - - 29 49 - 
118 - - 105 - - 32 - 
119 - - 62 - -- - - 
120 - - - -- - - - 
121 - - 162 - - - - 
122 - - 13 - - - - 
123 - +++++ - - -- 63 - 
124 - - - - -- - - 
125 - -- - - - 37 - 
126 - - 23 - - 31.770 - 
127 399 4 342 24 - - - 
128 - - - -- - - - 
129 - - - - - 26 - 
130 - - -- - - - - 
131 - -- -- - - 41 - 
132 - 25 179 14 - - - 
133 - - ++++ - - 68 - 
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134 - - 336. - - - - 
135 - - 76 - - 
62 - 
136 - - - - - 
32 - 
137 - - - - - - - 
138 - - - - - 
41 - 
139 - - - - - - - 
140 - - 88 - - - - 
141 - - - - - 
26 - 
142 53 - 359 - 
58 - - 
143 - - - - - - - 
144 - - - - - - - 
145 - - 76 - - - - 
146 18 - 94 - - 
36 - 
147 - - -- - - - - 
148 - - - - - - - 
149 - - - - - 65 - 
150 - - - - - 
34 - 
151 - - - - - - - 
152 - - 20 - - 
82 - 
153 - - 95 - 
133 42 - 
154 - +++++ - - - 
43 - 
155 - - 462 - - - - 
156 - 19 78 - - - - 
157 - - - - - 
45 - 
158 - - - - - 
43 - 
159 - 13 - - - - - 
160 11 - 194 - - - - 
161 - - 
63 - - 28 - 
162 - - 102 - - 
108 - 
163 - - 177 - - 
49 - 
164 - - - - - 
42 - 
165 - - - - - - 
166 - 26 127 - - 
46 - 
167 - 6.619 - - - - - 
168 - - - - - - - 
169 18 18 134 - - - - 
170 - - - - - 
53 - 
171 50 - 217 - - 
51 - 
172 - - - - - - - 
173 - - - - - - - 
174 - - - - - - - 
175 270 - - - - 
176 - -- 223 -- - 
33 - 
177 - -- - - - 
95 - 
178 - - - - - - - 
179 - - 68 - - 
76 - 
180 - - 474 - - 
31 - 
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181 - - - -- - - - 182 - - 53 - - - - 183 - - 89 - - - - 184 - 20 - - - - - 
185 36 - 116 - - 122 - 
186 - - -- - - 39 - 
187 - - 85 - -- 37 - 188 - - - -- -- 38 - 
189 - - 41 - -- - - 190 - - - - - 54 - 
191 - - 35 -- -- 34 - 
192 - - 116 - - 28 - 
193 - -- - - - - - 
194 - - - - - 33 - 
195 - - - - - 32 - 
196 17 - - - - 93 - 197 21 - 10 - - 64 - 
198 - - 22 - - - - 199 77 16 83 - - 43 - 
200 54.034 - 394.987 - - 117 - 
201 - - 48.707 - - - - 
201 - 2.623 104.347 - - 57 - 
203 - - - - - - - 
204 - - - - - - - 
205 - - 62 - - 57 - 
206 17 18 - - - 105 - 
207 - - - - - 97 - 
208 - - - - - 79 - 
209 - - - - - 55 - 
210 - - 16 - - 49 - 
211 - - 27 - - - - 
212 - - - - - - - 
213 15 - 88 - - 79 - 
214 - - 31 - - 26 - 
215 24 - 78 - - 65 - 
216 - - 88 - - 38 - 
217 - - - - - - - 218 - - 179 - - 25 - 
219 -- - - - - - - 
220 - 15.899 37 - - - - 
221 - - 75 - - - - 
222 - - 58 - - - - 
223 - - - - - 38 - 
224 17 - 91 - - 33 - 
225 - - 34 - - - - 
226 - 25 - 54 - 25 - 
227 - - - - - 41 - 
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228 - - 43 - - 
26 - 
229 - - - - - 
230 - - 93 - - - - 
231 - - - - - 
59 - 
232 20 - 116 - - 
44 - 
233 - - - - - 
45 - 
234 - - - - - 
67 - 
235 - 5 21 - - 
47 - 
236 - - 30 - - - - 
237 31 - - - - 
238 - - - - 
239 - - 13 - - 
51 - 
240 - - 16 - - - - 
241 - - - - - 
50. - 
242 - - - - - - 
243 40 - +++++ - - 
194 - 
244 - - 123 - - - - 
245 - -" - 
246 - - 63 - - 
46 " 
247 - - - - - 
38 - 
248 38 - +++++ - - - - 
249 - - - - - 
74 - 
250 - - - - - 
251 10 - 38 - - - - 
252 - - 
22 - -- - - 
253 - - - - - " 
254 29 - 115 
92 - 
255 17 - 91 
39 
256 - 100 - - - - 
257 - - 
13 - - 31 - 
258 - - - - - 
259 - - 
36 - - - - 
260 - - - - - 
114 - 
261 42 - 157 - - 
62 - 
262 - - 14 - - 
26 - 
263 - - - - - 
35 - 
264 - - +++++ - - 
41 - 
265 - - - - - 
45 - 
266 
267 
- 
107 
- 
- 
19 
- 
- 
- 
- 
27 
- 
84 
- 
- 
268 - - 
269 - - 16 - - 
27 - 
270 20 - - - - 101 - 
271 - - - - - 
272 - - 11 - - - - 
273 - - - - - 
66 - 
274 - -- 21 - - - - 
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275 - - - - - - - 
276 - - - - -- 47 - 
277 - - - - - - - 
278 - - 56 - - 37 - 
279 - - 24 - 43 34 - 
280 - +++++ 11 - - 42 - 
281 - - 207.545 - - - - 282 - +++++ - - - 61 - 
283 105 5 +++++ +++++ - - - 
284 - - 37 - - - - 
285 - - - - - 37 - 
286 - - - - - - - 
287 - - - - - - - 
288 - +++++ - - - - - 
289 - - - - - 70 - 
290 - - - - - - - 
291 13 - 92 - - 34 - 
292 - - 131 - - 46 - 
293 - - 12 - - 34 - 
294 - +++++ - - - 32 - 
295 - - - - - - - 
296 +++++ - +++++ ++++ - 37 194 
297 - - 109 - - 47 - 
298 - - - - - - - 
299 - - - - - - - 
300 - - 18 - - - - 
301 - - - - - - - 
302 13 - 143 - - 97 - 
303 - - 424 - - 88 - 
304 - - - - - - - 
305 - - 55 - 36 - 
306 - - 65 - - 36 - 
307 - - - - - 45 - 
308 14 - +++++ - - 64 - 
309 - - - - - - - 
310 - 21 38 47 
311 - - 269 - - - - 
312 - - - - - 31 - 
313 63 - +++++ - - 158 - 
314 - - 64 - - 54 - 
315 +++++ +++++ 169 95 - - - 
316 23 - - - - - - 
317 14 35 244 - - 42 - 
318 - - 448 - - 41 - 
319 - - - - - - - 
320 28 - - - - 45 
32 - - 157 - - - - 
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322 - 19 - - - 26 - 323 
324 +++++ - +++++ +++++ __ _ 325 - - 58 - _ 
326 - - 404 - - 35 - 327 - - - - - 28 - 
328 - - - - - 72 - 329 - - +++++ - _- _ 330 - - - - -- - 331 - - - - - 35 - 
332 - - - - - 26 - 333 - - +++++ - - 58 - 
334 - - - - - 54 - 335 - - - - -- - 
336 - - - - - 58 - 337 - - - - - 30 - 
338 - - - - - 32 - 339 - - - - - 33 - 
340 - - - - - 215 - 
341 - - +++++ - _- _ 
342 74 +++++ +++++ +++++ - 31 - 
343 - - - - - 38 - 
344 - - 68 - 
345 19 - ++++ +++++ - 27 _ 
346 - - +++++ - 44 74 - 
347 - - - - -- - 
348 - +++++ - - - 61 - 
349 - - - - - 35 - 
350 - - 38 - -- _ 
351 61 - 76 - - 32 - 
352 - - 33 - - 68 _ 
353 10 - - - - 29 - 
354 - - 36 
355 - 6 23 - - 29 _ 
356 - - - - - 29 - 
357 - - -- - -- - 
358 - - 95 - -_ - 
359 - 29 +++++ - - 34 - 
360 - - - - -- - 
361 - - - - - 35 - 
362 - - - - - 42 - 
363 - - 26 - - 32 - 
364 28 23 56 - -- _ 
365 28 34 - 
366 16 35 - 
367 16 67 88 
368 16 - ++++ - -_ - 
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369 20 - 91 - - - - 
370 24 - 36 - - - - 371 17 - 45 - - - - 372 21 - 88 - - - - 
373 26 - 33 - - - - 
374 21 - 33 - - - - 
375 - - - - - 34 - 
376 - - - - - - - 377 - - - - - - - 378 - 16 - - - - - 
379 - - - - - - - 
380 40 - 
381 - - - - 33 - 
382 - - - -- - 13 
383 - 31 - - 125 - 
384 - - - - - - 
385 3 - - - 29 - 
386 - - - - - - 387 25 5 - - - - - 
388 - 23 - - - - 
389 - 35 - - - - 
390 - - - - - - 391 - - - - - - 
392 41 - - -- - - 
393 - 47 - - 34 - 
394 - - - - - - - 
395 42 - - - - - - 
396 159 - - - - - - 
397 - - - - - - - 
398 +++++ - - - - - - 
399 - - - - - - - 
400 - - - - - - - 
Out of scale = (++++), Negative = (-) 
From these, a summary of the final results of EIA for drugs is given in Table 10.4 
and Figure 10.1: 
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Table 10.4 Number of positive cases by EIA and percentages of each drug group. 
Drug Group Number of positive 
cases 
Percentages (%) 
Opiates 194 48.5 
Benzodiazepines 81 20.3 
Cannabinoids 68 17 
Methadone 17 4.3 
Cocaine 12 3 
AM 9 2.3 
MA 186 46.5 
Number of EIA cases 
194 
40 17 
12 9 
20 
C 
Opiate Benzo Cann Methad Cocaine AM MA 
Figure 10.1 Number of positive cases of each drug group by EIA. 
10.4. Drugs used in Hospital: 
The EIA results indicated high percentages of the cases to be positive for both 
opiates and methamphetamine. so confirmation by GC/MS was carried out with 
reference back to the hospital files, when it was found that many of the mothers had 
been treated with drugs as follows: 
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Q Diamorphin Injection 5 mg (201 cases); 
Q Diamorphin injection 10 mg (291cases); 
i These represent about 52.8% in all cases born in October and 45.5% in December; 
L) Temazepam tablets also given to (200cases) which represent 18.8% of all cases 
born. 
10.5. Results of GC/MS analysis 
It was also found that the results for methamphetamine were different if Cozart or 
Technological kits (which used occasionally in some cases) were used, so GC/MS 
analysis was carried out for all positive cases with the following aims: 
1- Confirmation of EIA results as shown in Table 10.3 and 10.4; 
2- Quantification of all the cases if possible by GC/MS. These results are given in 
Table 10.5 and the percentages agreeing with EIA are shown in Table 10.6. 
3-, In the cases which were positive for methamphetamine, to apply the method 
described in Chapter 9 to detect and measure all the important members of the 
amphetamine group (AM, MA, MDA, MDMA and MDEA) and result of its 
quantify by GC/MS. These results are given in Table 10.7. 
4- In opiate-positive cases, which were found also positive for methadone, and 
codeine, and they are 9 cases, to distinguish between morphine derived from illict 
heroin and that originating in pharmaceutical diamorphine by analysing for 
impurities found in illicit heroin including 6-acetylcodeine, 6- 
monoacetylmorphine, dihydromorphine, dihydrocodeine, papaverine, and 
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thebaine. This was done by injecting standards of each of these substances to 
establish their retention times (given in Table 10.8). The results of the analysis 
of case samples are given in Table 10.9. 
5- Addict mothers are commonly poly-drug users. The most common cause of death 
in substance-related deaths in forensic medicine is due to a combination of drugs. 
The study of Chasnoff et al 1988,256 as mentioned before, reported that 32% of 
the cases which are drug-positive are positive for at least 2 drugs. In this survey 
an indication of the number of drug addicts can be obtained by taking notice of 
the methadone-positive group as these are most probably on a maintenance 
program, so in this study an additional aim was to try to establish the number of 
polydrug users during pregnancy, in those cases positive for methadone. The 
results are shown in Table 10.10. 
Table 10.5 Results of GC/MS Analysis 
Case Drug Concentration (ng/g meconium) 
No Diaz Temaz Morph Cod Metha Coc Benzo THC THCA AM 
Blank - - - - - - - - - - 
Casel 114 - 100 80 319 20 11 - - - 
2 147 128 38 110 - - - - - - 
3 - 4560 380 1600 - - - - - - 
4 1281 - 998 - - - - - - - 
5 680 432 1070 - 2190 - - 599 - - 
6 632 912 120 - 237 - - 1010 - - 
7 70 - 30 30 - - - - - - 
8 - - 30 80 - - - - - - 
9 110 60 510 - - - - - 
10 150 - - - - - - - 
11 - - 50 - - - - - - - 
12 - - 40 - - - - - - 
13 230 223 10 40 - - - - - - 
14 - - 15 40 - - - - - - 
15 240 51 14 50 - - - - - - 
16 - 10 50 - - - - - - 
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17 - - 14 50 - - - - - - 
18 - - 10 50 - - - - - - 
19 - - 10 60 - - - - - - 
20 - - 10 30 - - - - - - 
21 - - - - - - - - - - 
22 - - - 40 181 - - - - - 
23 - - - - - - 1 - - - 
24 - - 645 30 - - - 250 400 476 
25 - - 50 30 - - - - - - 
26 18 115 - - - - - - - - 
27 - - - - - - - - - - 
28 - - - - - - - - - - 
29 78 100 30 20 - - - - - - 
30 - - - - - - - - - - 
31 - - - - - - - - - - 
32 - - 50 15 - - - 175 180 - 
33 - - 70 60 - - - - - - 
34 - - 90 110 - - - - - - 
35 - - 50 40 - - - - - - 
36 - - 30 20 - - - - - - 
37 - - 50 10 - - - - - - 
38 - - - - - - - - - - 
39 - - 50 10 - - - - - - 
40 - - 30 10 - - - - - - 
41 53 273 - - - - - - - - 
42 - - 30 10 - - - - - - 
43 - - 70 10 - - - 
175 180 - 
44 - - 20 - - - - 150 180 - 
45 - - 30 10 - - - 100 - - 
46 - - 50 30 - - - 
750 - - 
47 - - 70 20 - - - 
125 120 - 
48 - - 20 500 - - - 200 - - 
49 560 766 160 20 - - - 175 160 240 
50 510 1003 50 54 - - - 500 - - 
51 - - 50 50 - - - 300 - - 
52 - - 50 70 - - - - - - 
53 - - - - - - - 
800 - - 
54 - - 50 - - - - 
525 - - 
55 554 130 - - - - - 100 - - 
56 220 - - - - - - - - - 
57 - - - - - - - - 320 
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58 - - - - - - - - - - 
59 - - - - - - - 50 - - 
60 - - - - - - - - - - 
61 670 3330 - - - - - - - - 
62 - - - - - - - - - - 
63 - - 32 30 - - - - - - 
64 - - 50 10 - - - - - - 
65 - - - - - - - - - - 
66 - - - - - - - - - - 
67 - - 357 119 - - - - - - 
68 - - - - - - - - - - 
69 - - - - - - - 100 
70 - - - - - - - - - - 
71 - - 132 10 - - - - - - 
72 - - - - - - - - - - 
73 - - - - - - - - - - 
74 - - - - - - - - - - 
75 - - - - - - - - - - 
76 - - 614 - - - - - - 
77 - - - - - - - - - - 
78 - - - - - - - - - - 
79 - - - - - - - - - - 
80 - - - - - - - - - - 
81 - - - - - - - - - - 
82 400 1120 - 
83 - - - - - - - - - - 
84 - - - - - - - - - - 
85 - - - - - - - - - - 
86 - - - - - - - - - - 
87 - - - 1325 - - - - - - 
88 - - - - - - - - - - 
89 - - - - - - - - - - 
90 - - 70 58 - - - - - - 
91 - - 20 - - - - - - - 
92 - - 30 13 - - - - - - 
93 - - - - - - - - - - 
94 - - - - - - - - - - 
95 - - - - - - - - - - 
96 - - - 13 - - - - 416 - 
97 - - - - - - - - - - 
98 _ - 30 110 - - - - - - 
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99 - - 40 - - - - - - - 
100 240 250 - - - - - 300 785 - 
101 - - - - - - - - - - 
102 - - - - - - - - - - 
103 - - 40 80 - - - - - - 
104 1810 - 1442 58 1434 - - 500 375 - 
105 - - - - - - - - - - 
106 - - - - - - - - - - 
107 - - - - - - - - - - 
108 - - 48 16 - - - - - - 
109 - - - - - - - - - - 
110 - - 23 16 - - - - - - 
111 - - - - - - - - - - 
112 - - - - - - - - - - 
113 - - 48 237 - - - - - - 
114 - - 100 24 - - - - - - 
115 - - - - - - - - - - 
116 - - - - - - - - - - 
117 - - - - - - - - - 
118 - - 48 24 - - - - - - 
119 - - 48 32 - - - - - - 
120 - - - - - - - - - - 
121 - - 48 55 - - - - - - 
122 - - 160 16 - - - - - - 
123 - - - - - 
30 25 6200 268 - 
124 - - - - - - - - - - 
125 - - - - - - - - - - 
126 - - 48 16 - - - - - - 
127 394 100 210 - 162 - - 4530 2050 - 
128 - - - - - - - - - - 
129 - - - - - - - - - - 
130 - - - - - - - - - - 
31 - - - - - - - - - - 
132 2080 554 268 - - 5467 2320 - 
133 - - 160 1013 - - - - - - 
134 - - 128 40 - - - - - - 
135 - - 5785 356 - - - - - - 
136 - - - - - - - - - - 
137 - - 2147 736 - - - - - - 
138 - - - - - - - - - - 
139 - - - - - - - - - - 
Analysis of Multiple Drugs In Small Blood Specimens and Meconium 
Page 192 
140 - - 2484 1092 - - - - - - 
141 - - - - - - - - - - 
142 704 25.9 351 204 - - - - - 56 
143 - - - - - - - - - - 
144 - - 160 79 - - - - - - 
145 - - 640 94 - - - - - - 
146 39 119 369 10 - - - - - - 
147 - - - - - - - - - - 
148 - - - - - - - - - - 
149 - - - - - - - - - - 
150 - - - - - - - - - - 
151 - - - - - - - - - - 
152 - - 41 40 - - - - - - 
153 - - 10 2 - - - - - 71 
154 - - - - - - - 1301 308 - 
155 - - 20 40 - - - - - - 
156 - - 10 20 - - - 1717 1717 - 
157 - - - - - - - - - - 
158 - - - - - - - - - - 
159 - - - - - - - 
1063 923 - 
160 400 167 3 - - - - - - - 
161 - - - - - - - - - - 
162 - - - - - - - - - - 
163 - - 383 140 - - - - - - 
164 - - - - - - - - - - 
165 - - - - - - - - - - 
166 - - - - - 
40 31 - 462 - 
167 - - - - - - - - 1423 - 
168 - - - - - - - - - - 
169 200 - 10 - - - - - - - 
170 - - - - - - - - - - 
171- -100 -39-10 43 - - - - - - - 
172 - - - - - - - - - - 
173 - - - - - - - - - - 
174 - - - - - - - - - - 
175 - - 40 21 - - - - - - 
176 - - 4 - - - - - - - 
177 - - - - - - - - - - 
178 - - - - - - - - - - 
179 - - 13 - - - - - - - 
180 - - - - - - - - - - 
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181 - - - - - - - - 
182 - - 5 - - - - - - - 
183 - - - - - - - - - - 
184 - - - - - - - - 303.8 - 
185 400 5450 - 6.2 - - - - - - 
186 - - - - - - - - - - 
187 - - - - - - - - - - 
188 - - - - - - - - 
189 - - 3 - - - - - - - 
190 - - - - - - - - - - 
191 - - 13 3 - - - - - - 
192 - - - - - - - - - - 
193 - - - - - - - - - - 
194 - - - - - - - - - - 
195 - - - - - - - - - - 
196 - 4087 - - - - - - - - 
197 131 1088 - 34 - - - - - - 
198 - - - 2.5 - - - - - - 
199 203 1163 - 20 - - - 1120 112.5 - 
200 1256 2775 14 15 - - - - - - 
201 - - 14 10 - - - - - - 
202 - - - 530 - - - 
2100 287.5 - 
203 - - - - - - 
04 - - - - - - - - - - 
205 - - 14 50 - - - - - - 
206 46.6 1050 - - - - - 400 1250 - 
207 - - - - - 
22 22 - - - 
208 - - - - - - - - - - 
209 - - - - - - - - - - 
210 - - 15 50 - - - - - - 
211 - - 165 - - - - - - - 
212 - - - - - - - - - - 
213 26 - - - - - - ' 
214 - - - - - - - - 
215 4 300 4 - - - - - - 
216 - - - - - - - - - - 
217 - - - - - - - - - - 
218 - - - - - - - - - - 
219 - - - - - - - - - - 
? 20 2250 113.75 - 
221 5 11 - - - - - - 
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222 - - - - - - - 
223 - - - - 
224 5 26.3 1.4 - - - - - 
225 - - - - - - 
226 - - - 1394 112.5 256 
227 - - - - 
228 - - - - - - - - - - 
229 - - - - - - - - - - 
230 - - - - - - - - - - 
231 - - - - - - - - - - 
232 - - - - - - - - - - 
233 - - - - - - - - - - 
234 - - - - - - - - - - 
235 - - - - - - - - - - 
236 - - - - - - - - - - 
237 63.1 15 - - - - - 4800 150 - 
238 - - - - - - - - - - 
239 - - 43 11 - - - - - - 
240 - - - - - - - - - - 
241 - - - - - - - - - - 
242 - - - - - - - - - - 
243 52 14 128.6 5 - - - - - - 
244 - - 28.6 - - - - - - 
245 - - - - - - - - - - 
246 - - 64.3 35 - - - 
125 - 
247 - - - - - - - - - - 
248 133 32.3 61.6 154 - - - - 
249 - - - - - - - - - - 
250 - - - - - 25 
15 - - - 
251 271 24.9 - - - - - - - - 
252 - - - 136.4 - - - - - - 
253 - - - - - - - - - - 
254 61 32 15 6.6 - - - - - - 
255 472 13.8 48.6 17.2 - - - - - - 
256 - - 33 - - - -- - - 
257 - - 17 106.1 - - - - - - 
258 - - - - - - - - - - 
59 - - - - - - - - - - 
260 - - - - - - - - - - 
261 103 11 - 101 - 
- 
- 
7 
- - - - 
262 - - 28.6 - 
1 
- 773! - - - - 
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263 - - - - - - - - - - 
264 - - 63 217.2 - - - - - - 
265 - - - - - - - - - - 
266 - - 28.6 - - - - - - - 
267 17 5 - - - - - - - 28 
268 - - - - - - - - - - 
269 - - 29 12.1 - - - - - - 
270 90 25 - - - - - - - - 
271 - - - - - - - - - - 
272 - - 28.6 35.4 - - - - - - 
273 - - - - - - - - - - 
274 - - 14.3 33 - - - - - - 
275 - 28.6 35.4 - - - - - - 
276 - - - - - - - - - - 
277 - - - - - - - - - - 
278 - - 71.4 25.3 - - - - - - 
279 - - - - - - - - - - 
280 - - 41 195 - - - - - - 
281 - - - - - - - - - - 
282 - - 460 - - - - 
18 - - 
283 350 - 2100 240 2400 - - 
2100 240 - 
284 - - 30 600 - - - - - - 
285 - - - - - - - - - - 
286 - - - - - - - - - - 
287 - - - - - - - - - - 
288 - - - - - - - 
1022 175 - 
289 - - - - - - - - - - 
291 495 14 - - - - - - - - 
292 - - - - - - - - - - 
293 - - - - - - - - - - 
294 - - - - - - - - 
590 - 
295 - - - - - - - - - - 
296 93 10 105 75 140 62 40 - - - 
297 5 46 - - - - - - 
298 - - - - - - - - - - 
299 - - - - - - - - - - 
300 - - 6 - - - - - - - 
301 - - - - - - - - - - 
302 51.2 267 72 - - - - - - - 
303 - - 8 
207 - - - - - - 
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304 - - -- - - - - - - 
305 - - - 94 
306 - - 11 - 
307 - - -- - - - - - - 
308 950 1900 16 
309 - - -- - - - - - - 
310 - - 5- 33 - - 188 300 - 
311 - - 16 - - - - - - _ 
312 - - -- - - - - - - 
313 450 - 450 - 
314 - - 79 - - - - - - - 
315 61 - 57 - 33 - - 241 350 - 
316 2 - -- - - - - - - 
317 60 - 31 - - - - - 160 - 
318 - - -- - - - - - - 
319 - - -- - - - - - - 
320 - - -- - - - - - - 
321 - - 19 - - - - - - - 
322 - - -- - 41 40 943 - - 
323 - - -- - - - - - - 
324 - - -- - - - - - - 
325 - - -- - - - - - - 
326 - - 21.2 48 - - - - - - 
327 - - -- - - - - - - 
328 - - -- - - - - - - 
329 - - -- - - - - - - 
330 - - -- - - - - - - 
31 - - -- - - - - - - 
332 - - -- - - - - - - 
333 - - 98 195 - 
334 811 - 6- 23 - - - - - 
335 - - 133 31.5 - 
336 - - -- - - - - - - 
337 - - -- - - - - - - 
338 - - -- - - - - - - 
339 - - 16 - - - - - - - 
340 - - -- - - - - - - 
341 - - 500 15 - 
342 1520 3380 98 - 305 - - 240 - 
343 - - -- - - - - - - 
344 --7- - 62 14 - - - - - - 
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345 521 133 - - 240 - - - - - 
346 - - 415 106 - - - - - - 
347 - - - - - - - - - - 
348 - - - - - - - 500 119 - 
349 - - - - - - - - - - 
350 - - - 10 - - - - - - 
351 129 825 - - - - - - - - 
352 - - 370 15 - - - - - - 
353 1110 - - - - - - - - - 
354 - - - 578 - - - - - - 
355 - - 680 28 - - - 265 262 - 
356 - - - - - - - - - - 
357 - - - - - - - - - - 
358 - - 94 - - - - - - - 
359 - - - 131 - - - 1265 - - 
360 - - - - - - - - - - 
361 - - - - - - - - - - 
62 - - - - - - - - - - 
363 - - 13 30 - - - - - - 
364 948 - 15 - - - - - 161 - 
365 240 - - - - - 70 - 171 - 
366 300 - - - - - - 70 476 - 
367 247 1530 11 - - - - - - - 
368 478 - 6 - - - - - - - 
369 472 - 138 - - - - - - - 
370 372 - 3 - - - - - - - 
371 633 - 40 - - - - - - - 
372 677 55 - - - - - - - - 
373 369 - 66 - - - - - - - 
374 197 - - - - - - - - - 
375 - - - - - - - - - - 
376 - - - - - - - - - - 
377 - - - - - - - - - - 
378 - - 538 - - - - - - - 
379 - - - - - - - - - - 
380 - - - - - - - - - - 
381 - - - - - - - - - - 
382 - - - - - - - - - - 
383 - - - - - - - - - - 
384 - - - - - - - - - - 
385 - - 538 190 - - - - - - 
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386 - - - - - - - - - - 
387 458 545 500 71 - - - - - - 
388 - - - - - - - - - - 
389 - - - - - - - - - - 
390 - - - - - - - - - - 
391 - - - - - - - - - - 
392 - - 500 119 - - - - - - 
393 - - - - - - - - - - 
394 - - - - - - - - - - 
395 417 545 - - - 55 40 - - - 
396 458 - - - - - - - - - 
397 - - - - - - - - - - 
398 458 1318 - - - - - - - - 
399 - - - - - - - - - - 
400 - - - - - - - - - - 
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Table 10.6 Percentages of cases in which EIA results are confirmed by GC/MS. 
Drug Number of Cases Percentage Confirmed 
(%) 
Morphine 155 80 
Codeine 116 60 
Diazepam 70 80 
Temazepam 48 59 
THC 41 68 
THCA 40 67 
Methadone 17 100 
Cocaine 9 70 
Benzoylecgonine 8 68 
186 
T/N = total number NA= not analysied Neg= negative 
Figure 10.5 Number of cases of amphetamines confirmed by GC/MS. 
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Table 10.7 Results of GC/MS for cases positive for amphetamines. 
case weight Concentrations of drugs ( ng/g meconium) 
AM MA MDA MDMA MDEA 
25 462 55.3 620 25.8 19.3 25.3 
28 494 1 - - - - 
29 275 - - - - - 
32 NS NS NS NS NS NS 
33 500 63.2 670 15.4 - 55.3 
34 505 - - - - - 
38 NS NS NS NS NS NS 
41 510 - 90 61.5 - - 
47 507 2.2 44 6.7 16.7 20 
49 251 - 6.8 1.5 - - 
53 NS NS NS NS NS NS 
57 417 2.86 - 8.7 - - 
60 502 - - 1 - - 
61 NS NS NS NS NS NS 
62 500 - - - - - 
65 494 - 60 1.5 0.8 34.2 
66 213 - 60 1.5 - 1.6 
69 491 - - - - - 
70 409 - 66 1 375 0.8 
71 497 - - 1.5 - - 
73 284 - - 1 - - 
74 293 - - - - - 
76 477 - - 1 370 0.5 
77 496 - - 1 - - 
80 78 - - 1 - - 
81 498 - - 1 2.5 1.1 
83 131 - 19 1 - - 
86 NS NS NS NS NS NS 
87 499 - 810 1 - 42.9 
89 503 3.3 170 2.1 - - 
90 547 - - 1 214 - 
91 NS NS NS NS NS NS 
92 532 - - 10.3 
366 44.7 
94 563 - - 28 
750 41.3 
95 NS - - - - - 
98 504 - - 1 583 39.5 
100 632 - - 1 5.2 - 
101 NS NS NS NS NS NS 
Analysis of Multiple Drugs In Small Blood Specimens and Meconium 
Page 204 
103 397 - 0.6 1 0.8 1.5 
104 472, - - - - - 
106 499 - - - - - 
107 NS NS NS NS NS NS 
113 542 - - 1 - - 
117 212 - - - - - 
118 NS NS NS NS NS NS 
123 NS NS NS NS NS NS 
125 419 - - 1.5 4000 - 
126 NS NS NS NS NS NS 
129 NS NS NS NS NS NS 
131 NS NS NS NS NS NS 
133 NS NS NS NS NS NS 
135 513 - 150 2.1 8.3 - 
136 496 - - - - - 
138 494 - - 2.1 - - 
141 497 - - - - - 
142 99 - - 200 - - 
146 NS NS NS NS NS NS 
149 189 - - 36 - - 
150 NS - - 30.8 - - 
152 NS NS NS NS NS NS 
153 433 - - - 
250 
154 NS NS NS NS NS NS 
157 NS NS NS NS NS NS 
158 503 - - - - ' 
161 NS NS NS NS NS NS 
162 NS NS NS NS NS NS 
163 314 - 2 1 18.2 8.2 
164 NS NS NS NS NS NS 
166 NS NS NS NS NS NS 
170 86 - - - ' 
171 507 - - - -- 
176 NS NS NS NS NS NS 
177 274 5.5 11 6.2 3.6 76.3 
179 503 - - - - 
180 507 - - - ' 
185 503 - - - - 
186 420 - - - 199 - 
187 122 7.1 14 10.8 390 0.3 
188 327 7.5 16 5.1 872.7 0.5 
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190 432 - - - -- 
191 NS NS NS NS NS NS 
192 NS NS NS NS NS NS 
194 502 - - - -- 
195 317 - - - -- 
196 NS NS NS NS NS NS 
197 NS NS NS NS NS NS 
199 NS NS NS NS NS NS 
200 NS NS NS NS NS NS 
201 185 NS NS NS NS NS 
205 501 7.3 15 - 981.8 - 
206 264 - - - - - 
207 501 - - - - - 
208 NS NS NS NS NS NS 
209 some - 3 - 5.5 0.1 
210 506 - - - - - 
213 376 4.6 - - - - 
214 NS NS NS NS NS NS 
215 276 - 30 1 
8.3 6.1 
216 505 - 2 1 
140 1.3 
218 255 - - - - 
223 464 - 
150 
224 NS NS 
I 
NS NS NS 
226 NS NS NS NS NS 
227 some NS S NS NS NS 
228 185 - - - - - 
231 501 - 2 1 
16.7 0.3 
232 
233 
500 
500 
- 
- 
1 
- 
1 
- 
250 
- 
- 
- 
234 505 - - 54.4 - - 
235 499 - 110 1.02 - 16.8 
239 433 - - - - - 
241 329 - ---- 
243 505 - ---- 
246 169 - --8.9 - 
247 189 - - 56.4 
5.5 - 
249 NS NS NS NS NS NS 
254 some NS NS NS 
NS NS 
255 NS NS NS NS NS NS 
257 NS NS NS NS NS NS 
260 358 72.9 - 21.5 - - 
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261 508 - - - - - 
262 NS NS NS NS NS NS 
263 508 - - - - - 
264 241 - - - - - 
265 498 - - - - - 
276 NS - - - - - 
269 504 - - - - 
270 NS NS NS NS NS NS 
276 NS NS NS NS NS NS 
278 NS NS NS NS NS NS 
279 NS NS NS NS NS NS 
280 527 - - - - - 
282 NS NS NS NS NS NS 
285 84 - - - - - 
289 318 - - - - - 
291 NS NS NS NS NS NS 
292 NS NS NS NS NS NS 
293 NS NS NS NS NS NS 
294 NS NS NS NS NS NS 
296 505 - - - - ' 
297 NS NS NS NS NS NS 
302 345 - - - - 
303 322 - - - - - 
305 504 - - - - - 
. 306 326 - - - - ' 
307 NS NS NS NS NS NS 
308 296 - - - - ' 
312 505 - - 82.1 
1.7 36.8 
313 NS NS NS NS NS NS 
314 155 - - - ' 
320 NS NS NS NS NS NS 
322 NS NS NS NS NS NS 
326 343 - - - 
327 532 - 44 0.8 
5 5 
328 521 - 300 1 - 
62.8 
331 505 - - 0.5 - 
52.6 
332 NS - - 1 - - 
333 NS NS NS NS NS NS 
334 NS - - - - - 
336 
337 
185 
125 
- 
- 
- 
91 
0.5 
0.5 
- 
- 
51.3 
52.6 
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338 122 - 12 0.5 - - 
339 155 - 54 0.5 - 50 
340 198 - 1 03 981 55.3 
342 502 - 5 1.5 134.5 0.8 
343 112 - 1 13.8 7.3 8.4 
344 502 - - 1.5 - - 
345 506 - - - 7.3 8.9 
346 522 - - - - - 
348 NS NS NS NS NS NS 
349 NS NS NS NS NS NS 
351 NS NS NS NS NS NS 
352 506 - 1 1 90.9 0.8 
353 379 - - - - - 
355 101 - - - - - 
356 507 - - - 
'359 507 - - - - - 
361 NS NS NS NS NS NS 
362 NS NS NS NS NS NS 
363 352 - - - - - 
375 504 - - - - - 
380 337 - - - - - 
381 503 - 34 1.5 3.6 - 
383 504 - - - - - 
385 501 - - - - - 
393 439 - - 1.5 - - 
NS No sample remain (-) =negative 
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Table 10.8 Retention times and selected ions of markers of illicit heroin. 
Drug Retention Time Ion Selected Quantitation ion 
Papaverine 14.62 339 339 
6-MAM 12.62 399,340,287 399 
6-Acetylcodeine 12.05 341,282 341 
Thebaine 11.68,11.78 383,353 383 
Dihydromorphine 13.23 268.369.268 369 
Acetylcodeine 10.95 341,281,228 281 
Dihydrocodeine 11.12 373,282,315 373 
6-MAM-d3 12.61 402,343,290 402 
Morphine 429,414 429 
Codeine 371,343 371 
Methadone 9.13 294,72,164 72 
Table 10.9 Results of analysis for markers of illicit heroin. 
Case 
No 
Papaverine 6-MAM 
(ng/g) 
6-AC Thebaine DHM AC DHC 
5 N N N P N N N 
104 N 85.3 P P N N N 
2 N N P P N P N 
22 P 0.6 N P N N N 
23 N 81.9 P P P N p 
283 N 73.4 P P N P N 
296 N 73.1 N P N N p 
310 P 1.1 N P N N p 
315 N 73.6 P P N N p 
. N=negative 
6-AC=6-Acetylcodeine 
DHC= Dihydrocodeine 
P=positive 
DHM=Dihydromorphin AC= Acetylcodeine 
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Table 10.10 Summary of results for markers of illicit heroin. 
positive Negative 
Number of cases 9 
6-MAM 7 2 
6-acetylcodeine 5 4 
Dihydromorphine 2 7 
Papaverine 2 7 
Thebaine 8 1 
Dihydrocodeine 4 5 
Table 10.11 Number of cases involving more than one drug. 
Number of 
cases 
Positive drugs 
2 5 
12 4 
3 2 
10.5.1. Conclusion: 
This survey is the first one to have been done in Glasgow using meconium, and 
shows the percentages of mothers who used drugs during pregnancy. In this study all 
the drugs of abuse in Uk were analyzied, compared with other studies were only one 
or a maximum of three drugs were analyized. Also, in this study high percentages of 
drugs abuse were identified compared to the previous studies. For example there 
were 39% and 10% positive cases for opiates and cannabinoids respectivelly. The 
least percentages was found to be associated with cocaine abuse, this is in contrast 
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with the previous American studies which showed that most of their cases were 
positive for cocaine. Also all the 3.5% which are positive for methadone were 
polydrug addict to more than one drugs or their metabolites. The concentration of 
drugs screened ranged from low to very high, which points out to the risks associated 
with drug use by pregnant mothers as high concentrations of drugs were measured in 
the meconium from their neonates. Most of these drugs cause severe morbidity with 
major complication and mortality, which may affect the neonate throughout its life. 
Precautions must be taken with respect to all drugs given to the mother in hospitals, 
as it is clear that these can reach the foetus, and should be avoided except in critical 
cases. 
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11. Hydrolysis of Cannabinoids in Meconium. 
11.1. Introduction 
The survey reported in the previous chapter produced several cases which were 
positive by immunoassay and negative by GC/MS. One explanation of these 
differences is that the cannabinoids in meconium are significantly conjugated with 
glucuronic acid and an additional hydrolysis step is needed in the method before 
extraction and GC/MS analysis. The aim of this final study was to determine the 
effect on the incidence of confirmed cannabinoid positives by including a hydrolysis 
step in the method. The background to cannabis use and abuse will first be reviewed. 
11.1.1. History of Cannabis Use and Abuse 
The hemp plant and its products have been a valuable source for man's 
commercial, medical, religious and recreational use for thousands of years. Different 
parts can be used for different purposes. Its fibre can be made into rope, twine and 
bags, and the biologically active constituents can be used as relaxants and mild 
intoxicants. Its oil is used in painting and varnishing. 
The cannabis plant is called Cannabis Sativa L. or Indian hemp. It is a tall annual 
bushy plant present especially in high temperate and tropical zones of the world and 
is probably the oldest non-food plant ever cultivated. It contains over 400 chemical 
compounds amongst which more than 60 cannabinoids have been identified. The 
most important products are marihuana, consisting of the dried leaves and stems, and 
hashish, consisting of the dried buds. 
Cannabis plant is diaecious i. e. it has male and female plants, in which the female 
yields more but less potent resin than the male. 
283 Generally, the content of active 
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constituents decreases in the following order: bracts, flowering tops, leafy tops, small 
leaf, large leaf, and stem. No cannabinoids are found in the roots or seeds. The 
concentration of cannabinoids in the plant is a function of genetic and environmental 
factors (type of soil, water, temperature, growing space). Other factors include the 
time of collection (maturity of the plant) and the treatment of the sample taken 
(drying, storage, extraction and analysis). Marihuana, bhang, ganja, kif and macoha 
are the commonly used names for cannabis or its products in various countries. 
Differences in names refer to differences in the mixture of the leaves and flowering 
tops of the plant. For example, marihuana consists of the dried and crumbled stems, 
leaves and seed pods of the female plant. Bhang consists of specially dried leaves 
and flowering shoots of both male and female plants, wild or cultivated, while ganja 
refers to a specially cultivated hemp plant that contains an unusually large quantity of 
active materials. 
Meanwhile, hashish or charas are names often applied to the pure unadulterated 
resin from the top of the finest female plants of Indian hemp, which also contains a 
very high concentration of active constituents. Less common and strongest of all, is 
cannabis oil or hash oil, a liquid prepared from the resin. 
Under the Misuse of Drugs Act (1971), the terminology for materials derived 
from Cannabis Saliva L. are specifically defined. Under British law, only the name 
"cannabis" is used and there is no reference to "marijuana" or "marihuana". 
The first use for cannabinoids was in medicine as antiseptic and analgesic in 
China and India. Then its use spread throughout the Middle East, Africa and Eastern 
Europe, in treatment of pain, asthma, dysentery, the promotion of sleep, suppression 
of nausea, vomiting and the abolition of convulsion and spasm. 
284 Western medical 
practitioners accepted its spread several years after the return of Napoleon's army 
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from Egypt. In the late 19`s Century it began to lose its superiority in medicine. 
British doctors continued to have the right to prescribe cannabis (as a tincture for oral 
administration) until 1971. 
In the beginning of 20`h century, it became one of the serious social problems 
throughout the world. It became an illegal drug in many countries. In the United 
Kingdom under the Misuse of Drugs Act 1971, cannabis was deemed to have no 
valid medical use and was classified under Schedule 1. In the United States, some 
drug companies synthesised new analogues of tetrahydrocannabinol (THC) with the 
aim of developing some clinically useful preparations. Delta-9-THC has been 
prepared and used as an antiemetic during cancer chemotherapy which has proved 
unresponsive to other drugs, and this is the best known and accepted therapeutic use 
of cannabinoids. 285 The use of cannabinoids in cancer chemotherapy as an anti 
emetic represents, in essence, the use of a drug with a relatively undefined 
mechanism of action to treat the side effects of other drugs, also with relatively 
undefined mechanisms of action, which are being used to treat cancer, a disease or 
series of diseases the precise nature of which remains enigmatic. 
11.1.2. Routes of Administration: 
Marihuana and hashish are usually smoked but are sometimes eaten in cookies 
and (rarely) used in drinks. The effects depend heavily on the situation (group 
effects), the personality of the user, the route of administration and of course, the 
dose. Smoking involves parts of the plant which are dried, chopped and rolled up 
into a cigarette and smoked, often combined with tobacco. Cannabis can be smoked 
in a pipe, brewed into a drink or cooked in foods. Cannabinoids are rapidly absorbed 
on inhalation from smoked cannabis preparation, with a bioavailability of 20-45%. 
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Its effect is obtained within seconds and become fully apparent in a matter of 
minutes. Its absorption is very slow when taken orally and concentrations reached are 
25-30% of those obtained by smoking the same dose due to the fact that some of it is 
degraded by metabolism in the liver before reaching the circulation (first pass 
metabolism). The onset of effects of 11-hydroxy-delta-9-THC is delayed by a period 
ranging from 0.5-2 hours, and its duration is prolonged due to continual slow 
absorption from the gut. 
Conversion of THC precursor acids to active THC during marihuana smoking 
may increase the potency of a cigarette, and a similar process may occur during the 
baking of brownies and other forms of cooking with marihuana plant material. 286 
The prolonged heating may also destroy THC. One study on smoking cigarettes 
found that 50% of the THC is absorbed by the lungs if the smoking is done in 10 
minutes and each inhalation was retained for 30 seconds with no side-stream loss287. 
THC is insoluble in water, but highly soluble in lipids. It is rapidly distributed 
throughout the body, reaching first the tissues with a high blood supply (brain, lungs, 
liver, adrenals, kidney, ovaries, and testes). High concentrations reach the brain 
within 15 minutes, which coincides with the onset of maximum psychological and 
physiological effects. A plateau is reached after 2-4 hours. 
When taken orally the maximal effect is reached after 1 hour and lasts 5-6 hours 
because of continued absorption from the gut, but its effects may persist more. 288. 
Lemberger et al. 289, by administration of radiolabelled THC, Cone et a1.290 and Law 
et al. 291 showed the pharmacokinetic differences between smoking and oral 
administration. 
Cannabinoids also cross the placenta enter the circulation, and penetrate into 
breast milk. 
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Generally, the effects produced by ingested THC or ingested marihuana extract 
are comparable to those produced by nearly one third the amount of smoked and 
inhaled THC or marihuana. 292 Perez-Reyes et al. 293 found that it is the rate of THC 
absorption, and the duration of its action which are affected by chosen routes of 
administration. 
11.1.3. Chemistry: 
H3C. 
H3C 
A°-Tetrahydrocannabinol 
(A'-THC) 
A`-Tetrahydrocannabinol 
(t°-THC) 
Figure 11.1 Chemical structures of THC isomers 
The chemical formula is C21H2602. The molecular weight is 310.42 and carbon 
content is 81.25%174. THC is unstable, degraded by heat, light, acids and atmospheric 
oxygen, properties that account for the well known tendency of cannabis preparations 
to lose potency on storage292. 
11.1.4. Metabolism 
Cannabinoids are highly lipid soluble and accumulate in fatty tissues, being 
slowly released back into other tissue and organs, so 
it is slowly eliminated from the 
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body. In chronic use it accumulates in body and continues to reach the brain over a 
longer period. 
THC, the primary psychoactive component of marijuana is rapidly and 
extensively metabolised by humans. The major metabolic pathway involves the 
initial reaction of allylic hydroxylation in the lungs or in the liver, by different 
enzymes, at the C-11 or C-8 position in humans to give the major metabolite 11- 
hydroxy-O9- THC, which is more potent than A9- THC itself. Major lung metabolites 
are usually hydroxylated derivatives of the cyclohexane ring system. 294 This also is 
slowly excreted over days or weeks, in the urine and faeces. There are large 
interindividual differences in rates of metabolism, which is slow in old persons and 
in liver disease. 295 
The hydroxylation forming 11-hydroxy-09-THC is followed by further oxidation 
to 11-nor-9-carboxy-09-tetrahydocannabinol (THC-COOH), the major metabolite 
found in blood and urine. Conjugation of glucuronic acid with THC and its 
hydroxylated and carboxylated metabolites may occur, generating water-soluble 
compounds to facilitate urinary excretion. Glucronic acid conjugates of THCCOOH 
and THC were identified in human urine. In addition, it was shown that a 
dihydroxylated metabolite is excreted as a glucronoide conjugate in human urine 
following the inhalation of marijuana smoke. These metabolites are present in trace 
amounts in urine, so are ignored in forensic analytical literature. 
Agurell et al. 296 developed a method to identify and measure accurately 
nonlabelled delta-9-THC in the plasma of cannabis smokers. The results showed that 
within 10 minutes of smoking a cigarette containing 10mg of delta-9-THC, peak 
plasma levels of 19-26ng/ml were reached and later declined rapidly to < 5ng/ml 
within 2 hours. The method was based on the chemistry of the phenolic group 
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common to all cannabinoids, cannabinoid-like drugs and their metabolites. 
Rosenfed et a1297 developed and applied a mass fragmentographic assay for delta-9- 
THC in plasma of human volunteers. Results obtained were similar to those reported 
by Agurell et a1296 
Metabolism of THC involves two phases in plasma: an initial rapid phase 
representing metabolism by the liver and redistribution from the blood to the tissues. 
The second, slow, phase represents release from the tissues with subsequent 
metabolism. THC is essentially insoluble in water and is protein bound. Its terminal 
plasma half life is 28-56 hours and has been seen to be significantly shorter in daily 
users than in nonusers. Urinary excretion and biliary excretion (reflected a day later 
in the faeces) were found to be greatest during the initial 24 hours, then gradually 
tapering off. Law et al. 291 pointed out that following a single, moderate, oral dose of 
cannabis metabolites were detected in plasma samples for up 5 days and in urine 
samples for at least 12 days. 
11.1.5. Pharmacodynamics: 
There are natural specific receptors in human brain and spleen and natural 
(endogenous) substances have been identified which bind to the receptors to exert 
their effects. 298 Pharmacological actions of cannabis are highly subjective and are 
affected by a number of factors such as the quality of the drug, the dosage, the 
experience and expectations of the user and his environment. Its actions in man affect 
almost all systems. 299 
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Table 11.1 Effects of Cannabinoids. 
Central nervous system 
Psychological effects Euphoria (high), dysphoria, anxiety, depersonalisation, 
precipitation/aggravation of psychotic states. 
Effects on perception Heightened sensory perception, distortion of space and 
time sense, misperceptions, hallucinations. 
Sedative effects Generalised CNS depression, drowsiness, sleep, additive 
effects with other CNS depressants. 
Effects on cognition and Fragmentation of thoughts, mental clouding, memory 
psychomotor impairment of performance especially in complex and 
performance demanding tasks. 
Effect on motor function Increased motor activity followed by inertia and 
incoordination, ataxia, dysathria, tremulousness, 
weakness, muscle twitching 
Analgesic effects Similar in potency to codeine but by a nonopioid 
mechanism 
Antiemetic effects, In acute doses, effect reversed with larger doses or 
increased appetite chronic use 
Tolerance To most behavioural and somatic effects, including the 
high with chronic use 
Dependence, abstinence Rarely observed but has been produced experimentally 
syndrome following prolonged intoxication: symptoms include 
disturbed sleep, decreased appetite, restlessness, 
I irritability an sweating. 
Cardiovascular system 
Heart rate Tachycardia with acute dosage, bradycardia with chronic 
use 
Peripheral circulation Vasodilatation, conjunctival redness, postural 
hypertension 
Cardiac output Increased output and myocardial ox en demand. 
Cerebral blood flow Increased acutely, decreased with chronic use. 
Respiratory system 
Ventilation Small doses stimulate, large doses depress. 
Bronchodilatation Coughing, but tolerance develops. 
Airway obstruction Chronic smoking 
Eye Decreased intraocular pressure 
Reproductive system 
Males Antiandrogenic decreased sperm count and sperm 
motility (chronic use) 
Females Suppression of ovulation, complex effects on prolactin 
secretion, increased obstetric risks (chronic use) 
Immune system Impaired bactericidal activity of macrophages in lung 
and spleen (chronic use). 
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The psychomimetic activity due to inhalation or ingestion of low doses (25pg/kg) 
of delta-9-THC may cause euphoria, relaxation, talkativeness, bouts of hilarity and 
sensory enhancement. Large doses (250µg/kg) will give an intense hallucinogenic 
experience, perceptual distortion, temporal disintegration, and confusion and can be 
distressful. 
Death is rare with overdose of oral cannabis. The minimum fatal dose by oral 
ingestion of charas, ganja and bhang was 2,8 and 10 g/kg of body weight 
respectively. 300 The lethal dose of delta-9-THC, administered intravenously is 
30mg/kg of body weight301. 
Agurell et a1.302 pointed out the pharmacokinetics of delta-8-THC in man after 
smoking and the relationship of blood levels to physiological and psychological 
effects. It was shown that the increase in heart rate was well correlated with the 
delta-8-THC plasma levels but the alterations in mental performance were more 
delayed and prolonged than the peak plasma level. 
Hollister et al. 303 used 11 volunteers to address the question of whether THC 
levels reflected the state of cannabis intoxication. The volunteers were given about 
19mg THC by smoking, 20mg THC orally and 5mg THC intravenously. The THC 
plasma levels were measured by GC/MS up to 4 hours after administration. They 
concluded that the relationship between pulse rate and plasma concentration of THC 
was similar to that reported by Agurell et al. 302, but they saw no clear-cut relationship 
between plasma concentrations of THC and the degree of intoxication, in contrast to 
the case for ethyl alcohol. 
Cannabis is not physically addictive. Thus abstinence or abrupt cessation of intake 
will not produce distinct withdrawal symptoms. The relationship between different 
doses and effects of cannabis can be briefly summarised. In relation to impairment 
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of motor and mental performance, the dose and effect relationship was studied in the 
following scenario. Marihuana was administered by smoking (1.7g, 1.3% THC) to 
36 subjects, producing significantly more speed errors in a driving simulator. 304 In 
another study, 305 smoking 3.3-6.6 grams cannabis by ten experienced and ten naive 
subjects, produced equal impairment in driving performance. Delta-9-THC taken 
orally in doses of 350,400 and 450 µg/kg by 54 subjects, produced impairment of 
attention and concentration capacities, prolongation of reaction time, increased 
frequency of wrong and inadequate responses and smooth automation 
disturbances. 306 Smoking of only 18mg delta-9-THC by 58 subjects produced general 
impairment in roadside sobriety tests. 307 Ssmoking 6.3mg THC by 3 professional 
and 3 private pilots led to a deterioration in flying performance, 308 while smoking of 
a low dose of 0.09mg/kg of THC by 10 certified pilots caused significant 
deterioration in instrument flying ability in a flight simulator. 309 Smoking of 19mg 
THC by 10 private pilots resulted in performance decrements in a flight simulator. 
310 
11.1.6. Users 
Lindgren et al3 11 determined the plasma concentrations of THC given by smoking 
and IV administration in groups of light and heavy users of marihuana. Passive 
inhalation of cannabis smoke can result in absorption of THC without active use of 
cannabis, and this depends on the amount of cannabis smoked by active user, the 
duration and frequency of exposure, the room size and ventilation conditions and the 
individual metabolic factors of the passive inhaler. A study done by Morland et al. 312 
showed that the highest concentration of plasma THC reached by passive inhalation 
was 13ng/ml which corresponds to the concentration measured in plasma 
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approximately 30 minute after smoking of 15mg of THC. To avoid unfair 
penalisation of passive smokers a cut-off level is generally set up. 
11.1.7. Stability of cannabinoids in body fluids: 
A number of studies have been published on the stability of THC in body fluids 
during storage. Wong et al. 313 evaluated the effects of long term storage on the 
concentrations of THC in blood and serum stored between -20 and 5°C. They found 
that THC concentrations in blood and serum samples had decreased markedly after 
17 and 19 weeks respectively. In contrast, THC did not change in meconium after 
more than 3 months in the deep freeze at -20°C. 
Another study was done by Johnson et a1314about the stability of THC , 11- 
hydroxy-THC and THC-COOH in blood and plasma stored at -10 °C, 4°C and room 
temperature, with the result that it could be stored for up to 17 weeks without loss of 
analytes. However, the concentration was lower after 26 weeks at room temperature 
for THC and I 1-hydroxy- THC, but the concentration of THCCOOH did not change. 
Levine et al. 315 studied the stability of THC in dry form, chloroform, hexane, and 
carbon tetrachloride and found that it deteriorated about 10% each month, while is 
remain stable at ethanol solution at room temperature more than 75 days, and this 
period could be increased up to one year at 0-5°C. 
THC is a lipophilic molecule and tends to bind readily to hydrophilic surfaces. Its 
concentration will be greatly reduced if stored in certain types of containers. This is 
supported by results obtained from Garrett and Hunt316 who reported absorption of 
THC to rubber stopers, but in unsilanized glass, its absorption was apparently 
prevented by proteins in blood that bind over 97% of THC. However, in the study 
cited above, Johnson et al. 317 found no absorption to rubber stoppers. 
Analysis Of Multiple Drugs In Small Blood Specimens and Meconium 
Page 222 
11.1.8. Methods of analysis of cannabinoids in biological specimens. 
In recent years, the prevalence of marijuana use and the passage of legislation 
regulating its use have mandated the development of analytical procedures for 
detection of THC and its metabolic products in biological matrices. The most 
common biological samples used were urine, with testing procedures based on 
immunoassay or thin layer chromatography, and blood. These procedures, however, 
are limited for forensic science use, as they are not specific for the analytes due to 
false results caused by cross reactivity which occurs with other cannabinoid 
metabolites which cannot be measured318. In contrast, the presence of A9- 
tetrahydrocannabinol and its metabolites in blood can often be related to recent use 
of cannabis, and may be indicative of drug effects319 
The most sensitive and specific technique for the analysis of cannabinoids, gas 
chromatography- mass spectrometry, provides the necessary technology to detect the 
very low concentrations of A9-tetrahydrocannabinol and its metabolites often present 
in biological matrices. A number of these procedures including various extraction 
and derivatisation methods were recently reviewed32o 
The urinary concentrations of THC hydroxylated metabolites may however be 
important to the forensic and clinical community for the determination of accurate 
temporal relationships between marijuana smoking and the effects of the drug. 
Because cannabinoids and their metabolites are excreted as glucronic acid 
conjugates, hydrolysis of the bound compound is required to determine their 
concentration by GC/MS. Cleavage of the glucuronide bond can be accomplished 
chemically using alkaline conditions or enzymatically, using ß-glucuronidase. Base 
is the preferred method in most laboratories because of time and cost constraints. 
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Hydroxylated metabolites, however, form ether bonds with the glucuronic acid. The 
ether bonds are not susceptible to cleavage under alkaline conditions. Source species 
from which glucuronidase is obtained include mollusk, bacteria, cattle and limpets321 
Many methods have been used for the determination of cannabinoids including 
thin layer chromatography322'323 radioimmunassay324,325 EMIT326,327 and FPIA. 328,329 
HPLC330,331 and gas chromatography 332'333 which can used to confirm the 
identification of cannabinoids. Only GC/MS provides the sensitivity, selectivity and 
specificity necessary for confirmation of positive results generated by screening 
methods and for quantitative data needed in clinical studies on metabolic profiling 
and for evaluation of human performance 314. Many studies have shown that cannabis 
metabolites can be screened more effectively by hydrolysing the sample. McBurney 
et a1334 used bacterial ß-glucuronidase (Escherichia coli) for hydrolysis. The linearity 
ranged from (0-100ng/ml) in plasma and urine. Limits of detection ranged from 0.5- 
1.5ng/ml in urine and from 0.6-2.1ng/ml in plasma depending on the analyte. 
Several methods have been used to analyse cannabinoids in meconium and most 
commonly these have included a hydrolysis step. ß-glucuronidase enzyme was used 
by El Solhy et al. 335 and alkali by Moore et al. 
336 When using hydrolysis by enzyme, 
El Solhy328 mentioned that the recovery is very low and also there are many peaks 
which interfere with the peaks of THC and THCA. 
In this chapter is reported the effects of hydrolysis of cannabinoids on the cases 
which gave negative results by GC/MS but positive results 
by EIA, and also a 
comparison was made between two methods of hydrolysis applied by previous 
workers. 
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11.2. Experimental Section 
11.2.1. Materials and Methods: 
All chemicals including ß-glucuronidase were bought from SIGMA (Dorest, UK). 
Solvents and concentrated HCl were of HPLC grade supplied by BDH Laboratory 
Supplies. 
Phosphate buffer (0.1 M, pH 6.8) was prepared by dissolving 6.81 g of potassium 
dihydrogen phosphate in 450m1 of de-ionised water, adjusting the pH to 6.8 ±0.1 
with 1.0M potassium hydroxide, then making the total volume up to 500m1 with de- 
ionised water. 
E-Coli enzyme for hydrolysis (in vials of 500.000 units from Sigma) was 
dissolved in 20m1 water to give a concentration of 25,000 units/ml. A volume of 0.2 
ml was used for each sample. The THC glucuronide and THC glucuronide-d3 were 
from Alltech-Applied Science Labs (Carolean Industrial Drive, State College, PA ). 
Saturated potassium phosphate (monobasic) was prepared by dissolving 
potassium phosphate in 500 ml de-ionized water and shaking well until no more salt 
dissolved. 
Hydrochloric acid (1.0 M) was prepared by diluting 83.3ml concentrated HC1 to 
1L with de-ionised water. Hydrochloric acid 100mM was prepared by adding 4.2 ml 
concentrated HCl to 400 ml deionised water. This was diluted to 500m1 with de- 
ionised water and stored at 25°C in glass or plastic tubes. To prepare 7M 
hydrochloric acid, 294 ml concentrated HCl was diluted to 500ml with deionised 
water. 
0.2N NaOH: 2 gm of Na OH was dissolved in 250cm3 water or methanol, and to 
prepare IN Na OR 40 gm of Na OH was dissolved in 1 Litter H2O. 
Analysis of Multiple Drugs In Small Blood Specimens and Meconium 
Page 225 
Potassium hydroxide (11.8M) was prepared by dissolving 600 gm potassium 
hydroxide in 500-m1 deionised water. 
11.2.2. Instrumentation 
The instrumentation used was as described in the previous chapter. 
11.2.3. Methods 
(a) Sample collection: 
Meconium samples for analysis were collected anonymously from all infants born 
at Glasgow Royal Maternity Hospital, from the period of October 2000- until 
February 2001 and its count 450 cases( these were the same samples mentioned in 
paragraph 10.2.3). Control samples were collected from neonates delivered at 
hospitals in Egypt who were unlikely to have been exposed to drugs in utero. The 
meconium was collected from diapers of the newborn infants using a plastic spoon 
and stored in a plastic vial at -4°C until analyzed. 
(b) Sample preparation: 
Each meconium specimen was weighed (usual range from 0.5 g-0.8 g for the 
controls while the real cases according to weight which arrived) then put into a clean 
vial and centrifuged to bring the sample to the bottom. The specimens were mixed 
with 20 µl of IS of THC-d3 glucuronide, THC-d3, and THCOOH-d3 to givelOng/g, 
mixed well for 5 minutes and vortexed for 15 min 
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(c) Hydrolysis qf cannabinoids: 
1.1.1.1.1 1. F_nymaiie Hydmly is: 
0 4-ml methanol was added, mixed well, and the suspension was centrifuged at 
3000rpm/20 min. 
0 The supernatant was taken, and evaporated under nitrogen at 50°C, until 
completely dry. 
01 ml saturated potassium phosphate monobasic solution was added and 10 ml 
chloroform, then shaken for 20 min. 
0 The dark top aqueous layer was removed, and then the chloroform was evaporated 
under nitrogen at 50°C. 
0 The residue was dissolved in 1 ml of 0.1M phosphate buffer (pH 6.8) and 0.2 ml 
of ß-glucuronidase previously prepared was added. 
0 The samples were put in an oven at 37°C overnight (16h). 
0 The mixture was acidified with 0.5m1 of IN HCI, and 10 ml of hexane/ethyl 
acetate (9-1) was added, and shaken for 5 min. 
0 The top organic layer was transferred to another tube, and 1.5m1 of 1M NaOH 
was added. 
0 The top organic layer containing neutral analytes was transferred into another tube 
for determination of THC and I I-OH-THC. 
0 The bottom layer containing acidic analytes (THCCOOH and 80,11-di-HO-THC) 
was filtered through a cotton plug to remove the semi-solid material. 
1.1.1.1.2 2. Fraction containing neutral analyzes. 
04 ml of 0.2N NaOH in methanol solution was added to the organic extract 
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containing the neutral analytes, and shaken for 2 min. 
0 The top hexane layer was carefully removed and discarded. 
01 ml of IM HC1 and 3 ml deionised water was added to the bottom methanol 
layer, and shaken for 1 min. 
0 The top layer was separated and transferred to another tube. 
0 3ml of hexane/ethyl acetate (9-1) was added to the bottom layer, shaken/lmin. 
0 The solvent was evaporated under nitrogen, 50µ1 of BSTFA was added and the 
tube heated at 70°C/20min. 
0 The derivatised extract was injected into the GUMS instrument: the column temp 
was initially set at 220°C/O. Smin, then raised to 275°C at 30°C/min, held for 
5.0min. and finally raised to NOT at 30°C/min, and held for 8.0min. 
0 The target analytes were O9-THC and 11-OH-09-THC 
1.1.1.1.3 3. Fraction containing acidic analyte . 
02 ml IN HCI was added to the aqueous phase. 
0 4m1 hexane/ethyl acetate (9-1) was added, shaken /2 minute. 
0 The top organic layer was transferred to a clean tube. 
0 The solvent was evaporated at 50°C under N2. 
0 The residue was derivatised with 80pl of BSTFA at 70°C/30minute. 
0 Analysis was by GC/MS: the column temp was initially set at 200°C, held for 
0.5min. then increased to 280°C at 30°C/min. and held for 12 min. 
0 The target analytes were II -nor-i9-THC-9-COOH. 
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(d) Hydrolysis by Alkali: 
0 The meconium was weighed and spiked with THC-d3 and THCOOH-d3. 
0 4-ml methanol was added, mixed well, and the supernatant centrifuged at 
3000rpm/ 15min. 
0 0.5m1 potassium hydroxide 11.8M was added; left to stand 15 minute. 
0 It was centrifuged 5 min, and the supernatant was transferred to a clean tube. 
0 3m1 de-ionized water was added, then 6m1 of hexane/ethyl acetate (9-1). 
0 Allowed to stand for 15 min. and the organic layer was discarded. 
01 ml of HCI 7N was added, followed by 8ml hexane-ethyl acetate (9-1). 
0 Mixed well, and centrifuged; the supernatant was then evaporated to dryness. 
0 The residue was reconstituted in 100µl ethanol, transferred to autosampler vials, 
re-evaporated to dryness. 
0 The sample was derivitized with 50µl of BSTFA. 
0 Analysis by GC/MS: the oven temp started at 100°C held/1 min., then programmed 
to a final temperature of 3 10°C at 30°C/min., then held for 6.6min. 
11.2.4. Application to cases 
The two hydrolysis methods were applied when possible (depending on whether 
enough of the same sample remained) to cases which gave positive results by EIA 
and negative results by GC/MS when hydrolysis was not done. 
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11.3. Results and Discusion: 
The developed method was found to be satisfactory. The retention times of the target 
analytes were determined by analysing standards and are given in Table 11.1 and 
Figure 11.2. 
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Table 11.2 Retention times and selected ions for each analyte. 
Drug Retention time 
(min) 
Selected ions 
THC 7.65 371,386,389 
THCOOH 8.17 371,488,491 
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Figure 11.2 Chromatogram of THC and THCA Standards. 
For each analyte the calibration curves were linear. The THC and THCOOH 
calibration curves gave correlation coefficients (r2) of 0.890 and 0.891 respectively 
for enzymatic hydrolysis and 0.851 and 0.951 respectively for alkaline hydrolysis. 
The recovery and lower limits of detection of each method were calculated (Table 
11.2) and a comparison made of the sensitivity and specificity of the two methods of 
hydrolysis and the previous method without hydrolysis. 
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Table 11.3 Comparison of methods used for analysis of cannabinoids in meconium 
Method Recovery (%) LLD 
Not hydrolysed 100 100 ng/gm 
Enzymatic hydrolysis 45 35ng/gm 
Alkaline hydrolysis 75 ing/gm 
From these results it was found that the more sensitive method involved alkaline 
hydrolysis in which THC and THCOOH were detected at very low concentrations, 
followed by hydrolysis by enzyme. The lowest sensitivity was obtained when the 
samples were not hydrolysed. 
11.4. Application to cases: 
The method was applied to 21 authentic cases collected in the Royal Maternity 
Hospital, Glasgow from neonates as described earlier. These were cases which were 
previously analysed but without hydrolysis in the survey and gave positive results by 
EIA for cannabinoids. The samples weighed 546mg (±50mg), except in some cases 
in which the remainder was less than that. So in these cases the small sample weight 
allowed hydrolysis by one method only, which by preference was alkaline 
hydrolysis. 
The results of these analyses are summarised in Table 11.3. 
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Table 11.4 Results of analysis for cannabinoids in meconium, with and without 
hydrolysis. 
Case No EIA 
(ng/g) 
No Hydrolysis Alkaline Hydrolysis Enzymatic 
Hydrolysis 
THC THCA THC THCA THC THCA 
Case 1 4.1 N N + + N N 
Case 27 14.190 N N N + X X 
Case 47 17.727 125 120 + + + 
Case 54 ++++ 525 N + 
(321) 
+ 
(185) 
+ 
(122) 
++ 
(89) 
Case 59 ++++ 50 N N + N N 
Case 65 N N N N N N N 
Case 71 7.766 N N N + N N 
Case 104 50.000 500 375 + 
(321) 
+ 
(210) 
N N 
Case 156 19.080 1717 1717 + 
(687) 
+ 
(174) 
x x 
Case 184 20.192 N 303.8 N +++ 
(237) 
N N 
Case 202 2.623 2100 287 + 
(824) 
+ 
97 
+ 
(531) 
+ 
(58) 
Case 282 ++++ 18 N + 
(12) 
+ 
(16) 
N + 
(12) 
Case 342 ++++ 240 N + + N + 
Case 355 ++++ 265 262 + + X X 
Case 359 28.929 1265 N + 
(564) 
+ 
123 
+ 
(98) 
+ 
(55) 
Case 364 23.12 N 161 + + x x 
Case 365 33.54 N 171 + + + + 
Case 366 34.98 70 476 + + + N 
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Case 367 67.22 N N + +X X 
Case 385 3.183 N N N +N N 
Case 392 41.071 N N + ++ + 
+= Positive N=negative X=not analysed ++++ =out of scale in EIA 
A summary of the results of analysis of the 21 cases is given in Table 11.4. 
Table 11.5 Summary of the results of hydrolysis of cases 
Number Types of analysis % 
21 Positive by EIA 100 
14 Positive by EIA and negative by 
GC/MS when no hydrolysis was used. 
67 
20 Positive by alkaline hydrolysis 100 
6 Not analysed by enzymatic hydrolysis 29 
9 (out of 15) Positive by Enzymatic hydrolysis 60 
11.5. Conclusions 
This study showed that the alkaline hydrolysis of cannabinoid conjugates in 
meconium gives good results and the inclusion of this extra step gives a more 
sensitive method which can discover some cases which previously gave negative 
results. At least it can be concluded that hydrolysis of meconium for detection of 
cannabinoids is recommended. 
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12 Conclusions and Further Work 
12.1 Conclusions 
The work described in this thesis has achieved the goal of screening 
multiple drugs in neonates and has overcome the problems resulting from the small 
sample sizes available from the neonate regardless of the type of biological sample 
used. Two non-conventional biological samples were examined: blood and 
meconium. The methods which were produced were subsequently and successfully 
used to survey the incidence of illicit drug use in pregnancy in the Glasgow area. 
Firstly, as is known, there are routine analyses that are performed for all 
newborn infants in hospital. Usually this requires blood analysis, but only 1 ml of 
blood can be collected and the initial study was designed to find a method to analyse 
multiple drugs using this small amount of blood. The selected approach here was to 
use the small sample available and to extract all of the target analytes from it, rather 
than subdividing the sample and using the aliquots for sub-groups of the target 
analytes. By using a single SPE column, it was possible to do this and extract a 
mixture of acidic and basic drugs in an efficient way. The evaluation and validation 
of this process were carried out using examples of the most common drugs in the 
Glasgow area, which are also those which are most likely to be used by mothers 
during pregnancy. 
A simple and rapid solid phase extraction scheme was developed which could be 
employed for a high throughput of cases. The qualitative and quantitative analyses 
were carried out using gas chromatography with flame ionisation detection - an 
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instrument easily found in forensic laboratories around the world. Comparison was 
made between two SPE columns, both of which are used in the analysis of acidic and 
basic drugs. The method gave good recoveries f the target drugs and the method 
validation parameters were acceptable. The method was then applied to 13 samples 
of blood from cases arising under the Road Traffic Act Section 4, as examples of a 
situation in which only small samples are available. These were analysed using an 
enzyme immunoassay technique and the positive samples were confirmed by gas 
chromatography- mass spectrometry. It was concluded that the method was suitable 
for the intended purpose, and the approach was then developed to permit it to be 
applied to an alternative specimen, meconium. 
The second part of the study was based on using meconium, with a view to 
carrying out a survey of drug use during pregnancy. Meconium has many 
advantages, as drugs accumulate in it from the 16th week of pregnancy till delivery, 
so giving a wide window of detection with high concentrations of drugs. It is 
increasingly considered to be the most suitable biological specimen for the detection 
of drugs in the neonate. Suitable sample pretreatment was investigated to allow the 
solid phase extraction procedure to be used. The extracts could then be analysed by 
enzyme immunoassay and confirmed by gas chromatography- mass spectrometry to 
detect opiates, cannabinoids and cocaine plus its metabolites. The method was 
specific and sensitive with recoveries ranging from 60% to 100% for some drugs. 
All the target drugs could be analysed except the amphetamine group which was 
analysed separately using another SPE column. This method was also sensitive for 
amphetamine, methamphetamine and the ring-substituted analogues MDA, MDMA, 
and MDEA. This work was the first instance of the use of meconium for general 
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screening purposes based on a general/universal extraction and analytical process. 
Studies carried out by previous workers primarily used a conventional approach and 
used multiple analyses for groups of target analytes. 
The method was applied in the first survey which has been done in Glasgow 
on all neonates born at the Royal Maternity Hospital from period of December 2000- 
February 2001, covering all the commonly-used illicit drugs and their metabolites. 
Out of 450 cases collected, there was sufficient sample in 400 cases for the analyses 
to be done, including qualitative screening by enzyme immunoassay and quantitative 
confirmatory analysis by gas chromatography-mass spectrometry. The results of the 
survey confirmed that there is a significant number of mothers using drugs and also 
confirmed the dangers to the foetus and neonate of drug use by the pregnant mother 
as potentially harmful concentrations of drugs were found, ranging from ing/gm to 
1281 ng. gm. It was also very interesting that 17 cases were positive for more than 
one drug and 2 cases were positive for 4 drugs. This was in agreement with observed 
trends in other populations, in which polydrug use is very common. The study also 
made some new developments in this area by attempting to distinguish between the 
origin of morphine detected in meconium. In Glasgow, it is routine clinical practice 
to administer diamorphine to mothers prior to Caesarian section, leading to the 
presence of morphine in meconium but also to the problem of distinguishing this 
pharmaceutically-derived material from illicit street heroin. The traditional approach 
is to analyse for impurities present in illicit heroin, including other opium alkaloids 
such as papaverine and also by-products of heroin synthesis such as 6-acetyl- 
morphine. This was carried out for all cases that were positive for morphine, 
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codeine, and methadone. Nine cases were found to contain one or more of these 
marker substances, providing some evidence of illicit heroin use. 
The final study presented here was designed to investigate further cases which gave 
positive EIA results but which were not confirmed by GC/MS. One of the most 
likely explanations is that the cannabinoid metabolites in the meconium are largely 
conjugated with glucuronic acid and that the sample pre-treatment should involve a 
hydrolysis step. Two methods of hydrolysis were tried, using glucuronidase and 
alkali and a comparison between the two found that alkaline hydrolysis gave better 
results. Subsequent application to the same cases which had been analysed without 
hydrolysis found that most cases which gave negative GC/MS results without 
hydrolysis, were subsequently found, after hydrolysis to contain cannabinoids, 
especially 11-nor-O9-tetrahydrocannabinol-9-carboxylic acid. This has important 
implications for future surveys. 
12.2 Future Work: 
this study has confirmed the usefulness of meconium analysis, but there are 
still many aspects of analysis of meconium, which have not yet been done. Firstly, 
the analysis of sequential specimens of meconium from the same neonate, up to three 
diaper collections, for morphine to see if there are differences in concentration 
affected by the time of gestation. 
The analyses could also be extended to many other target analytes such as 
metabolites of methadone and other metabolites of cocaine, and see the 
concentrations are affected by time or not. 
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The analysis of benzodiazepines and other drugs could be investigated using 
other instruments such as LC-MS, which can detect small amounts of analyte. This 
has been applied to other biological samples like blood and urine but not to 
meconium. This technique would also allow the detection of intact polar metabolites 
such as glucuronide conjugates without the need for hydrolysis. 
Lastly a study cold be done to compare the concentrations of drugs in meconium, 
hair and nail in the neonate and determine if there is variation in drug concentrations 
and between the three samples. 
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